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Summary	
The	 selective	 modification	 of	 native	 biomolecules	 such	 as	 nucleic	 acid,	 signaling	 molecules,	 and	
peptides	offers	new	tools	for	 investigation	biological	processes.	These	chemically	modified	analogs,	
radiolabeled	analogs,	fluorescent	or	affinity	tags	can	be	used	to	label,	modify,	or	pull-down	a	molecule	
of	interest	to	probe	its	function.	Among	these	chemical	modifications,	diazo	compounds	are	the	most	
versatile	building	blocks	for	the	customization	of	diverse	biomolecules.	
In	chapter	1,	I	discuss	briefly	the	properties	of	diazo	compounds	and	their	application	in	chemistry	and	
chemical	biology.	The	transition-metal	catalyzed	XHI	reaction	of	stabilized	diazo	compounds	is	used	
later	in	chapter	2	and	the	alkylation	reaction	of	unstabilized	diazo	compounds	with	BrØnsted	acids	is	
used	in	chapter	3.		
In	chapter	2,	I	first	give	a	short	introduction	of	the	biological	role	of	CDNs	(c-di-nucleotides)	which	are	
very	 important	 signaling	 molecules	 for	 bacterial	 growth	 and	 human	 innate	 immune	 system	
stimulation.	 The	 rhodium	 catalyzed	 XHI	 reaction	 with	 stabilized	 diazo	 compounds	 proved	 to	 be	 a	
simple	method	for	selective	modification	of	the	exo-amine	of	CDNs.	The	method	tolerates	all	members	
of	the	cyclic	dinucleotide	family	and	could	be	used	to	modulate	their	function	or	introduce	useful	side-
chains	such	as	fluorophores	and	photo-crosslinking	groups.	Cu	catalyzed	NHI	for	short	hairpin	oligo	
and	the	auto-tandem	catalytic	process	of	NHI	and	Cu-catalyzed	azide–alkyne	cycloaddition	(CuAAC)	
are	also	reported	here.	
In	chapter	3,	I	present	the	O-alkylation	of	phosphate	groups	by	alkyl	diazo	compounds	in	a	range	of	
small	molecules	and	biopolymers.	The	 relatively	high	pKa	of	phosphate	 in	 comparison	 to	 the	other	
naturally	occurring	BrØnsted	acids	can	be	exploited	to	control	alkylation	selectivity.	I	describe	here	a	
simple	protocol	for	chemical	modification	of	some	of	the	most	important	instances	of	phosphates	in	
natural	compounds	including	small	molecule	metabolites,	nucleic	acids,	and	peptides.	
In	 chapter	 4,	 I	 talk	 about	 the	 base	modifications	 in	 gene	 regulation	 networks.	 I	was	motivated	 to	
investigate	dynamic	RNA	methylation	as	a	regulation	signal	because	we	had	hoped	to	use	some	of	our	
chemistry	to	prove	the	process.	Although	this	project	is	still	in	its	infancy,	I	have	already	accomplished	
a	convertible	nucleotide	RNA	synthesis	and	succeed	in	the	expression	of	FTO	protein.		
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Chapter	1	Introduction		
1.1	Diazo	chemistry	
Diazo	 compounds	 are	 versatile	 building	 blocks	 and	 used	 prevalently	 in	 synthetic	 chemistry	 and	
chemical	 biology.1,	 2	 Ethyl	 diazoacetate	 (EDA)	 was	 the	 first	 synthetic	 diazo	 compound	 which	 was	
preapred	by	Curtius	in	1883.3	The	structure	of	the	diazo	group	was	confirmed	to	be	in	a	linear	form	by	
isotopic	 labeled	 experiment	 (Scheme	1.1).4	 The	 terminal	 15N	 labeled	 EDA	was	 obtained	 from	ethyl	
glycinate	 diazotisition.	 After	 hydrogenation	 of	 the	 labeled	 diazo	 compound,	 the	 terminal	 15N	 was	
released	 in	 the	 form	of	 15NH3,	 the	 unlabeled	nitrogen	 stayed	 in	 the	 glycine	 ester.	 This	 experiment	
excludes	possibility	of	the	cyclic	diazirine	isomer.		
	
Scheme	1.1	Experimental	evidence	for	the	linear	structure	of	ethyl	diazoacetate	
The	general	form	of	diazo	compounds,	R2N2,	shows	high	negative	polarity	on	the	carbon	atom	adjacent	
to	nitrogen.	It	can	be	represented	as	two	resonance	structures	(Scheme	1.2).5	
		
Scheme	1.2	Resonance	structures	of	diazo	compounds	
The	stability	of	diazo	compounds	is	strongly	determined	by	its	neighboring	substitutions	(Scheme	1.2).	
Alkyl	diazo	compounds	such	as	diazoethane	and	diazopropane	are	very	unstable;	their	application	in	
organic	synthesis	is	therefore	rather	limited	because	they	tend	to	decompose	before	they	are	applied	
in	the	reaction	mixture.	Diazo	compounds	with	electron	withdrawing	groups	are	more	stable	since	the	
negative	 charge	 can	 be	 further	 delocalized	 to	 the	 substituted	 group	 such	 as	 aromatic,	 carbonyl,	
phosphoryl,	 and	 sulfonyl	 substituents.	 Thus	 the	 stabilized	 ones	 are	 more	 likely	 existing	 in	 the	
diazonium	 form	 (Scheme	 1.1,	 B).	 This	 trend	 is	 confirmed	 by	 IR	 measurements	 where	 increasing	
electron-withdrawing	leads	to	a	strong	N≡N	bond.5	
	
Scheme	1.3	The	stability	of	diazo	compounds	increase	with	the	electron	acceptor	substitution	groups	
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Among	stabilized	diazo	compounds,	diazoacetates	and	diazoketones	are	the	most	widely	applied	diazo	
species	 in	modern	organic	chemistry	due	to	their	easy	accessibility.	They	undergo	a	wide	variety	of	
transformations	with	high	chemoselectivity	under	mild	conditions.	2	
	
Scheme	1.4	Resonance	structures	of	stabilized	α‑diazocarbonyl	compounds	
The	 release	 of	 nitrogen	 gas	 is	 the	 driving	 force	 for	 the	 decomposition	 of	 diazo	 compounds.	 Acidic	
conditions	favor	the	thermodynamic	stable	nitrogen	formation	by	adding	a	proton	to	the	nucleophilic	
carbon	of	 the	diazo	 compound.	The	 instability	of	diazo	 compounds	 toward	acids	also	models	 their	
reactivity	with	Lewis	acidic	transition	metal	catalysts.	The	transition-metal-catalyzed	transformations	
of	diazo	compounds	to	stabilized	carbenoids	are	ubiquitous	in	diazo	chemistry.6-9	The	metal-carbenoid	
intermediates	 are	 capable	 of	 undergoing	 a	 range	 of	 reactions	 with	 high	 chemo-,	 regio-,	 and	
stereoselectivity	 such	 as	 cyclopropanation	 of	 alkenes;	 C−H	 activation;	 X-H	 (X=	 heteroatom)	 bond	
insertion	reactions;	and	ylide	formation.2,	10-13	Furthermore,	selective	bioconjugation	in	proteins	and	
nucleic	 acids	and	carbohydrates	exploiting	diazo	 compounds	has	also	been	demonstrated,	offering	
new	tools	for	application	in	chemical	biology.2	
The	synthesis	and	application	of	diazo	compounds	are	well	summarized	in	many	reviews.1,	2	Here	I	am	
going	 to	 focus	 the	discussion	on	 the	 transition	metal	 catalyzed	α-diazocarbonyl	 compounds	 in	XHI	
insertion	reaction	(X=	N,	O,	S);	and	unstabilized	diazo	esterification	with	acid	in	chemical	biology	which	
are	going	be	employed	in	chapter	2	and	chapter	3.	
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1.2	Carbenoid	formation	based	on	α-diazocarbonyl	compounds		
Catalyzed	X–H	insertion	reactions	into	diazo	compounds	(where	X	is	any	heteroatom)	are	a	powerful	
yet	underutilized	class	of	transformations.	X	can	be	nitrogen,	oxygen,	sulfur,	selenium,	phosphorus,	or	
a	halogen.14	It	is	a	ubiquitous	method	for	carbon-heteroatom	bond	generation	due	to	the	mild	reaction	
conditions	and	the	availability	of	diverse	diazo	compounds.	However,	the	successful	development	of	
C-H	insertion	into	diazo	compounds	should	not	be	overlooked.10	
In	these	reactions	a	metal–carbenoid	 is	 typically	generated	 in	situ	from	a	diazo	precursor	and	then	
reacts	with	an	X–H	bond	to	deliver,	either	in	concerted	or	stepwise	fashion	(scheme	1.5A),	to	afford	
the	X-H	insertion	product.	Coordination	of	the	negatively	polarized	carbon	of	the	diazo	substrate	to	
the	Lewis	acidic	metal	(Scheme	1.5C,	step	I)	is	the	first	productive	step	in	the	catalytic	cycle.	Loss	of	
nitrogen	from	the	resulting	intermediate,	as	shown	in	step	II,	then	delivers	the	metal–carbenoid.	A	few	
metal–carbenoids	have	been	characterized	spectroscopically	(Cu,	Rh).15	It	 is	generally	accepted	that	
the	metal-carbenoids	proceed	by	a	concerted	mechanism	with	non-polar	bonds	(Scheme	1.5B).12		With	
polar	 X-H	 bond	where	 X	 bears	 lone-pair	 electrons,	 the	 reaction	most	 likely	 undergoes	 a	 stepwise	
mechanism	(Scheme	1.5C).			
Scheme	1.5	The	mechanism	of	XHI	reaction	
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1.2.1	Catalyst	comparison	for	carbenoid	chemistry		
Rh2(OAc)4	 was	 first	 used	 by	 Teyssie	 in	 1973	 to	 decompose	 EDA	 to	 produce	 a	 rhodium–carbenoid	
intermediate,	 subsequent	O–H	 insertion	 then	delivered	ethers.16	 Later	 they	 reported	 that	 rhodium	
carboxylates	were	also	efficient	catalysts	for	N–H	and	S–H	insertion.	These	seminal	observations	set	
the	stage	for	forty	years	of	intensive	study	with	rhodium	(II)	catalysts.	As	a	result	the	substrate	scope	
has	 been	widely	 expanded	 to	 include	 aliphatic	 amine,	 aniline,	 amide,	 alcohols,	 phenols,	 thiols	 and	
silanes.	The	discovery	of	the	incredible	catalytic	abilities	of	rhodium	(II)	acetate	leads	the	attention	to	
creating	 asymmetric	 catalysts	 based	 on	 rhodium	 (II).	 Over	 the	 ensuing	 years,	 the	 development	 of	
asymmetric	 catalysts	 based	 on	 rhodium	 (II)	 has	 achieved	 a	 great	 success	 in	 enantioselective	 C–H	
insertion.		However	the	XHI	products	were	obtained	in	rather	low	enantioselectivity.		
The	above	mentioned	issues	with	rhodium	have	led	copper	catalysts	back	to	the	spot	 light	for	high	
enantioselectivity	in	XHI.	Although	first	reported	to	be	useful	for	XHI	reactions	in	the	early	fifties,17,	18	
XHI	chemistry	with	copper	remained	underutilized	until	recently–likely	as	a	result	of	the	harsh	reaction	
conditions,	low	insertion	yields,	and	sparing	solubility	of	the	copper	complexes.	Research	with	copper	
was	therefore	largely	abandoned	for	rhodium(II)	catalysts.	In	2002,	a	report	from	Pérez	and	co-workers	
demonstrated	that	copper(I)	complexes	with	homoscorpionate	ligands	could	catalyze	the	insertion	of	
EDA	 into	 N–H	 bonds	 of	 amines	 and	 amides	 in	 high	 yields	 under	mild	 conditions.19	 The	 electronic	
interaction	between	the	copper	and	the	heterocyclic	 ligand	not	only	enhanced	its	stability,	but	also	
improved	its	reactivity	and	selectivity	in	the	XHI	reaction	as	a	result	of	its	unique	structure.		Especially	
the	 development	 of	 spiro	 ligands	 in	 highly	 enantioselective	 XHI	 reactions	 has	 led	 copper	 to	 a	
renaissance	in	XHI	applications	(Scheme	1.6).	
	
Scheme	1.6	Cu	and	Fe	catalyzed	asymmetric	XHI	by	using	spiro	ligands		developed	by	Zhou	
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A	tenable	explanation	for	the	poor	ability	of	rhodium(II)	complexes	in	promoting	enantioselectivity	in	
O–H	insertion	has	been	put	forth	by	the	Yu	group	based	on	DFT	calculations	of	both	the	copper(I)	and	
rhodium(II)-catalyzed	 reaction	 paths	 (Scheme	 1.7).20	 They	 found	 that	 a	 crucial	 difference	 in	 the	
stereogenesis	 is	 that	 whereas	 copper	 complexes	 prefer	 to	 remain	 bound	 to	 the	 substrate	 during	
protonation,	the	rhodium	catalysts	favor	dissociation	leading	to	a	metal-free	ylide	pathway	and	hence	
cannot	transfer	chiral	information.	Shown	in	Scheme	1.7	are	the	calculated	free	energies	of	the	proton	
transfer	transition	states	that	led	to	this	mechanistic	hypothesis.	The	copper-associated	structure	is	
nearly	10	kcal	mol−1	lower	in	energy	than	the	metal-free	transition	state,	which	in	turn	is	approximately	
6	kcal	mol−1	lower	in	energy	than	the	rhodium	associated	transition	state.	Even	though	the	free	ylide	
intermediate	has	not	been	observed	in	the	rhodium	catalyzed	NHI	process,	it	could	be	inferred	from	a	
few	other	examples.	Oxonium	ylide	has	been	trapped	with	imine	electrophiles.21	Ally	alcohol	facilities	
the	tandem	ylide	intermediate	formation	during	the	process	of	rhodium-catalyzed	[2,3]-Sigmatropic	
Rearrangement.22	Besides	O-H	 insertion,	 the	 spiro-bisoxazoline	 ligands	developed	by	Zhou	strongly	
suggest	Cu(I)	catalyzed	N-H	insertion	also	proceeds	by	the	metal	associated	ylide	pathway.	
	
Scheme	1.7	Comparison	of	Cu	and	Rh	catalyzed	XHI	
Given	the	costs	associated	with	the	rarer	transition	metals,	processes	based	on	iron	would	be	well-
received	 by	 potential	 users.	 The	Woo	 and	 Gross	 groups	 have	 independently	 shown	 that	 iron(III)–
corrole	and	 iron(III)–porphyrin	complexes	are	excellent	catalysts	 for	N–H	 insertion	 into	a	variety	of	
amines	 and	 diazo	 substrates.23,	 24	 Furthermore,	 the	 recent	 application	 of	 iron–spirobisoxaline	
complexes	 in	highly	efficient	enantioselective	X–H	 insertion	should	stimulate	 further	developments	
with	this	practical	alternative	to	the	precious	metal	catalysts.9	
Despite	the	preference	for	the	metal-free	ylide	pathway	in	XHI,	enantioselective	processes	based	on	
rhodium(II)	may	yet	be	realized.	A	recent	report	demonstrating	that	an	achiral	rhodium(II)	carbene	can	
be	intercepted	by	an	imine	activated	with	a	chiral	BrØnsted	acid	indicates	that	cooperative	rhodium(II)–
8	
	
BrØnsted	acid	catalysis	may	offer	an	alternative	approach	towards	enantioselective	XHI.25	Indeed	Saito	
and	coworkers	have	found	that	cinchona	alkaloid	additives	can	deliver	enantiomeric	excesses	of	up	to	
50%	in	the	O–H	insertion	of	α-diazoesters	with	water	catalyzed	by	achiral	rhodium(II)	catalysts.26	The	
Zhou	group	has	also	recently	discovered	that	BINOL-based	chiral	phosphoric	acids	(CPA)	deliver	high	
levels	of	enantioinduction	in	N–H	insertion	reactions	(Scheme	1.8)27.	These	promising	initial	findings	
suggest	that	XHI	coupled	with	enantioselective	protonation	is	an	area	poised	for	further	development.	
	
Scheme	1.8	CAP	ligand	mediated	rhodium	catalyzed	asymmetric	NHI		
Ruthenium,	one	of	rhodium’s	direct	neighbours	in	the	periodic	table,	was	first	introduced	to	catalyze	
EDA	insertion	into	S–H	and	N–H	bonds	in	1997.28	Recent	results	on	ruthenium	catalysed	N–H29	and	O–
H	 insertion30	 reactions,	 reported	 by	 the	 Che	 and	 Lacour	 groups	 respectively,	 demonstrate	 that	
ruthenium	 complexes	 can	 sometimes	 offer	 unique	 reactivity	 in	 comparison	 with	 other	 catalysts.	
Although	a	relative	newcomer	in	XHI,	the	favourable	properties	of	ruthenium	(its	similar	reactivity	to	
rhodium,	lower	cost,	more	available	oxidation	states,	and	rich	coordination	chemistry)	suggest	a	bright	
future.	
Over	 the	past	 two	decades	 the	 catalysis	 field	 has	 proven	 in	 countless	 cases	 that	 the	properties	 of	
templating	and	turn-over	offered	by	a	catalyst	can	deliver	benefits	that	no	stoichiometric	process	can.	
Tuning	catalyst	structure	can	offer	the	prospect	of	controlling	chemo-,	diastereo-,	enantio-,	regio-,	and	
site-selectivity.	An	overview	was	summarized	here	in	tabular	format	of	the	breadth	of	substrates	and	
reaction	 types	 each	 catalyst	 has	 so	 far	 been	 applied	 to	 (see	 Table	 1.1).	 The	 rhodium,	 copper,	
ruthenium,	and	iron	catalyzed	versions	of	this	reaction	are	tolerant	to	a	range	of	reaction	conditions	
9	
	
and	functional	groups,	and	can	accommodate	a	variety	of	heteroatom	donors.	The	assessment	of	their	
strengths	and	weaknesses	are	also	included	here	for	comparison.	
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1.2.2	Modifications	in	chemical	biology	with	α-diazocarbonyl	compounds	based	on	metal-
carbenoid	XHI	
Nucleophilic	heteroatoms	are	highly	abundant	 in	nucleic	acid,	protein,	 carbohydrates	and	signaling	
molecules.	Selective	modification	of	the	native	biomolecular	structures	by	targeting	the	nucleophilic	
heteroatom	could	gain	great	benefit	from	XHI	reactions.	Given	the	right	catalysts	and	ligands	it	should	
be	possible	for	chemists	to	imitate	the	kind	of	selectivity	achieved	by	enzymes,	but	progress	in	creating	
artificial	 catalysts	 to	selectively	 target	 intact	biomolecules	has	 thus	 far	been	modest.	Nevertheless,	
much	of	the	progress	has	been	achieved	to	date	with	catalysts	for	XHI.		
Examination	of	protein	active	sites	by	diazo	modification	is	nearly	as	old	as	the	discovery	of	copper-
carbenoid	chemistry.	Rajagopalan	and	coworkers31	as	well	as	Delpierre	and	Fruton32	discovered	almost	
simultaneously	 that	 the	active-site	carboxyl	 residue	of	pepsin	 is	modified	with	diazo	compounds	at	
least	103	 fold	 faster	 in	 the	presence	of	 large	excesses	of	copper(II)	 salts.	Although	the	mechanistic	
underpinnings	 of	 the	 reaction	 were	 unknown	 at	 the	 time,	 such	 reactivity	 with	 carboxylates	 is	
reasonable	 considering	 that	XHI	would	prefer	 the	protonated	 form	of	 the	acid.	 These	authors	also	
observed	a	short	induction	period	before	protein	modification	began,	consistent	with	the	necessity	to	
generate	copper(I)	from	a	sacrificial	diazo-coupling	before	effective	catalysis	can	ensue.33	
	
Scheme	1.9	XHI	in	protein	labeling	
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It	was	many	years	later,	before	the	potential	of	rhodium(II)	complexes	to	promote	XHI	reactions	for	
applications	in	chemical	biology	was	recognized.	Antos	and	Francis	reported	in	2004	that	tryptophans	
in	 myoglobin	 and	 subtilisin	 could	 be	 modified	 at	 low	 pH	 using	 α-diazo	 esters	 and	 dirhodium	
tetraacetate	 (see	 Scheme	 1.9).34	 The	 reaction	 seems	 to	 proceed	 by	 a	 mixture	 of	 XHI	 and	
cyclopropanation	 of	 the	 tryptophan	 indole	 moiety.	 Their	 refined	 method	 using	 tert-butyl	
hydroxylamine	hydrochloride	as	the	buffer	condition	leads	to	smooth	alkylation	of	tryptophan	residues	
on	a	variety	of	proteins.	For	the	metal-mediated	protein	labelling	to	proceed	efficiently	its	nucleophilic	
residues	must	be	exposed	to	the	carbenoid	intermediate.	Surface-exposed	cysteine	residues	in	cystic	
fibrosis	transmembrane	conductance	regulator-associated	ligand	(CAL)	and	its	PDZ	domain	CALP	react	
selectively	with	diazo	reagents	via	S-H	insertion	using	rhodium	acetate	as	the	catalyst.35		The	selectivity	
of	 cysteine	over	 tryptophan	 is	 remarkably	high	after	 screening	a	 few	other	proteins.	 This	 could	be	
explained	that	tryptophan	residues	are	buried	 in	the	hydrophobic	pocket	thus	they	are	not	solvent	
accessible.	Besides	tryptophan	and	cysteine,	it	would	be	ideal	to	be	able	to	modify	nearly	any	desired	
amino	acid	side-chain	with	the	site-selectivity	controlled	by	the	catalyst.	Targeting	strategies	to	deliver	
a	 rhodium–carbenoid	 intermediate	 to	 specific	 amino	 acids	 were	 achieved	 by	 the	 combination	 of	
peptide	 molecular	 recognition	 and	 residue-selective	 dirhodium	 catalysis.	 XHI	 modification	 of	
nucleophilic	residues	such	as	Phe,	Tyr,	Asn,	Gln,	Lys	was	achieved	through	applying	the	well	understood	
binding	rules	of	helix-interaction,	where	the	helix	carried	a	rhodium	catalyst.36	
	
Scheme	1.10	Rh	catalyzed	alkylation	of	nucleic	acid	
While	 customized	 nucleic	 acids	 could	 be	 obtained	 by	 oligonucleotide	 solid	 support	 synthesis,	
comprehensive	laborious	work	is	needed.	Our	group	recently	reported	that	rhodium-carbenoids	can	
target	 the	exocyclic	N-H	group	of	 various	native	nucleic	 acids.	 The	Rh2(OAc)4	 reacts	with	 the	diazo	
compound	to	create	a	rhodium	carbenoid	which	can	further	react	with	nucleophilic	groups	on	nucleic	
acids	(Scheme	1.10).37	Although	a	number	of	reaction	pathways	of	rhodium	carbenoids	with	nucleic	
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acids	 are	 conceivable,	 only	 N–H	 insertions	 into	 exocyclic	 amines	 of	 nucleobases	 were	 observed;	
thymidines,	 uridines,	 and	 the	 ribophosphate	 backbone	 were	 unreactive.	 The	 site	 and	 mode	 of	
reactivity	in	the	alkylation	was	precisely	determined	through	a	combination	of	NMR	studies	with	a	13C-
labeled	diazo	substrate,	as	well	as	tandem	MS	experiments.	In	contrast	studies	on	hairpin	sequences	
revealed	that	double-stranded	stretches	were	unreactive.	It	seems	that	if	the	N-H	bonds	are	engaged	
in	Watson-Crick	base-	pairing	they	are	unavailable	for	reaction	with	the	rhodium.		
The	previous	development	of	diazo	compounds	based	modification	of	protein	and	nucleic	acid	greatly	
helps	the	further	studies	and	substrate	and	reaction	scope.	The	recent	developments	applying	XHI	to	
the	modification	of	intact	proteins	and	nucleic	acids	certainly	give	us	hints	for	further	application	in	
this	 field.	 We	 could	 apply	 these	 theories	 and	 methods	 to	 expand	 the	 application	 in	 many	 other	
interesting	biomolecules	which	are	shown	in	the	chapter	2.	
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1.3	Alkylation	with	unstabilized	diazo	compounds	in	chemical	biology	
Alkyl	diazo	compounds	such	as	diazomethane,	diazoethane,	diazopropane	are	explosive	compounds	
and	the	difficulty	of	preparation	limited	their	use	in	organic	synthesis.	For	example,	diazomethane	is	
an	extremely	sensitive	yellow	gas.	It	might	explode	even	passing	over	sharp	surfaces.	Its	permissible	
exposure	 limit	 is	 0.2	ppm	due	 to	 its	 high	 toxicity.	Diazomethane	generated	 in	 situ	 from	N-nitroso-
derivatives	 by	 base-promoted	 decomposition	 can	 be	 managed	 at	 a	 safe	 level.38	 Recently,	 the	
developments	of	flow	systems	combined	with	micro-reactor	technology	to	generate	diazomethane	in	
situ	 inside	 the	 reactor,	 greatly	 diminishing	 the	 chances	 of	 accidents.38,	 39	 On	 the	 other	 hand,	
trimethylsilyl	diazomethane	 is	more	 thermally	 stable	and	 less	explosive,	used	 frequently	 in	organic	
synthesis	as	a	safer,	commercially	available	alternative	to	diazomethane.	However,	precaution	to	its	
toxicity	should	be	raised	after	two	fatal	incidents.40		
Despite	 these	 safety	 concerns,	 alkyl	 diazo	 compounds	 are	 very	 useful	 precursors	 in	 synthetic	
chemistry.	 They	 undergo	 carboxylic	 acids	 alkylation,41	 homologation	 of	 carbonyl	 compounds,42	
cyclopropanation	of	alkenes,43	3-dipolar	cycloadditions44,	45	to	name	a	few.	
In	aqueous	condition,	the	alkyl	diazo	compounds	are	extreme	acid	labile	(Scheme	1.11).	BrØnsted	acids	
catalyze	reactions	by	protonation	of	the	partially	negatively	charged	carbon	of	diazo	compounds	and	
forming	 the	 unstable	 diazocarbonoid	 to	 be	 attacked	 by	 nucleophiles.	 The	 equilibrium	 favoring	 the	
carbocation	(and	thus	the	rate	of	subsequent	reactions)	is	determined	by	the	strength	of	the	BrØnsted	
acid	and	the	stability	of	the	carbocation	produced	(Scheme	1.11).	Carbocations	generated	from	alkyl	
dizao	 compound	 are	 very	 unstable,	 immediately	 get	 attacked	 by	water	 leading	 to	 hydrolysis.	 The	
extreme	acid	sensitivity	and	the	lack	of	selectivity	limit	alkyl	diazo	compounds’	utility	with	biomolecule	
in	aqueous	solution.		
	
Scheme	1.11	The	acid	catalyzed	decomposition	of	diazo	compounds.		
In	 stabilized	 diazo	 compounds,	 the	 carbon	 adjacent	 to	 the	 nitrogen	 group	 is	 weakly	 basic.	 The	
pronation	 is	much	slower	 than	 the	carbon	 in	alkyl	diazo	compounds.	For	example,	diazomalonates	
have	very	long	life	time	in	water.	However,	the	stability	renders	them	of	little	value	in	BrØnsted	acid	
alkylation.	The	strength	and	nature	of	BrØnsted	acids	also	play	a	determinant	role	in	the	fate	of	the	
protonated	diazo	compound,	which	can	form	a	tight	ion	pair	with	the	carbocation	expelled	from	the	
solvent,	yielding	esterification	products.	Half	stabilized	diazo	compounds	such	as	TMS,	aryl	substituted	
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diazo	 methanes	 are	 in	 the	 middle	 ground	 between	 these	 two	 extremes	 which	 is	 essential	 for	
controlling	selectivity	in	diazo-type	esterifications	(Scheme	1.12).		
	
Scheme	1.12	Selected	half	stabilized	diazo	compounds	used	as	alkylating	reagents	
Alkyl	 diazo	 compounds	 are	 potent	 alkylating	 reagents.	 They	 modify	 DNA	 at	 many	 different	 sites,	
thereby	producing	lethal	and	mutagenic	lesions	(Scheme	1.13).	The	alkylation	only	occurs	at	different	
sites	of	bases,	including	exocyclic	oxygens	and	most	ring	nitrogens,	but	also	happens	to	phosphates	of	
the	 DNA	 backbone,	 thereby	 generating	 phosphotriesters	 (Scheme	 1.13	 lower,	 modification	 site	 is	
corresponding	 to	 the	 nucleophilicity	 of	 the	 nucleic	 acids).46	 Diazo	 precursors,	 such	 as	 N-nitroso-
derivatives	or	triazene	are	often	used	in	the	cancer	chemotherapy	to	alkylate	DNA	in	the	cancer	cell	
inhibiting	DNA	replication	and	leading	to	cell	death	(Scheme	1.13	upper).46	
 
 
Scheme	1.13	Diazo	precursor	used	in	cancer	chemotherapy	
Alkylation	 of	 the	 phosphate	 group	 of	 nucleic	 acids	 with	 aryl	 diazo	 compounds	 has	 a	 long	 history.	
Dibenzyl	 uridine	 3’-mono-phosphate	 has	 been	 prepared	 in	 anhydrous	MeOH	 using	 corresponding	
diazoalkanes	in	1955	(Scheme	1.14).47	The	phosphotriester	was	decomposed	in	aqueous	solution	to	a	
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mixture	of	phosphodiester.	It	is	considered	that	the	occurrence	of	phosphotriester	group	in	ribonucleic	
acids	is	unlikely.		
	
Scheme	1.14	Alkylation	of	UMP	to	phosphotriester	and	its	stability	in	aqueous	solution	
Later,	an	expanded	series	of	aryl	diazo	compounds	were	investigated	in	alkylation	of	the	phosphate	
group	of	nucleic	acids.48		Typically,	excess	amounts	of	diazo	compounds	are	employed	in	anhydrous	
solvents	 to	 achieve	 phosphotriesters.	 Among	 them,	 coumarine	 diazo49	 and	 2-nitro-phenyl	 diazo	
methane50,	51	modified	nucleic	acids	are	capable	to	release	the	native	nucleic	acid	by	photolysis,	thus	
these	are	widely	used	as	nucleic	acid	caging	agents.	6-Bromo-4-diazomethyl-7-hydroxycoumarin	(Bhc-
diazo)	has	been	employed	 to	 react	with	 the	phosphate	moiety	of	 the	backbone	of	RNA,	modifying	
approximately	30	sites	on	the	phosphate	moieties	per	1	kb	of	RNA	sequence.52	The	Bhc-caged	green	
fluorescent	 protein	 (GFP)	 mRNA	 has	 severely	 reduced	 translational	 activity	 in	 vitro,	 whereas	
illumination	of	Bhc-caged	mRNA	with	ultraviolet	light	leads	to	partial	recovery	of	translational	activity.	
In	 embryos	 injected	with	 Bhc-caged	GFP	mRNA	 at	 the	 one-cell	 stage,	 GFP	 protein	 expression	 and	
fluorescence	 is	specifically	 induced	by	ultraviolet	 light.	However,	Friedman’s	 lab	demonstrated	that	
the	diazo	 compounds	 react	 very	poorly	with	backbone	phosphates.	 Instead	 they	 show	 remarkable	
specificity	for	terminal	phosphates	and	very	modest	modification	of	nucleobase.53,	54	
Scheme	1.15	Inactivation	of	mRNA	by	caging	with	Bhc-diazo	and	reactivation	by	photo-illumination.	
While	the	alkyl	diazo	compounds	are	too	reactive	and	difficult	to	handle,	their	application	in	aqueous	
buffer	is	unselective.	Half	stabilized	diazo	compounds	which	are	between	too	reactive	alkyl	diazo	and	
stabilized	 carbonyl	diazo	moieties,	 are	employed	 in	 frequently	 in	 alkylation	of	 carboxylic	 acids	 and	
phosphate	esters.		
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Chapter	2	Catalytic	NHI	of	nucleic	acids	by	diazo	compounds	
2.1	Cyclic-di-nucleotides	as	important	signaling	molecules	
The	3’,	5’	linked	cyclic	dinucleotides	(CDNs,	Figure	2.1)	play	diverse	and	important	roles	as	bacterial	
second	 messengers	 in	 response	 to	 environmental	 changes.	 Bis-(3'-5')-cyclic	 dimeric	 guanosine	
monophosphate	(c-di-GMP)	is	a	ubiquitous	signaling	molecule	in	bacteria.55	Fluctuating	levels	of	c-di-
GMP	controls	their	lifestyle,	from	a	swarming	motile	phase	to	sessile	biofilm	formation,	which	is	an	
essential	 step	 for	 virulence	 and	 pathogenesis.56	 A	 c-di-GMP	 analog,	 c-di-AMP,	 is	 involved	 in	 the	
regulation	 of	 bacterial	 cell	 wall	 metabolism,	 osmotic	 stress	 responses	 and	 in	 pathogen-host	
interaction.57-59	C-di-GAMP	as	is	the	newest	member	of	second	messengers,	its	biological	role	is	still	
unknown.60	 Understanding	 how	 bacteria	 thrive	 and	 spread	 their	 population	 is	 important	 for	
environmental	protection	and	human	health.	Once	mammalian	cells	have	been	infected	by	bacteria,	
these	exogenous	3’,	5’-linked	CDNs	will	be	recognized	by	STING	of	the	host’s	innate	immune	system,	
thus	 CDNs	 become	 the	 host’s	 immunity	 alarmins.61	 STING	 (the	 name	 deriving	 from	 stimulator	 of	
interferon	genes),	is	a	transmembrane	protein	in	mammalian	cell	that	acts	as	an	innate	immune	sensor	
of	CDNs.	STING	promotes	the	induction	of	type	I	interferons	(IFN-α	and	IFN-β).62-64	Stimulation	of	host	
immune	response	with	CDNs	could	be	an	alternative	approach	in	combating	antibacterial	 infection.	
Such	alternative	approaches	are	becoming	more	valuable	due	to	the	increase	of	antibiotics	resistant	
in	 bacterial	 pathogens.	 The	 large	 scale	 overuse	 of	 antibiotics	 in	 livestock	 farming	 and	 fish	 farming	
becomes	 a	 big	 issue	 and	 alternative	 strategies	 are	 in	 urgent	 need	 instead	 of	 developing	 stronger	
antibiotics.		
Until	recently	CDNs	were	not	thought	to	be	produced	by	mammalian	cells	and	should	appear	in	the	
cytosol	 only	 because	 of	 the	 presence	 of	 invading	 bacteria.65	 Only	 very	 recently	 was	 c-di-GAMP	
discovered	in	mammalian	cell	in	an	unusual	isomeric	form	of	previous	CDNs.66,	67	This	unique	secondary	
messenger	 c-G(2',5')pA(3',5')p	 is	 produced	 endogenously,	 as	 the	 result	 of	 an	 mammalian	 innate	
immune	 response	 to	 pathogen-derived	 cytoplasmic	 double	 stranded	 DNA	 (dsDNA).67,	 68	 The	 c-
G(2',5')pA(3',5')p	 synthase	 (cGAS)	 has	 been	 shown	 to	 be	 an	 innate	 immune	 sensor	 of	 retroviruses	
including	HIV	and	Herpes	virus.68	All	3’,	5’-and	2’-3’-linked	CDNs	are	high-affinity	 ligands	 for	STING,	
thereby	ensuring	successful	host	defenses	against	pathogen	infection.69	
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Figure	2.1	Structures	of	the	natural	CDNs	
2.1.1	c-di-GMP	as	a	ubiquitous	second	messenger	
C-di-GMP	was	first	discovered	in	1987	by	Benziman’s	group70	as	a	cofactor	needed	to	activate	cellulose	
biosynthesis	in	Gluconacetobacter	xylinus.	The	level	of	c-di-GMP	is	controlled	by	specific	diguanylate	
cyclases	(DGCs)	and	phosphodiesterases	(PDEs).	DGC	enzymes	contain	a	GGDEF	amino	acid	sequence	
motif	 in	 the	 active	 domains	 and	 use	 two	 GTP	molecules	 to	 synthesize	 one	 c-di-GMP.	While	 PDEs	
contain	either	an	EAL	or	an	HD-GYP	amino	acid	motif,	and	they	degrade	c-di-GMP	to	GMP.	The	cyclases	
and	phosphodiesterases	regulate	the	c-di-GMP	at	the	appropriate	 level	according	to	environmental	
changes	(Figure	2.2).56,	71,	72	C-di-GMP	is	a	prevalent	signaling	second	messenger	in	a	wide	variety	of	
bacteria,	but	not	found	in	archaea	yet.	It	has	only	been	observed	in	eukaryotes	in	Dictyostelium	very	
recently.73	 Increasing	 levels	 of	 c-di-GMP	 lead	 to	 biofilm	 formation	 by	 enhancing	 the	 synthesis	 of	
adhesive	 structures	and	biofilm	matrix	 components.	While	decreasing	 levels	of	 c-di-GMP	stimulate	
dispersal	 of	 biofilms	 and	 promotes	 a	 planktonic	 lifestyle.	 Fluctuating	 levels	 of	 c-di-GMP	 initiate	
adaptive	 responses	 in	bacterial	 cells	when	 they	are	exposed	 to	various	 sources	of	 stress,	 including	
antibiotics,	 nutrient	 limitation,	 anaerobiosis,	 heat	 shock.	 The	 c-di-GMP	 signaling	 is	 not	 only	 at	 the	
transcriptional	 level	 by	 binding	 specific	 regulator	 protein	 or	 riboswitches,	 but	 also	 at	 a	 post-
translational	level	via	PilZ	domain	containing	proteins.	C-di-GMP	binds	to	its	effector	components	and	
receptors	regulating	a	wide	range	of	bacteria	cell	 functions	 including	mobility,	adhesion,	cell	 to	cell	
communication,	quorum	sensing,	exopolysaccharide	synthesis,	biofilm	formation	and	virulence.55,	56,	72	
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Figure	2.2	Biosynthesis	of	c-di-GMP	and	its	role	in	regulating	cell	responses	to	environment	changes	
The	c-di-GMP	mediated	cell	to	cell	communication	is	integrated	with	quorum	sensing	helping	bacteria	
in	 the	 host	 cell	 colonization,	 against	 cellular	 immunity	 attack	 and	 antimicrobial	 treatments.74	 An	
association	between	high	levels	of	c-di-GMP	and	antibiotic	resistance	may	be	expected	because	c-di-
GMP	regulates	biofilm	formation.	The	highly	structured	surface	of	the	biofilm	as	the	physical	barrier	
of	bacteria	is	extraordinary	resistant	to	antimicrobial	agents.75,	76	However,	a	clear	understanding	of	
this	correlation	has	not	been	established.	Chua	showed	that	P.	aeruginosa	cells	with	 low	c-di-GMP	
levels	were	found	to	be	more	resistant	to	colistin	than	P.	aeruginosa	cells	with	high	c-di-GMP	levels.77		
At	 the	same	 time,	Sauer’s	group	demonstrated	elevated	 level	of	 c-di-GMP	 in	 the	planktonic	cell	of	
Pseudomonas	 aeruginosa	 benefits	 the	 brIR	 expression	 (brIR	 is	 a	 c-di-GMP	 responsive	 transcription	
regulator).	The	downstream	response	will	increase	the	survival	rate	against	antimicrobial	agents.78,	79	
Nevertheless,	 understanding	 the	 increased	 antibiotics	 tolerance	 is	 very	 important	 for	 bacterial	
infection	 treatment	 in	 long	 term.	 Especially	 now,	 the	 increased	 drug	 tolerance	 turns	 some	biofilm	
infections	in	human	into	a	chronic	problem.80,	81	Interfering	with	the	c-di-GMP	signaling	pathway	has	a	
great	potential	application	in	new	therapeutics	that	specifically	target	biofilms.	
The	formation	of	biofilms	not	only	signiﬁcantly	harms	human	health,	but	also	damage	a	large	amount	
of	 industrial	 structures,	 especially	 in	 aquatic	 environments.	 In	 contaminated	 marine	 engineering	
systems,	tremendous	efforts	are	needed	to	remove	biofilm	colonization.	The	cleaning	combined	with	
antibiotics	is	losing	its	efficiency	in	treating	industrial	biofilm	damage	due	to	the	increased	antibiotic	
resistance.	Manipulation	of	bacteria	from	biofilm	lifestyle	to	dispersed	motile	phase	by	controlling	c-
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di-GMP	level	is	a	new	trend	in	research	which	could	lead	to	a	new	strategy	in	the	treatment	of	biofilm	
formation	in	industry.82			
2.1.2	c-di-AMP	as	a	newly	discovered	CDN	draws	attention	
Cyclic	 di-adenosine	 monophosphate	 (c-di-AMP)	 was	 discovered	 in	 the	 DNA	 damage	 checkpoint	
initiation	system	in	2008.83	In	nutrition	limited	environments,	the	soil	bacteria	Bacillus	subtilis	will	go	
through	a	sporulation	process	in	which	the	cell	will	divide	unequally	to	produce	a	spore	cell	which	is	
more	resistant	to	the	unfavorable	environmental	conditions.	The	spore	then	regains	its	viability	when	
conditions	become	favorable.	During	the	sporulation	process,	if	a	cell	is	introduced	with	unexpected	
DNA	double-strand	break83	or	DNA-damaging	agents84,	the	DNA	integrity	scanning	protein	(DisA)	will	
bind	tightly	to	the	unexpected	DNA	damage,	initiating	a	DNA	repair	response.	As	a	result,	decreased	
levels	of	c-di-AMP	are	observed,	and	the	sporulation	also	slows	down	(Figure	2.3).	In	the	absence	of	
DNA	 damage,	 the	 level	 of	 c-di-AMP	 is	 restored	 and	 the	 sporulation	 is	 continued.	 DisA	 forms	 an	
octameric	complex	(Figure	2.3),	one	tetramer	is	arranged	in	a	parallel,	interacting	head	to	head	with	
another	DisA	tetramer	according	to	its	structural	and	biochemical	analyses.83	Each	monomer	consists	
of	three	distinct	domains.	The	HhH	domain	is	responsible	for	checking	DNA	damage,	while	the	DAC	
(diadenylyl	cyclase)	domain	is	responsible	for	c-di-AMP	synthesis.	DisA	slides	smoothly	on	intact	DNA.	
Its	activity	is	unaffected,	thereby	producing	c-di-AMP	and	later	initiating	sporulation.		
	
Figure	2.3	Biosynthesis	of	c-di-AMP	and	its	role	in	cell	sporulation	
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C-di-AMP	is	likely	to	be	widely	distributed	among	bacteria	and	is	also	found	in	a	subset	of	archaea85.	
Like	 c-di-GMP,	 c-di-AMP	 is	 synthesized	 from	 ATP	 by	 DAC	 enzymes	 and	 is	 hydrolyzed	 by	
phosphodiesterase	(PDE)	enzymes.	Recently,	several	c-di-AMP	receptors	were	identified	to	be	involved	
in	 the	 regulation	 of	 bacterial	 cell	 wall	 metabolism,86	 osmotic	 stress	 responses87.	 However	 the	
understanding	of	how	these	signals	are	transduced	is	still	limited.		
2.1.3	CDN	signaling	in	eukaryotes	domain	
	
Figure	2.4	STING	is	a	direct	innate	immune	sensor	of	cyclic	di-GMP.	[Reprinted	with	permission	from	Elsevier	Publishers	
Ltd:	[Immunity]	(S.	Ouyang,	X.	Song,	Y.	Wang,	H.	Ru,	N.	Shaw,	Y.	Jiang,	F.	Niu,	Y.	Zhu,	W.	Qiu,	K.	Parvatiyar,	Y.	Li,	R.	
Zhang,	G.	Cheng	and	Z.-J.	Liu,	Immunity,	2012,	36,	1073-1086),	copyright	(2012)].	
The	 innate	 immune	 system,	 also	 known	 as	 in-born	 immunity	 system,	 recognizes	 and	 responds	 to	
pathogens	in	a	generic	way,	defending	the	host	from	infection.	STING	has	proved	to	be	a	key	player	in	
recognition	of	pathogens,	triggering	type	I	interferons	(IFNs)	protection,	especially	critical	in	detecting	
foreign	nucleic	acids	like	cytosolic	DNA	and	CDNs.62,	63,	88	X	ray	structures	showed	that	a	V	shaped	dimer	
of	STING’s	C-terminal	domain	binds	to	a	V-shaped	c-di-GMP	monomer	at	the	interface	of	the	STING	
dimer	(Figure	2.4).	Isothermal	titration	calorimetry	showed	c-di-GMP	binds	to	STING	with	high	affinity	
(Kd	2.5–5	μM).63	Additionally,	Parvatiyar	et.	al	proved	that	another	protein	DDX41	has	greater	binding	
affinity	for	CDNs	(Figure	2.6).	It	was	hypothesized	that	DDX41	was	the	main	sensor	of	c-di-GMP	and	c-
di-AMP	 and	 operated	 upstream	 of	 STING.89	 STING’s	 recognition	 of	 CDNs	 as	 the	 danger	 signal	 and	
stimulation	 of	 immune	 response	 against	 bacterial	 infection	 suggested	 that	 CDNs	 could	 be	 used	 as	
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innate	 immune	 agonists.	 Encouragingly,	 in	 the	 preclinical	 development,	 c-di-GMP	 proved	 to	 be	 a	
potential	vaccine	adjuvant	against	mucosal	infections.90	
Very	recently,	STING	activation	was	found	to	be	triggered	by	a	new	type	of	CDN,	c-GAMP,	the	first	
known	CDN	produced	in	animals.66	When	the	pathogen	enters	the	host	cell,	its	dsDNA	will	be	detected	
by	c-GAMP	synthase	(cGAS)	in	the	cytosol.	Upon	binding	dsDNA	cGAS	produces	c-GAMP	which	then	
binds	to	STING,	turning	on	a	downstream	immune	response.68	The	structure	of	c-GAMP	was	presumed	
to	be	similar	to	previous	CDNs	by		Wu,66	but	soon	it	was	revised	to	be	c-G(2',5')pA(3',5')p	by	Gao.67	The	
2ʹ-5ʹ	phosphodiester	 linkage	is	very	unusual.	Very	few	nucleases	are	known	to	be	able	to	hydrolyze	
such	a	linkage.	The	exact	structure	was	carefully	co-examined	by	X-ray,	HPLC	and	NMR	analysis	(Figure	
2.5).	In	the	NMR	spectrum	of	c[G(2ʹ-5ʹ)pA(3ʹ-5ʹ)p],	the	1’	position	proton	of	guanosine	(the	proton	in	
blue,	Figure	2.5C)	is	a	doublet	(3JHH	=	9	Hz),	but	1’	position	proton	of	adenosine	a	singlet	(the	proton	in	
red,	Figure	2.5C)	when	the	phosphate	ester	is	attached	to	the	3ʹ	position.	Combined	with	X-ray	analysis,	
the	structure	of	this	unusual	CDN	was	confirmed.	This	unusual	2ʹ-5ʹ	 linkage	has	greater	affinity	and	
stronger	activation	towards	human	STING	than	exogenous	3ʹ-5ʹ	linkage	CDNs,	thus	strongly	boosting	
antigen-specific	T	cell	activation	and	antibody	production.	This	antiviral	property	of	this	non-canonical	
CDN	attracts	great	interest	as	a	drug	adjuvant	in	treating	HIV	and	Herpes	virus.68	
Figure	2.5	Structure	study	of	c-G(2',5')pA(3',5')p	by	X-ray,	HPLC	and	proton	NMR	analysis	
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Figure	2.6	CDNs	signaling	in	innate	immune	system.	[Reprinted	with	permission	from	Nature	Publishers	Ltd:	[Nat	Rev	
Micro	(R.	M.	Corrigan	and	A.	Grundling,	Nat	Rev	Micro,	2013,	11,	513-524),	copyright	(2013)].		
CDNs	are	good	 factors	 for	 activating	 STING	 (Figure	2.6),	 thus	 stimulating	 the	expression	of	 various	
interferons,	cytokines	and	T	cell	recruitment	factors.	They	could	be	employed	in	cacer	immunotherapy	
to	amplify	and	strengthen	immune	activity.	Aduro	Biotech	has	proved	that	CDNs	and	their	derivatives	
generate	a	potent	immune	response	in	preclinical	models	that	specifically	attacks	tumor	cells.91-93	The	
development	of	next	generation	cancer	immunotherapies	targeting	the	STING	pathway	has	raised	a	
great	hope	for	cancer	patients.91,	94	
In	summary,	3’-5’	CDNs	produced	by	bacteria	act	as	key	factor	in	regulating	their	 lifestyle.	They	are	
recognized	in	the	host	cell	as	exogenous	alarmins	by	the	innate	immune	sensor	STING.	Endogenous	
production	of	 2’-3’	 c-di-GAMP	 is	 stimulated	 after	 detection	of	 pathogens’	 dsDNA	 leading	 to	 STING	
activation	(Figure	2.6).	The	exogenous	or	endogenous	CDNs	interacting	with	STING	study	provides	a	
great	 perspective	 in	 stimulating	 innate	 immune	 system	 for	 treatment	 of	 chronic	 infection,	
inflammatory	states,	and	cancer	immunotherapy.		
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2.2	Rh	catalyzed	NHI	for	customization	of	CDNs	
2.2.1	Previous	synthesis	and	modification	of	CDNs	
Given	the	diverse	roles	of	CDNs	in	prokaryotes	and	eukaryotes,	great	efforts	have	been	devoted	to	the	
synthesis	of	CDNs	and	their	derivatives.	A	One-Pot	synthesIs	of	3’-5’-c-di-GMP	and	its	thiophosphate	
analogues	developed	by	Gaffney	et	al	made	large	scale	CDNs	accessible	(Scheme	2.1).95	They	started	
the	total	synthesis	with	the	most	common	commercially	available	phosphoramidite.	After	8	step	 in	
one	flask,	gram	scale	of	CDNs	could	be	obtained	within	2	days.	This	method	is	also	applicable	in	the	
synthesis	 of	 c-G(2',5')pA(3',5')p	 and	 its	 thiophosphate	 derivative	 utilizing	 DMT-3'O-TBDMS-	 2'O-
phosphoramidite.67	
	
Scheme	2.1	One-Flask	Syntheses	of	c-di-GMP	
Levels	 of	 CDNs	 are	 regulated	 by	 synthases	 and	 phosphodiesterases	 in	 biological	 conditions.	
Phosphorothioate	was	introduced	to	prevent	enzymatic	hydrolysis	because	this	artificial	linkage	can	
not	be	recognized	by	phosphodiesterases.	The	thioester	derivatives	have	similar	binding	affinities	to	
natural	 occurring	 CDNs.	 This	 has	 made	 the	 study	 of	 CDNs	 in	 artificial	 biological	 models	 possible	
(Scheme	2.2).	The	thioester	derivatives	of	CDNs	have	been	tested	in	many	medical	trials	due	to	CDNs’	
potent	impact	on	the	innate	immune	system.	For	example,	the	structural	analogue	dithio-(RP,	RP)-[c-
A(2ʹ,5ʹ)pA(3ʹ,5ʹ)p]	was	shown	to	generate	a	potent	anti-tumor	response	in	mouse	tumor	models.93	
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Scheme	2.2	CDNs	and	their	phosphorothioate	derivatives	engineered	for	phosphodiesterase	resistance	
When	we	started	our	project	 in	2013,	 the	modification	of	previous	work	on	CDN	modification	had	
focused	on	making	changes	 to	 the	phosphate	 linkage	or	2’	position	of	 the	 ribose.96	For	example,	a	
propargyl	group	was	introduced	at	2’	position	of	the	phosphoramidite	before	the	total	synthesis.	The	
propargylated	 CDNs	 provide	 the	 possibility	 for	 conjugating	 other	 functional	 groups	 like	 biotin	 or	
fluorescent	tags.97	Direct	modification	of	CDNs	was	reported	with	more	than	a	thousand	equivalents	
of	N-methylisatoic	anhydride	in	the	presence	of	1M	NaOH,	however	the	yield	was	not	clear,	and	the	
structure	of	the	product	was	only	confirmed	by	tandem	MS.98	
	
Scheme	2.3	previous	modification	of	CDNs	
Unravelling	 and	 reprogramming	 the	 complex	 biology	 of	 CDNs	 hinges	 on	 the	 ready	 availability	 of	
chemically	tailored	variants.	While	total	chemical	synthesis	gives	access	to	any	variation,	substantial	
expertise	and	labor	are	required.	Direct	modification	is	simpler,	but	until	now	these	have	focused	on	
changes	in	the	phosphate	linkage	or	2’	position	of	the	ribose	with	very	low	efficiency.		
	
2.2.2	Preparative	synthesis	of	exo-amine	modified	CDNs	
In	this	chapter,	our	development	of	a	one-step	method	to	target	the	exocyclic	amine	of	nucleobases	
in	 all	 types	 of	 natural	 3’-5’-linked	 CDNs	 utilizing	 catalytic	 rhodium-based	 carbene	 transfer	 will	 be	
discussed.	 Direct	 nucleobase	 modification	 has	 never	 explored,	 but	 would	 provide	 an	 important	
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complement	to	previous	approaches.	As	we	discussed	in	chapter	1,	metal	catalyzed	carbene	reactions	
have	emerged	as	a	powerful	technology	in	chemical	biology.	Our	group	recently	has	developed	Rh-
catalyzed	NHI	with	diazo	as	a	new	tool	for	modifying	nucleobases	in	DNA	and	RNA.	While	the	technique	
is	unselective	in	long	single-stranded	oligos,	CDNs	presented	the	more	tractable	problem	of	selecting	
between	only	two	reactive	N–H	groups.		
The	test	reaction	started	with	c-di-GMP	and	methyl	2-(4-azidophenyl)-2-diazoacetate	(Scheme	2.4).		
While	the	initial	reaction	started	with	10mM	c-di-GMP,	no	modification	was	observed.	C-di-GMP	forms	
interesting	polymorphism	of	various	oligomeric	forms	at	millimolar	concentrations,	which	causes	base	
stacking	 and	G-quartet	 interactions.99,	 100	When	 the	 c-di-GMP	 concentration	was	 reduced	 to	 2mM,	
within	 20min,	 58%	 of	 c-di-GMP	 was	 converted	 to	 the	 desired	 product.	 After	 preparative	 HPLC	
purification,	39%	isolated	yield	was	obtained	(see	also	in	Table	2.1,	entry	4).	The	modified	position	was	
confirmed	 by	 2D-NMR	 spectra.	 NMR	 assignments	 are	 available	 in	 the	 experimental	 part.	 The	
microscale	thermophoresis	confirms	that	the	modified	CDN	bounds	to	its	receptor	protein	DgrA	at	a	
similar	level	as	the	natural	CDN,	validating	the	exocyclic	amine	as	a	viable	site	for	modification	in	the	
study	of	CDN	biology.		
	
Scheme	2.4		Direct	purine	exocyclic	amine	modification	of	c-di-GMP		
A	handful	of	diazo	compounds	bearing	common	functional	tags	(amine	for	water	solubility,	azide	for	
photo-crosslinking,	alkyne	for	click	chemistry)	were	synthesized	and	tested	with	CDNs	(see	Table	2.1).	
The	reactions	deliver	mainly	mono-modified	CDNs	along	with	some	unproductive	O-H	insertion	of	the	
diazo	 starting	material	 (hence	 10	 equivalents	 are	 required);	 in	 some	 cases	minor	 double-modified	
products	 are	 also	 observed	 (0-18%).	 As	 shown	 in	 Table	 2.1	 the	 conversions	 range	 from	 33-80%	
depending	upon	the	precise	substrate	and	diazo	compound.	The	reactions	are	fast,	requiring	at	most	
2	 hours	 to	 reach	 completion	 (entry	 1-3,	 Table	 2.1).	 We	 also	 investigated	 the	 phosphodiesterase	
resistant	phosphorothioate	derivative	c-di-GMPS.	Sulphur	derivatives	often	hinder	carbene	transfer	
reactions,	but	in	this	case	phosphorothioates	are	well-tolerated,	delivering	80%	conversion	and	41%	
isolated	yield	(entry	6,	Table	2.1).		
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Table	2.1	Rh-catalysed	N-H	insertion	of	CDNs	with	diazo	compound	
	
	
	 	 	 	 	 	
Entry	 CDN	 Ar	 Main	product	 Time	
(min)	
Conv	(%)	
(yield)a	
1	 c-di-GMP	
	
	
120	 51	(39)	
2	 c-di-AMP	
	
	
120	 33b	
3	 c-GAMP	
	
	
120	 73	(19)	
4	 c-di-GMP	
	
	
20	 58	(40)	
5	 c-GAMP	
	
	
60	 67	(25)	
6	 c-di-GMPS	
	
	
50	 80	(41)	
7	 c-di-GMP	
	 	
120	 30b	
	 	
a	yield	after	prep-HPLC;	b	yield	not	determined	due	to	low	conversion.	
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Figure	 2.7	MS–MS	analysis	 of	 alkylation	 products.	Panel	 A:	 the	major	 product	 from	entry	 3	 in	 Table	2.1	delivered	 a	
daughter	ion	consistent	with	guanine	alkylation;	panel	B:	the	minor	product	was	consistent	with	adenine	alkylation;	panel	
C:	the	only	isolated	product	from	entry	5	in	Table	2.1	delivered	a	daughter	ion	consistent	with	guanine	alkylation.	
One	unexpected	observation	in	Table	2.1	relates	to	the	mixed	dinucleotide	c-GAMP:	in	the	case	of	the	
dimethylamino	derived	diazo	compound	a	mixture	of	guanine	and	adenine	modified	products	were	
obtained	in	a	2	:	1	mixture	according	to	HPLC	analysis	(entry	3,	Table	2.1),	but	with	the	azide	containing	
diazo	substrate	targeting	of	the	guanine	was	far	more	selective	(entry	5,	Table	2.1	>80%	selectivity	for	
G	 alkylation	 according	 to	 integration	 of	 HPLC).	 The	 structures	 of	 the	 products	 were	 gleaned	
independently	from	NMR	(ROESY,	HMQC,	and	HMBC,	see	the	experimental	part	for	details)	and	MS–
MS	 fragmentation	 (Figure	 2.7).	With	 the	 sample	 from	 entry	 3	 in	 Table	 2.1,	 the	major	mass	 peaks	
matched	the	guanine-modified	structure	(see	panel	A,	Figure	2.7).	In	contrast,	the	minor	product	from	
entry	 3	 in	 Table	 1	delivered	 the	modified	 adenine	 fragment	 (panel	 B,	 Figure	 2.7);	while	 the	 azide-
containing	diazo	substrate	(entry	5,	Table	2.1)	almost	exclusively	targeted	the	guanine	(panel	C,	Figure	
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2.7).	Alkylation	on	the	phosphate	was	ruled	on	the	basis	that	there	was	a	strong	HMBC	correlation	
between	the	α-hydrogen	derived	from	the	diazo	substrate	and	the	nearest	carbon	on	the	nucleobase	
in	each	case.	We	had	expected	that	the	unsymmetrical	CDN	c-GAMP	would	represent	a	substantial	
challenge	 in	 chemoselectivity	 since	 adenine	 and	 guanine	 display	 similar	 functional	 groups	 to	 the	
catalyst.	However,	as	entries	3	and	5	demonstrate,	the	substrate	can	play	a	role	in	controlling	the	site-
selectivity.	The	source	of	the	change	could	be	related	to	the	charge	of	the	dimethylamino	group,	or	
the	 propensity	 of	 certain	 CDNs	 to	 form	higher-order	 aggregates	 in	 solution.	 Although	 the	 product	
mixture	 obtained	 from	 entry	 3	 of	 Table	 2.1	 was	 more	 complex,	 we	 were	 able	 to	 separate	 each	
component	(the	39%	reported	yield	corresponds	to	the	mixture)	and	therefore	c-GAMP	derivatives	are	
available	with	alterations	at	either	base	through	one	protocol.	
In	 prokaryotes	 CDNs	 are	 involved	 in	 a	 complicated	 regulatory	 network	 involving	 a	 multitude	 of	
individual	protein	components	and	several	riboswitches.	The	modified	CDN	derivatives	shown	in	Table	
1	 are	 versatile	 starting	 points	 for	 exploring	 the	 biology	 of	 these	 second	messenger	molecules.	 For	
example,	the	azide	motif	can	be	converted	to	a	fluorescent	CDN	derivative	through	a	catalytic	azide-
alkyne	cycloaddition	(Scheme	2.5).	Furthermore,	the	aryl	azide	itself	is	a	common	photo-crosslinking	
group	and	therefore	compounds	such	as	those	found	in	Table	2.1	(entries	4-6)	could	be	used	to	probe	
binding	sites	of	c-di-GMP	receptors.	Although	2’-hydroxyl	derived	probes	are	known,	a	family	of	photo-
crosslinkers	is	important	since	different	receptors	will	have	different	binding	constraints.	
	
	
Scheme	2.5	Synthesis	of	a	fluorescent	CDN	derivative	through	a	catalytic	azide–alkyne	cycloaddition	
2.2.3	Photocrosslinking	of	modified	CDN	with	its	receptor	protein	
To	explore	the	photo-crosslinking	of	azide-modified	CDNs	we	selected	the	known	c-di-GMP	receptor	
DgrA,	 a	 PilZ	 homolog	 that	 mediates	 c-di-GMP-dependent	 control	 of	 Caulobacter	 crescentus	 cell	
motility.	Its	high	affinity	and	specificity	towards	c-di-GMP	and	the	availability	of	binding	mutants	make	
this	protein	an	ideal	test	bed.	The	aryl	azide	modified	c-di-GMP	(c-di-GMP-N3)	was	incubated	with	the	
protein	for	15	h	under	366	nm	irradiation	(see	top	of	Figure	2.8).	The	mixtures	were	analyzed	by	high-
resolution	ESI	mass	spectrometry,	gel	electrophoresis,	MALDI-TOF,	and	finally	the	site	of	modification	
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was	determined	by	a	trypsin	digest	(see	experimental	for	details).	Even	with	a	single	equivalent	of	c-
di-GMP-N3	(lane	3,	Figure	2.8)	DgrA	was	covalently	modified	in	a	yield	of	17%	(according	to	integration	
of	the	gel	bands).	At	10	equivalents	of	c-di-GMP-N3	there	was	complete	conversion	(lane	8,	Figure	2.8),	
but	the	diffuse	bands	suggested	competitive	unspecific	modification.	Previous	work	has	shown	that	
Arg11,	 Arg12,	 and	 Trp75	 are	 important	 residues	 for	 c-di-GMP	 binding	 of	 dgrA:	 A	 W75A	 mutant	
decreased	binding	102-103-fold,	while	binding	was	completely	abrogated	 in	the	R11A/R12A	double	
mutant.	Consistent	with	the	reported	binding	studies,	reaction	of	c-di-GMP-N3	with	the	W75A	mutant	
gave	reduced	crosslinking	(cf.	lane	5	versus	lane	3,	Figure	2.8)	and	the	R11A/R12A	was	not	detectably	
modified	(lane	7).	A	trypsin	digest	of	the	photo-crosslinking	reaction	revealed	one	new	peak	in	the	LC-
MS	whose	mass	was	consistent	with	modification	of	the	GGR	peptide	fragment	shown	in	red	in	Figure	
2.8.	This	tripeptide	sits	directly	 in	the	region	of	the	purported	c-di-GMP	binding	site	(blue	 in	Figure	
2.8).	 Taken	 together	 these	 results	 demonstrate	 that	 c-di-GMP-N3	 is	 a	 selective	 cross-linking	 probe	
efficient	enough	to	determine	binding	sites	in	CDN	receptors.	
	
	
Figure	2.8	Modified	c-di-GMP-N3	maintains	binding	to	DgrA	and	can	be	used	for	photo-crosslinking.	The	peak	at	14059.2	
is	 likely	 a	 post-translational	modification	which	 is	 also	 cross-linked	with	 the	 azide	 compound	 (14910.7).	 The	 baseline	
impurities	in	the	ESI	stem	from	gradual	photolytic	degradation	of	DgrA	
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2.2.4	Conclusion	
In	summary,	we	describe	a	direct	method	for	the	synthesis	of	CDN	derivatives	modified	at	the	exocyclic	
amine	of	the	purine	bases.	This	method	tolerates	all	members	of	the	cyclic	dinucleotide	family	and	
could	be	used	 to	modulate	 their	 function	or	 introduce	useful	 side-chains	 such	as	 fluorophores	and	
photo-crosslinking	 groups.	 The	 reaction	 is	 trivial	 to	execute,	making	 it	 accessible	 to	non-experts	 in	
synthesis	and	catalysis.	The	most	synthetically	challenging	aspect	of	the	approach	is	in	the	synthesis	of	
the	diazo	compounds,	which	typically	require	3-5	operations.	
New	aspects	of	CDN	biology	are	continually	being	unveiled.	A	challenge	for	chemical	biologists	is	to	
provide	a	selective	probe	for	each	natural	CDN	receptor.	The	process	we	have	described	adds	a	new	
method	for	such	bespoke	probe	development.		
Further	 study	 could	be	 continued	 in	 two	directions	due	 to	 the	 important	 role	of	CDNs	 in	 chemical	
biology.	How	modifications	of	the	exocyclic	amine	of	CDNs	behave	with	innate	immune	sensor?	Will	
the	covalent	linked	CDNs	and	receptor	(CDN-STING	for	example)	stimulate	the	immune	response	since	
the	receptor	is	in	the	constant	active	form?	Answering	these	questions	might	offer	new	insights	for	
CDN	inspired	therapeutics.	
2.3	Copper	catalyzed	NHI	with	diazo	compound	
I	was	involved	in	this	project	with	Kiril	Tishnov,	and	contribute	my	work	in	double-stranded	DNA	motif	
alkylation	and	the	auto-tandem	catalytic	reaction.	
Our	group	recently	reported	Rh-carbenoids	derived	from	α-diazo	carbonyl	compounds	can	target	the	
exocyclic	N–H	group	of	various	nucleic	acids	including	short	ssDNA,	hairpin	DNA,	ssRNA,	hairpin	RNA	
and	CDNs.	 The	dominance	of	 rhodium-based	 catalysts	has	 left	Cu(I)	 systems	underdeveloped	even	
though	they	were	reported	earlier	than	Rh	(See	the	discussion	in	Chaper	1).	Tracing	through	the	past	
years	of	developments,	there	are	a	few	reactions	employing	cooper	as	the	XHI	catalyst	 in	chemical	
biology.	In	the	sixties	large	excesses	of	Cu(II)	salts	were	used	to	effect	protein		modification		with	diazo	
peptides.31,	32	A	very	recent	report	has	shown	that	intramolecular	Cu-catalyzed	cyclopropanation	can	
be	carried	out	 in	aqueous	media	using	DNA	as	a	chiral	control	element.	These	observations	hint	at	
unrealized	 potential	 for	 catalytic	 Cu(I)-carbenoid	 chemistry	 in	 water.101	 Combined	 with	 recently	
development	 of	 Cu(I)-carbenoids	 with	 diazo	 compounds	 in	 XHI	 reactions,	 it	 could	 offer	 another	
possibility	for	introducing	unnatural	chemical	motifs	into	native	nucleic	acid.	Additionally	the	Cu(I)	is	
also	a	well-known	catalyst	in	click	reaction	which	enable	the	efficient	and	straight-forward	introduction	
of	 a	 variety	of	 functionally	 important	 tags	 and	 reporter	 groups.	 Thus	 the	Cu(I)	 in	 the	NHI	 reaction	
system	could	be	also	used	for	click	reaction.	
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2.3.1	Copper	(I)	catalyzed	NHI	in	dsDNA	alkylation	
Given	our	interest	in	catalytic	methods	for	NA	alkylation,	our	initial	examination	of	the	catalytic	NHI	
started	with	the	short	oligonucleotide	d(ATGC)	in	aqueous	MES	buffer	at	pH	6.	Further	refinement	of	
the	reaction	conditions,	including	testing	different	ligands	and	copper	sources,	led	to	a	convergence	
with	 the	CuAAC	conditions	 for	bioconjugation	developed	by	Finn.	The	key	components	of	 the	Finn	
conditions	are	sodium	ascorbate	and	the	tris(3-hydroxypropyltriazolyl-	methyl)amine	(THPTA)	ligand.	
Ascorbate	 insures	 the	 Cu(I)	 oxidation	 state	 is	 maintained	 even	 in	 the	 presence	 of	 oxygen.	 A	
consequence	of	Cu(I)	in	the	presence	of	oxygen	is	the	formation	of	reactive	oxygen	species	(ROS).	The	
role	of	the	THPTA	ligand	seems	to	be	as	a	sacrificial	substrate	to	scavenge	ROS	before	they	damage	
nucleic	acid.	The	modification	of	the	model	oligonucleotide	d(ATGC)	was	a	lot	more	efficient	than	with	
Rh,	as	the	conversion	of	up	to	70%,	accompanied	by	formation	of	over	twelve	alkylation	products	were	
observed.	Other	short	ssDNA	oligomers	were	also	tested	within	this	system.	It	gave	higher	conversion	
and	 more	 alkylation	 sites	 compared	 to	 rhodium	 catalyzed	 system.	 Based	 on	 LC-MS	 date,	 the	
modification	is	mainly	on	the	base,	could	be	exo	and	endocyclic	nitrogen,	but	we	could	not	completely	
characterize	these	products	due	to	insufficient	material.		
The	propensity	of	double-stranded	DNA	motifs	to	react	was	tested	on	three	hairpin	structures	(Table	
2.2).	All	three	hairpins	were	significantly	less	reactive	than	the	single-stranded	NAs	tested,	delivering	
only	modest	yields	of	modified	DNA	at	extended	reaction	times.	As	expected	the	hairpin	containing	
only	 Ts	 in	 the	 loop	 proved	 to	 be	 the	 least	 reactive	 with	 only	 9%	 conversion.	 In	 comparison	 the	
remaining	two	hairpins	exhibit	a	two-fold	increase	in	reactivity.	These	contain	an	unpaired	A	as	either	
a	3ʹ-overhang	or	in	the	loop	region,	indicating	that	copper	preferentially	targets	nitrogens	that	are	not	
involved	in	Watson–Crick	base-pairing.	
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Table	2.2	hairpin	DNA	modification	
	
	
Based	 on	 the	 fact	 that	 our	 NHI	 process	 is	 fully	 compatible	 with	 the	 Cu-catalyzed	 azide–alkyne	
cycloaddition	 (CuAAC),	 therefore	 we	 attempted	 to	 investigate	 the	 possibility	 of	 a	 simultaneous	
CuAAC/NHI	 process.	 The	 concept	 was	 tested	 with	 a	 collection	 of	 different	 amines,	 alkynes,	 diazo	
compounds,	and	azides	as	shown	in	Table	2.3.	Our	initial	experiments	with	small	molecule	substrates	
and	in	all	cases	the	N-aryl	triazole/NHI	products	were	obtained	in	good	yields	(53–70%).	Furthermore,	
changing	 the	 position	 of	 the	 participating	 functional	 groups	 had	 little	 impact	 on	 the	 reaction.	 The	
system	was	later	tested	with	more	challenging	DNA-based	substrates	and	as	we	expected	it	gave	two	
consecutive	modifications	in	one	pot	reaction.	
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Table	2.3	Auto-tandem	catalytic	CuAAC/NHI	
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2.3.2	Conclusion	
Our	work	 outlines	 a	 novel	 approach	 for	molecular	 conjugation	 based	 on	 the	 discovery	 that	 Cu(I)-
carbenoid	chemistry	is	viable	in	water.	The	efficacy	of	Cu(I)	for	catalyzing	both	CuAAC	and	NHI	drove	
us	to	combine	both	reactions	in	a	one-pot	operationally	simple	process.	The	substrate	range	includes	
simple	arylamines	as	well	as	the	nucleobases	in	DNA	and	RNA.	This	multi-component	catalytic	process	
not	 only	 reduces	 the	 set	 up	 cost	 but	 also	 saves	 purification	 labor	work.	 It	 should	 prove	useful	 for	
medicinal	and	combinatorial	chemists	since	it	provides	a	robust	strategy	to	quickly	assemble	complex	
molecular	scaffolds.		
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2.4	Experimental	part	
2.4.1	General	
All	reagents	and	solvents	used	were	of	analytical	grade.	Buffers	were	prepared	with	ultrapure	water.	
All	chemicals	were	purchased	from	Sigma-Aldrich,	Fluka	or	Acros	and	used	as	received.	Analytical	TLC	
was	 performed	 on	 Silica	 gel	 60	 F254	 pre-coated	 aluminium	 sheets.	 Flash	 chromatography	 was	
performed	 on	 Silica	 gel	 60	 40-63	µm	 (230-400	mesh)	 (SiliCycle,	Quebec).	 1H	 and	 13C	NMR	 and	 2D	
spectra	of	modified	CDN	were	acquired	on	a	Bruker	AvanceIII+	600	MHz	using	Shigemi	NMR	tube.	
Other	compounds	were	recorded	on	400	MHz	proton	frequency	spectrometer	at	298	K.	Chemical	shifts	
relative	to	TMS	were	referenced	to	the	solvent’s	residual	peak	and	are	reported	in	ppm.	ESI	MS-MS	
spectra	 were	 obtained	 on	 a	 Bruker	 Esquire3000plus	 spectrometer	 by	 direct	 injection	 in	 positive	
polarity	of	the	ion	trap	detector.	High	resolution	mass	spectra	were	acquired	on	a	Bruker	maXis	4G	
QTOF	 ESI	 mass-spectrometer.	 MALDI	 TOF	 analyses	 were	 carried	 out	 on	 a	 Bruker	Microflex	 mass-
spectrometer	in	linear	positive	mode	using	sinapic	acid	as	matrice.	HPLC	procedures	were	carried	out	
on	an	Agilent	1100	LC	system	equipped	with	Eclipse	XDB-C8	5µm	4.6	x	100	mm	column	(Agilent)	for	
analytic	analysis.	Shimadzu	preparative	HPLC	(LC-20AP)	equipped	with	phenomenex	column	(Gemini®	
10	µm	C18	110	Å,	LC	Column	250	x	21.2	mm,	AXIA™	Packed)	was	employed	for	preparative	purification.	
100	mM	triethylammonium	acetate	(pH	7.2)	and	acetonitrile	was	used	as	a	mobile	phase.	For	analytical	
measurement:	1	mL/min:	0-35	%	acetonitrile	in	12	min,	35-80	%	acetonitrile	in	3	min,	80%	acetonitrile	
in	2	min.	For	preparative	separation:	flow	rate:	20	mL/min,	0%	acetonitrile	in	2	min,	0-60	%	acetonitrile	
in	27	min.	Detection	was	carried	out	by	monitoring	the	absorbance	of	the	column	effluent	at	254	nm.	
UV	cross	linking	reaction	was	carried	out	with	CAMAG	TLC	UV	lamp	at	366	nm.	The	sample	was	placed	
2	cm	away	from	the	UV	lamp.	
2.4.2	 General	 procedure	 for	 Rh2(OAc)4-catalyzed	 CDN	 modification	 with	 diazocarbonyl	
compounds.		
For	analytical	reactions,	typically	20	µL	reaction	mixtures	containing	2	mM	oligonucleotide,	200	µM	
Rh2(OAc)4	and	20	mM	a-diazocarbonyl	compound	in	100	mM	MES	buffer,	pH	6.0	were	reacted	at	room	
temperature.	Only	aryl	azide	diazo	modification	of	CDN	was	carried	out	in	50%	water	and	50%	t-BuOH	
due	to	the	solubility	of	aryl	azide	diazo	compound.	The	reaction	was	traced	by	analytic	HPLC	and	the	
identity	of	the	product	in	each	fraction	was	confirmed	by	HR-ESI.		
To	 obtain	 enough	 products	 for	 NMR	 characterization	 preparative	 reactions	 were	 run	 on	 a	 24	mL	
reaction	scale.	For	example	4.8	mL	10	mM	c-di-GMP,	2.4	mL	2	mM	Rh2(OAc)4	and	12	mL	40	mM	aryl	
azide	diazo	in	t-BuOH	and	additional	4.8	mL	water	were	mixed	together.	The	reaction	finished	in	30	
minutes.	3	mL	ethyl	acetate	was	added	to	the	reaction	mixture	to	remove	the	organic	side	product,	
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and	aqueous	layer	was	freezed	dried	and	applied	to	preparative	HPLC	for	purification.	The	modified	
compounds	 were	 freeze	 dried	 and	 confirmed	 by	 HRMS	 (ESI)	 and	 NMR.	 In	 some	 cases,	 pure	
diastereomers	could	be	separated.	However	epimerization	occurred	very	faster	after	purification.	Due	
to	 epimerization	 and	 low	 conversion,	 only	 c-di-GMP-N3	 and	 C-GAMP-N3	 pure	 diastereomers	 were	
successfully	characterized	by	2D	NMR,	and	the	modification	on	the	exocyclic	amine	of	guanine	was	
confirmed	by	COSY,	HMQC,	and	separately	by	MS-MS	analysis.	
	
	
12	mL	reaction	mixtures	containing	2	mM	c-di-GMP,	200	µM	Rh2(OAc)4	and	20	mM	a-diazocarbonyl	
compound	in	100	mM	MES	buffer,	pH	6.0	were	kept	at	room	temperature	for	3h.	The	reaction	was	
traced	by	analytic	HPLC	(conv.	51%)	and	the	mixture	of	diasteromer	was	isolated	by	preparative	HPLC	
(39%).	1H	NMR	(600	MHz,	DMSO)	δ	8.01	(d,	J	=	7.4	Hz,	1H),	7.99	–	7.93	(m,	2H),	7.43	(t,	J	=	8.2	Hz,	2H),	
7.35	(dd,	J	=	13.6,	8.0	Hz,	3H),	7.25	(d,	J	=	7.9	Hz,	1H),	6.62	(s,	2H),	6.29	(s,	1H),	5.77	(t,	J	=	8.0	Hz,	1H),	
5.67	(d,	J	=	8.2	Hz,	1H),	5.41	(dd,	J	=	19.0,	6.2	Hz,	1H),	4.89	(s,	1H),	4.65	(dd,	J	=	38.2,	17.6	Hz,	4H),	4.18	
(dd,	J	=	10.5,	5.8	Hz,	2H),	4.00	(s,	2H),	3.79	(dd,	J	=	21.2,	11.1	Hz,	3H),	3.69	(d,	J	=	14.0	Hz,	3H),	2.45	(q,	
J	=	7.1	Hz,	6H),	1.87	(s,	6H),	0.94	(t,	J	=	7.1	Hz,	9H).HRMS	(ESI):	calcd	for	[C32H40N11O16P2]+	896.2051,	
found	896.2121.		
	
S	2.1	HPLC	trace	
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S	2.2	NMR	assignment	
	
	
S	2.3	1H	NMR	in	DMSO,	313	K,	600	MHz	
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S	2.4	13C	NMR	in	DMSO,	313	K,	600	MHz	
	
S5	31P	NMR	in	DMSO,	313	K,	600	MHz	
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		S6 
S	2.6	HMQC	spectrum	in	DMSO,	313	K,	600	MHz	
	
S	2.7	COSY	spectrum	in	DMSO,	313	K,	600	MHz	
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12	 mL	 reaction	 mixtures	 containing	 2	 mM	 c-GAMP,	 200	 µM	 Rh2(OAc)4	 and	 20	 mM	 aryl	 azide	
diazocarbonyl	compound	in	50%	water	and	50%	t-BuOH	were	kept	at	room	temperature	for	30	min.	
The	reaction	was	traced	by	analytic	HPLC	(conv.	67%)	and	isolated	by	preparative	HPLC	(iso.	22%).	1H	
NMR	(600	MHz,	MeOD)	δ	8.44	(s,	1H),	8.15	(s,	1H),	8.04	(s,	1H),	7.55	(d,	J	=	8.4	Hz,	2H),	7.10	(d,	J	=	8.5	
Hz,	2H),	6.08	(s,	1H),	5.82	(s,	1H),	5.61	(s,	1H),	5.00	(s,	1H),	4.95	(d,	J	=	4.7	Hz,	1H),	4.41	–	4.29	(m,	5H),	
4.13	–	4.09	(m,	2H),	3.78	(s,	3H),	3.20	(q,	J	=	7.3	Hz,	3H),	1.30	(t,	J	=	7.3	Hz,	5H).	13C	NMR	(151	MHz,	
MeOD)	 δ	 173.10,	 159.23,	 156.91,	 153.10,	 150.92,	 150.00,	 142.03,	 141.10,	 138.05,	 135.32,	 131.05,	
120.67,	91.77,	91.43,	82.30,	82.06,	75.96,	75.77,	72.91,	72.70,	64.10,	59.62,	53.77,	49.44,	49.30,	49.15,	
9.51.	31P	NMR	(243	MHz,	MeOD)	δ	-0.67,	-0.84.	HRMS	(ESI):	calc’d	for	[C29H32N13O15P2]+	=	864.5821;	
found	864.1605.	
	
S	2.8	HPLC	trace	
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S	2.9	MS/MS	fragment	of	product	
	
S	2.10	NMR	assignment	
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S	2.11	1H	NMR	in	CD3OD,	318	K,	600	MHz	
 
	
S	2.12	13C	NMR	in	CD3OD,	318	K,	600	MHz	
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S	2.13	13C	NMR	in	CD3OD,	318	K,	600	MHz	
	
	
12	mL	reaction	mixtures	containing	2	mM	c-GAMP,	200	µM	Rh2(OAc)4	and	20	mM	a-diazocarbonyl	
compound	in	100	mM	MES	buffer,	pH	6.0	were	kept	at	room	temperature	for	2h.	The	reaction	was	
traced	by	analytic	HPLC	(73%)	and	the	mixture	of	diasteromer	was	isolated	by	preparative	HPLC	(29%).	
1H	NMR	(600	MHz,	DMSO)	δ	10.67	–	10.45	(m,	2H),	8.42	(d,	J	=	10.8	Hz,	1H),	8.15	(s,	1H),	8.00	(s,	1H),	
7.96	(d,	J	=	17.9	Hz,	1H),	7.44	(t,	J	=	8.8	Hz,	2H),	7.40	–	7.31	(m,	2H),	7.27	(d,	J	=	11.3	Hz,	2H),	6.63	(s,	
1H),	6.54	(s,	1H),	5.88	(d,	J	=	7.7	Hz,	1H),	5.74	(d,	J	=	8.4	Hz,	1H),	5.66	(s,	1H),	5.43	(d,	J	=	6.1	Hz,	1H),	
5.39	(s,	1H),	4.95	(s,	1H),	4.86	(s,	1H),	4.75	(d,	J	=	34.2	Hz,	1H),	4.65	(d,	J	=	32.0	Hz,	2H),	4.20	(d,	J	=	19.9	
Hz,	2H),	4.02	(s,	1H),	3.93	(d,	J	=	26.0	Hz,	2H),	3.70	(d,	J	=	8.8	Hz,	3H),	1.91	(s,	6H).	HRMS	(ESI):	calc’d	
for	[C32H40N11O15P2.Et3N]	+	=	980.2102;	found	980.2210.		
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S	2.14	HPLC	trace	
	
S	2.15	MS/MS	fragment	of	main	product	
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S	2.16	MS/MS	fragment	of	side	product	
	
	
S	2.17	NMR	assignment	of	main	product:	major	diastereomer	
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S	2.18	NMR	assignment	of	main	product:	minor	diastereomer	
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12	mL	reaction	mixtures	containing	2	mM	c-di-GMP,	200	µM	Rh2(OAc)4	and	20	mM	a-diazocarbonyl	
compound	in	100	mM	MES	buffer,	pH	6.0	were	kept	at	room	temperature	for	3h.	The	reaction	was	
traced	by	analytical	HPLC	(conv.	51%)	and	the	mixture	of	diasteromers	was	 isolated	by	preparative	
HPLC	(39%).	1H	NMR	(600	MHz,	DMSO)	δ	8.01	(d,	J	=	7.4	Hz,	1H),	7.99	–	7.93	(m,	2H),	7.43	(t,	J	=	8.2	Hz,	
2H),	7.35	(dd,	J	=	13.6,	8.0	Hz,	3H),	7.25	(d,	J	=	7.9	Hz,	1H),	6.62	(s,	2H),	6.29	(s,	1H),	5.77	(t,	J	=	8.0	Hz,	
1H),	5.67	(d,	J	=	8.2	Hz,	1H),	5.41	(dd,	J	=	19.0,	6.2	Hz,	1H),	4.89	(s,	1H),	4.65	(dd,	J	=	38.2,	17.6	Hz,	4H),	
4.18	(dd,	J	=	10.5,	5.8	Hz,	2H),	4.00	(s,	2H),	3.79	(dd,	J	=	21.2,	11.1	Hz,	3H),	3.69	(d,	J	=	14.0	Hz,	3H),	2.45	
(q,	J	=	7.1	Hz,	6H),	1.87	(s,	6H),	0.94	(t,	J	=	7.1	Hz,	9H).HRMS	(ESI):	calc’d	for	[C32H40N11O16P2]+	=	896.2051;	
found	896.2121.	
S	2.20	HPLC	trace	of	reaction	mixture	and	purified	product	
	
49	
	
	
S	2.21	1HNMR	in	DMSO	600MHz	
	
20	µL	reaction	mixtures	containing	2	mM	c-di-GMP,	200	µM	Rh2(OAc)4	and	20	mM	a-diazocarbonyl	
compound	in	100	mM	MES	buffer,	pH	6.0	were	kept	at	room	temperature	for	2h.	The	reaction	was	
monitored	by	analytical	HPLC	(conv.	33%).	HRMS	(ESI):	calc’d	for	[C32H40N11O14P2.Et3N]	+	=	965.3358;	
found	965.3430.	
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S	2.22	HPLC	trace	of	reaction	mixture	and	purified	product	
 
2.4	 mL	 reaction	 mixtures	 containing	 2	 mM	 c-di-GMPS,	 200	 µM	 Rh2(OAc)4	 and	 20	 mM	 aryl	 azide	
diazocarbonyl	compound	in	50%	water	and	50%	t-BuOH	were	kept	at	room	temperature	for	50	min.	
The	reaction	was	monitored	by	analytical	HPLC	(80%)	and	the	product	 isolated	by	semi-preparative	
HPLC	(41%	yield).	The	pure	diastereomer	was	separated	by	HPLC,	however	it	epimerized	after	adding	
DMSO-d6.	1H	NMR	(600	MHz,	DMSO)	δ	7.98	(d,	J	=	3.1	Hz,	1H),	7.81	(dd,	J	=	33.5,	7.7	Hz,	1H),	7.65	–	
7.57	(m,	1H),	7.51	(d,	J	=	8.8	Hz,	2H),	7.34	(s,	1H),	7.19	(d,	J	=	8.4	Hz,	2H),	6.99	(s,	1H),	6.83	(s,	1H),	6.71	
(d,	J	=	22.8	Hz,	2H),	5.75	(d,	J	=	6.1	Hz,	1H),	5.65	(s,	1H),	5.47	(s,	1H),	5.40	(s,	1H),	4.80	(s,	1H),	4.72	(s,	
1H),	4.29	(s,	2H),	4.10	(s,	2H),	3.94	(dd,	J	=	24.2,	12.7	Hz,	2H),	3.69	(d,	J	=	18.7	Hz,	3H).	HRMS	(ESI):	
calc’d	for	[C29H31N13O16P2.2Et3N]+	=	1082.3896;	found	1082.3973.		
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S	2.23	HPLC	trace	of	reaction	mixture	and	pure	product	
 
S	2.24	1H	NMR	in	DMSO	600MHz	
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20	µL	reaction	mixtures	containing	2	mM	c-di-GMP,	200	µM	Rh2(OAc)4	and	20	mM	a-diazocarbonyl	
compound	in	100	mM	MES	buffer,	pH	6.0	were	kept	at	room	temperature	for	2h.	The	reaction	was	
traced	 by	 analytic	 HPLC	 (conv.	 30%).	 HRMS	 (ESI):	 calc’d	 for	 [C37H45N12O16P2]+	 =	 975.2473;	 found	
975.2488.	
	
S	2.25	HPLC	trace	of	reaction	mixture	
Click reaction to synthesize fluorescent tag on c-di-GMP 
	
S	2.26	preparation	of	fluorescent	tag	
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Rhodamine	 B	 (0.600	 g,	 1.35	mmol),	 2,3,4,5,6-pentafluorophenol	 (0.250	 g,	 1.36	mmol)	 and	 4-(N,N-
dimethylamino)pyridine	(0.021	g,	0.17	mmol)	were	dissolved	in	20	ml	of	dry	DCM	under	nitrogen	and	
N,N’-dicyclohexylcarbodiimide	 (0.327	 g,	 1.59	mmol)	 as	 a	 solution	 in	 2	ml	 of	 DCM	was	 added	with	
continuous	stirring.	The	mixture	was	stirred	at	room	temperature	until	complete	as	judged	by	TLC	(2	
h).	 It	 was	 then	 evaporated	 and	 the	 residue	 purified	 by	 column	 chromatography	 on	 Si60	 in	
DCM/methanol	to	afford	0.46	g	target	product	as	a	dark	purple	solid	(55%).	The	obtained	rhodamine-
pentafluoroester	 (0.092	 g,	 0.14	mmol)	 was	 dissolved	 in	 11	ml	 of	 dry	 acetonitrile	 and	 N-propargyl	
piperazine	(0.018	g,	0.17	mmol)	as	a	solution	in	2.5ml	of	acetonitrile	was	added	with	continuous	stirring	
under	nitrogen.	The	mixture	was	stirred	for	24	h	at	room	temperature,	then	evaporated	under	vacuum	
and	the	residue	purified	by	column	chromatography	on	Si60	in	DCM/methanol	(20:1	to	10:1)	to	afford	
a	deep	purplish-violet	solid	0.4	g	(40%).	1H	NMR	(400	MHz,	CDCl3)	δ	7.69	–	7.60	(m,	2H),	7.53	(dd,	J	=	
6.7,	2.1	Hz,	1H),	7.34	–	7.29	(m,	1H),	7.21	(d,	J	=	9.5	Hz,	2H),	6.91	(dd,	J	=	9.5,	2.2	Hz,	2H),	6.77	(d,	J	=	
2.4	Hz,	2H),	3.60	(dt,	J	=	11.9,	7.3	Hz,	8H),	3.37	(d,	J	=	37.7	Hz,	4H),	3.25	(d,	J	=	2.3	Hz,	2H),	2.68	(s,	2H),	
2.36	(s,	2H),	2.23	(s,	1H),	1.29	(t,	J	=	7.1	Hz,	13H).	13C	NMR	(101	MHz,	CDCl3)	δ	167.33,	157.65,	155.60,	
155.54,	135.30,	131.99,	130.35,	130.10,	129.82,	127.56,	113.97,	113.61,	96.29,	77.32,	77.00,	76.68,	
73.96,	51.42,	50.87,	47.16,	46.46,	46.01,	41.36,	12.52.	HRMS	(ESI):	calc’d	for	[C35H41N4O2]+	=	549.3224;	
found	549.3225.	
	
S	2.27	1HNMR	in	CDCl3	400MHz	
54	
	
	
S	2.28	13CNMR	in	CDCl3	400MHz	
A	reaction	mixture	of	0.4	mM	c-di-GMP-N3,	4	mM	Rhodamine	alkyne,	0.2	mM	CuSO4	and	0.16	mM	
sodium	ascorbate	was	left	over	night	and	check	by	HPLC	and	the	product	confirmed	by	HRMS	(ESI):	
Calc’d	for	[C64H72N17O18P2]+	=	1428.4711;	found	1428.4726.		
	
S	2.29	Click	reaction	of	fluorescent	c-di-GMP	
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S	3.30	HPLC	trace	of	click	reaction	of	fluorescent	c-di-GMP		
2.4.3	Protein	modification	
The	production	of	DgrA	and	 its	mutant	have	been	reported	previously.102	DgrA	was	subcloned	 into	
pET42b	vector	to	include	an	N-terminal	His6	tag	for	purification	of	the	protein.	The	construct	was	then	
transformed	into	Escherichia	coli	BL21	(DE3).	Cells	were	grown	in	LB	medium	at	37	°C	to	an	OD600	of	
approximately	0.6–0.9.	Protein	expression	was	induced	by	adding	IPTG	to	a	final	concentration	of	0.5	
mM	and	left	to	grow	for	another	2-3	hours.	Cells	were	collected	by	centrifugation	at	6,500	r.p.m.	and	
resuspended	in	15	ml	of	lysis	buffer	(20	mM	PBS,	pH	7.0)	per	liter	of	culture.	Resuspended	cells	were	
then	lysed	by	sonication,	and	cell	debris	was	removed	by	centrifugation	at	22,000	r.p.m.	0.7	mL	NTA	
solution	was	added	to	the	clear	 lysis	solution	and	stirred	for	half	an	hour	then	loading	onto	a	5-mL	
HisTrap	column	(GE	Healthcare).	Impurities	were	washed	away	with	20	mM	imidazole	in	lysis	buffer,	
and	target	protein	was	eluted	with	250	mM	imidazole.	The	peak	fractions	were	checked	by	SDS-PAGE,	
and	fractions	containing	the	target	protein	were	pooled	together	and	dialysis	 in	10	mM	PBS	buffer	
overnight.		
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Sequence	of	DgrA	
WT:	
MVMVETSGAERRAHPRMPAARKIYIVDDPRSWKASLLDVAEKGGRISIAGIASPPDTFVFVDAGGRRVHLANVVW
RSGTEVGVQFAATQRIGPRAGGAAGALEIARRFLATLPAEDDALEHHHHHHHH	
W75A:	
MVMVETSGAERRAHPRMPAARKIYIVDDPRSWKASLLDVAEKGGRISIAGIASPPDTFVFVDAGGRRVHLANVVA
RSGTEVGVQFAATQRIGPRAGGAAGALEIARRFLATLPAEDDALEHHHHHHHH	
R11A/R12A:	
MVMVETSGAEAAAHPRMPAARKIYIVDDPRSWKASLLDVAEKGGRISIAGIASPPDTFVFVDAGGRRVHLANVVW
RSGTEVGVQFAATQRIGPRAGGAAGALEIARRFLATLPAEDDAHHHHHH	
DgrA	modification	
The	reaction	was	carried	out	by	mixing	protein	and	c-diGMP-N3	together	 in	 following	step	and	the	
protein	concentration	was	kept	at	115	µM.	The	reaction	was	put	under	UV	light	366	nm	for	15	hours	
and	later	the	sample	was	applied	to	18%	SDS	gel	and	HR-ESI	and	MALDI-TOF	analysis.		
1:	2	µL691	MM	DgrA-wt	and	10	µL	water	
2:	1.5	µL	1	mM	c-diGMP-N3	was	added	to	2	µL	691	µM	DgrA-wt	and	8.5	µL	water	protein		
3:	1.2	µL	1	mM	c-diGMP-N3,	8	µL	148	µM	DgrA-R11/R12A	protein	and	1 µL	water	
4:	8	µL	148	µM	DgrA-R11A/R12A	protein	and	2.2	µL	water	
5:	1.6	µL	1	mM	c-diGMP-N3,	6	µL	270	µM	DgrA-W75A	protein	and	6.4 µL	water	
6:	6	µL	270	µM	DgrA-W75A	protein	and	7.6 µL	water		
7:	1.5 µL	10	mM	c-diGMP-N3	was	added	2	µL	691	µM	DgrA-wt	protein	8.5	µL	water	
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Modification	of	DgrA-wt	
	
S	3.31	HR-ESI	of	DgrA-wt	after	UV	irradiation	(reaction	1)	
	
	
S	2.32	HR-ESI	of	modified	DgrA	after	UV	irradiation	(reaction	2)	
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S	2.33	MALDI-TOF	of	modification	of	DgrA	(reaction	2)	
	
	
S	2.34	HR-ESI	of	modification	DgrA-wt	with	10	equivalents	of	c-di-GMP-N3	(reaction	7)	
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Modified	MS	of	mutant	dgrA-W75	and	DgrA-R11A/R12A	was	not	observed	in	HR-ESI	or	in	MALDI-TOF	
when	treated	with	1	equiv.	of	c-di-GMP-N3.	Even	when	c-di-GMP-N3	was	increased	to	10	equiv.	the	MS	
spectrum	showed	only	broad	 indistinct	peaks	due	to	 the	high	concentration	of	c-di-GMP-N3.	These	
observations	are	consistent	with	the	gel	data	suggesting	low	or	no	modification	with	these	mutants	
and	with	the	low	binding	constant	measured	in	the	microscale	thermophoresis.	
	
Trypsin	digestion	for	DgrA-wt	modification	(digestion	of	reaction	2)	
 final concentration stock solution volume  
protein 107 µM  115 µM  15 µL 
Trypsin 2.1 µM  85 µM  0.4 µL 
CaCl2 4.2 µM  100 µM  0.7 µL 
	
The	trypsin	digestion	reaction	mixture	was	left	at	37	°C	for	3-4	h	and	quenched	by	10%	formic	acid	and	
then	 injected	 to	 UPLC-MS	 to	 analyze	 the	 digested	 fractions.	 The	 mass	 of	 the	 fragment	 shown	
corresponds	to	the	GGR	peptide	fragment	plus	the	azide	cross-linker.	This	fragment	is	the	only	species	
not	seen	in	the	control	digestion	of	DgrA.	The	peak	at	1118.4	Da	is	a	dehydration	product	of	the	initial	
fragment,	which	likely	forms	from	the	acidic	formic	acid	quench.	
	
S	2.35	UPLC-MS	of	trypsin	gigestion	of	modified	DgrA-c-d-GMP-N3	
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Microscale	thermophoresis	
DgrA	and	DgrA	W75A	were	labeled	with	the	fluorescent	dye	DyLight488	NHS	Ester	according	to	the	
manufacturer’s	protocol	(ref.	46402,	ThermoScientific,	Rockford,	IL-USA),	with	a	degree	of	labeling	of	
80%	 and	 33%,	 respectively.	 The	 excess	 of	 free	 dye	 was	 removed	 by	 dialysis.	 DyLight488-labelled	
protein	concentration	was	kept	constant	at	50	nM	for	DgrA	and	100	nM	for	DgrA	W75A,	while	c-di-
GMP	and	c-di-GMP-N3	were	 titrated	 in	PBS-T	 (PBS,	0.1%	v/v	Tween-20,	pH	7.4).	The	samples	were	
loaded	into	MonolithTM	standard-treated	capillaries	and	thermophoresis	was	measured	at	25	°C	after	
15	and	30	min	incubation	using	a	Monolith	NT.115	instrument	(NanoTemper	Technologies,	München,	
Germany).	Laser	power	was	set	to	100%	using	30	seconds	on-time.	The	LED	power	was	set	to	100%.	
The	Kd	values	were	fitted	from	triplicates	with	Prism	6.00	(GraphPad	Software)	and	expressed	as	mean	
±	SD.		
	
S	2.36	MST	spectrum	of	modified	c-di-GMP-N3	and	c-di-GMP		
Microscale	thermophoresis	of	the	DyLight488-labelled	DgrA	(A)	and	DgrA	W75A	(B)	shows	binding	to	
c-di-GMP	(black	circles)	and	c-di-GMP-N3	(grey	squares).	The	thermophoresis	change	upon	addition	of	
c-di-GMP	 is	 plotted	 as	 normalized	 fluorescence.	 DgrA	 and	 DgrA	 W75A	 showed	 a	 decreased	
fluorescence	in	the	bound	state.	The	Kd	of	DgrA	was	fitted	to	79	±	12	nM	for	c-di-GMP	and	231	±	48	
nM	for	c-di-GMP-N3	(n	=	3).	The	Kd	of	DgrA	W75A	was	fitted	to	372	±	190	µM	for	c-di-GMP	and	397	±	
202	µM	for	c-di-GMP-N3	(n	=	3).	The	error	bars	represent	SD	(n	=	3).	The	Kd	of	DgrA	was	fitted	to	79	
nM	for	c-di-GMP	and	231	nM	for	c-di-GMP-N3,	and	the	Kd	of	DgrA	W75A	was	fitted	to	372	µM	for	c-
di-GMP	and	397	µM	for	c-di-GMP-N3	(n	=	3).	The	aryl	azide	modification	of	c-di-GMP	has	a	very	minor	
effect	on	the	binding	affinity	for	DgrA	and	DgrA	W75A	(2.9	and	1.1	fold	Kd	increase	respectively).	
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2.4.4	General	procedure	for	Cu(I)-catalyzed	hairpin	oligonucleotide	modification	using	a-
diazocarbonyl	compounds.		
Solid-phase	 oligonucleotide	 synthesis	 was	 carried	 out	 on	 1	 µmol	 CPG	 columns	 using	 standard	
phosphoramidite	 chemistry	 with	 0.3	 M	 5-benzylthio-1-H-tetrazole	 as	 activator.	 The	 DNA	
oligonucleotides	were	cleaved	from	the	support	with	32	%	(v/v)	aqueous	ammonia	for	2	h	at	room	
temperature	and	deprotected	for	18	h	at	55	°C,	then	freeze-dried	and	purified	by	micropreparative	
HPLC	with	TEAA	buffer	pH	7.2	(Method:	5	mL/min,	0-2	min,	0%	CH3CN,	2-40	min,	70%	CH3CN).	
Typically	 10	 or	 20	µL reaction	mixtures	 containing	 5	mM	oligonucleotide,	 500	µM	CuSO4,	 2.5	mM	
THPTA	and	50	mM	a-diazocarbonyl	compound,	and	10	mM	sodium	ascorbate	in	100	mM	MES	buffer,	
pH	6.0	were	kept	at	20	°C	for	48	h.	Analysis	of	the	reaction	products	was	carried	out	by	HPLC-separation	
of	5	µL	aliquots	of	the	reaction.	The	collected	peak	fractions	were	further	confirmed	by	ESI	and	MALDI	
TOF.	The	designations	of	the	chromatographic	peak	fractions	indicate	there	are	only	mono-alkylated	
products	at	different	position	of	the	hairpin.	
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2.4.5	General	procedure	for	auto-tandem	catalytic	CuAAC/NHI	
	
Methyl	2-(4-azidophenyl)-2-diazoacetate	(	14	mg,	0.064	mmol),	4-iodoaniline	(	15.5	mg,	0.071	mmol)	
and	propargyl	alchol	(3.6	mg,	0.064	mmol)	were	mixed	in	tert-butanol	(1.37	mL)	under	nitrogen,	and	
500	mM	MES	buffer,	pH	6.0	(0.514	mL),	100	mM	CuSO4	 in	water	(0.032	mL)		were	then	added,	the	
mixture	was	stirred,	and	400	mM	sodium	ascorbate	in	water	(0.32	mL),	0.5	mL	water	was	introduced.	
The	mixture	was	stirred	for	overnight	at	room	temperature.	Then	an	equal	volume	of	10	%	(w/v)	K2CO3	
was	added,	and	the	mixture	was	extracted	with	3	×	6	mL	of	dichloromethane.	The	combined	organic	
layers	were	dried	with	anhydrous	sodium	sulfate,	evaporated	under	vacuum	and	the	residue	purified	
by	column	chromatography	on	Si60	in	dichloromethane/methanol	to	yield	the	desired	product	as	a	
white	solid	(70	%).	TLC	(DCM-methanol	30:1	v/v)	Rf	=0.23.	IR	(film)	3368,	3151,	1734,	1497,	1184,	1059,	
1005,	928,	749	cm-1.	1H	NMR	(500	MHz,	CDCl3)	δ/ppm:	8.18	(s,	1H),	7.80	(d,	J	=	8.7	Hz,	2H),	7.71	(dd,	J	
=	7.8,	1.5	Hz,	1H),	7.66	(d,	J	=	8.4	Hz,	2H),	7.12	–	7.05	(m,	1H),	6.49	–	6.37	(m,	2H),	5.68	(d,	J	=	5.8	Hz,	
1H),	5.35	(d,	J	=	5.8	Hz,	1H),	4.69	(d,	J	=	5.5	Hz,	2H),	3.73	(s,	3H),	3.30	(t,	J	=	5.7	Hz,	1H).	13C	NMR	(126	
MHz,	CDCl3)	δ/ppm:		172.28,	149.92,	145.93,	140.17,	138.84,	138.15,	130.41,	129.67,	121.86,	121.62,	
120.66,	 112.97,	 85.99,	 60.68,	 56.52,	 53.87.	 HRMS	 (ESI)	 calc.	 for	 C18H18IN4O3+:	 [M	+	 H]+,	 465.0345;	
Found:	[M	+	H]+,	465.0418. 	
	
	
Methyl	 2-(4-azidophenyl)-2-diazoacetate	 (14	mg,	 0.064	mmol),	 aniline	 (6.57	mg,	 0.071	mmol)	 and	
propargyl	alchol	(3.6	mg,	0.064	mmol)	were	mixed	in	tert-butanol	(1.37	mL)	under	nitrogen,	and	500	
mM	MES	buffer,	pH	6.0	(0.514	mL),	100	mM	CuSO4	in	water	(0.032	mL)	were	then	added,	the	mixture	
was	stirred,	and	400	mM	sodium	ascorbate	 in	water	 (0.32	mL),	0.5	mL	water	was	 introduced.	 	The	
mixture	was	stirred	for	overnight	at	room	temperature.	Then	an	equal	volume	of	10	%	(w/v)	K2CO3	was	
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added,	and	the	mixture	was	extracted	with	3	×	6	mL	of	dichloromethane.	The	combined	organic	layers	
were	 dried	with	 anhydrous	 sodium	 sulfate,	 evaporated	 under	 vacuum	and	 the	 residue	 purified	 by	
column	chromatography	on	Si60	in	dichloromethane/methanol	to	yield	the	desired	product	as	white	
solid,	(70	%)	TLC	(DCM-methanol	30:1	v/v)	Rf	=0.31.	IR	(film)	3279,	3119,	1731,	1516,	1191,	1011,	765,	
693	cm-1.	1H	NMR	(500	MHz,	CDCl3)	δ/ppm:	8.18	(s,	1H),	8.19	(s,	1H),	7.80	(d,	J	=	8.7	Hz,	2H),	7.68	(d,	J	
=	8.5	Hz,	2H),	7.11	(dd,	J	=	8.5,	7.5	Hz,	2H),	6.65	(dt,	J	=	8.5,	1.1	Hz,	3H),	5.30	(d,	J	=	5.7	Hz,	1H),	4.70	(s,	
2H),	3.70	(s,	3H).	13C	NMR	(126	MHz,	CDCl3)	δ/ppm:	δ	172.74,	149.89,	147.26,	139.58,	137.98,	130.10,	
129.81,	122.04,	121.72,	121.63,	118.88,	114.42,	60.58,	56.52,	53.40.	HRMS	(ESI)	calc.	for	C18H19N4O3+:	
[M	+	H	]+,	339.1379;	Found:	[M	+	H]+,	339.1452.		
	
Methyl	2-(4-azidophenyl)-2-diazoacetate	(	0.100	mmol),	aniline	(0.110	mmol)	and	N,N-dimethylprop-
2-yn-1-amine	(0.1	mmol)	were	mixed	in	tert-butanol	(2	mL)	under	nitrogen,	and	500	mM	MES	buffer,	
pH	6.0	(0.8	mL),	100	mM	CuSO4	in	water	(0.05	mL)	were	then	added,	the	mixture	was	stirred,	and	400	
mM	sodium	ascorbate	in	water	(0.5	mL),	0.63	mL	water	was	introduced.	The	mixture	was	stirred	for	
overnight	at	room	temperature.	Then	an	equal	volume	of	10	%	(w/v)	K2CO3	was	added,	and	the	mixture	
was	 extracted	 with	 3×	 6	 mL	 of	 dichloromethane.	 The	 combined	 organic	 layers	 were	 dried	 with	
anhydrous	 sodium	 sulfate,	 evaporated	 under	 vacuum	 and	 the	 residue	 purified	 by	 column	
chromatography	on	Si60	in	dichloromethane/methanol	to	yield	a	white	product	white	solid	(63%).	TLC	
(DCM-methanol	20:1	v/v)	Rf	=	0.31.	IR	(film)	3366,	3292,	1728,	1525,	1223,	860,	830,	515	cm-1.	1H	NMR	
(500	MHz,	CDCl3)	δ/ppm:	8.14	(s,	1H),	7.80	(d,	J	=	8.7	Hz,	2H),	7.67	(d,	J	=	8.6	Hz,	2H),	7.14	–	7.07	(m,	
2H),	6.68-6.64	(m,	3H),	5.39	(d,	J	=	7.1	Hz,	1H),	5.29	(d,	J	=	7.2	Hz,	1H),	3.69	(s,	3H),	3.59	(s,	2H),	2.23	(s,	
6H).	13C	NMR	(126	MHz,	CDCl3)	δ/ppm:	172.74,	147.26,	146.66,	139.48,	138.03,	130.09,	129.79,	122.49,	
121.62,	121.55,	118.87,	118.32,	114.42,	60.58,	54.77,	53.39,	45.22.	HRMS	(ESI)	calc.	for	C20H24N5O2+:	
[M	+	H]+,	366.1852;	Found:	[M	+	H]+,	366.1925	
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Methyl	2-diazo-2-(4-((dimethylamino)methyl)phenyl)	acetate	(	30	mg,	0.128	mmol),	aniline	(20.61	mg,	
0.15	mmol)	and	propargyl	alcohol	(7.2	mg,	0.128	mmol	)	were	mixed	in	tert-butanol	(0.8	mL)	under	
nitrogen,	and	500	mM	MES	buffer,	pH	6.0	(0.93	mL),	100	mM	CuSO4	in	water	(0.064	mL)	were	then	
added,	the	mixture	was	stirred,	and	400	mM	sodium	ascorbate	in	water	(0.64	mL),	0.12mL	water	were	
introduced.		The	mixture	was	stirred	for	overnight	at	room	temperature.	Then	an	equal	volume	of	10	
%	 (w/v)	 K2CO3	was	 added,	 and	 the	mixture	was	 extracted	with	 3×	 6	mL	 of	 dichloromethane.	 The	
combined	organic	 layers	were	dried	with	anhydrous	sodium	sulfate,	evaporated	under	vacuum	and	
the	 residue	purified	by	column	chromatography	on	Si60	 in	dichloromethane/methanol	 to	yield	 the	
desired	product	as	a	colorless	oil	(62	%).	TLC	(DCM-methanol	10:1	v/v)	Rf	=	0.45.	IR	(film)	3366,	3292,	
1728,	1525,	1223,	860,	830,	515	cm-1.	1H	NMR	(500	MHz,	CDCl3)	δ/ppm:	8.00	(s,	1H),	7.59	(d,	J	=	8.2	Hz,	
2H),	7.49	(dd,	J	=	18.1,	8.6	Hz,	4H),	6.75	(d,	J	=	9.0	Hz,	2H),	5.30	(s,	1H),	4.66	(s,	2H),	4.18	(s,	2H),	3.70	
(s,	3H),	2.71	(s,	6H).	13C	NMR	(126	MHz,	CDCl3)	δ/ppm:	172.43,	147.64,	140.31,	132.44,	131.29,	129.21,	
129.09,	122.98,	118.33,	114.55,	60.93,	60.67,	56.56,	53.47,	42.71.	HRMS	(ESI)	calc.	for	C21H26N5O3+:	[M	
+	H]+,	396.1957;	Found:	[M	+	H]+,	396.2030.	
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Chapter	3	Selective	alkylation	of	biological	phosphates	by	unstabilized	
diazo	compounds	
3.1	phosphate	 is	one	of	 the	most	 important	 functional	 groups	 in	 chemical	
biology		
The	phosphate	group	and	its	ester	are	present	in	almost	all	biological	process.	In	primary	metabolism,	
once	glucose	goes	into	the	cell	by	the	glucose	transporter	protein,	it	immediately	gets	phosphorylated	
to	form	glucose	6-phosphate	(G	6-P).	The	negatively	charged	phosphate	group	prevents	the	diffusion	
of	glucose	outside	of	 the	membrane.	 It	also	helps	glucose	 to	be	broken	down	 into	pyruvate	 in	 the	
glycolysis	pathway	yielding	ATP	(adenosine	triphosphate)	and	NADH	(reduced	nicotinamide	adenine	
dinucleotide).	Later	different	phosphorylated	intermediates	are	involved	in	each	step	of	the	glucolysis	
pathway.	 These	 phospho-metabolites	 are	 also	 very	 important	 substrates,	 starting	 materials	 or	
cofactors	 in	 many	 other	 biological	 pathways	 (Figure	 3.1).	 For	 example,	 the	 intermediate	
dihydroxyacetone	phosphate	(DHAP)	is	the	source	of	the	glycerol	which	can	couple	with	fatty	acids	to	
form	 body	 fat.	 Furthermore,	 G	 6-P	 also	 supplies	 ribulose	 5-phosphate	 in	 the	 pentose	 phosphate	
pathway	 when	 the	 ratio	 of	 NADP+:	 NADPH	 increases.	 Later	 it	 is	 converted	 to	 phosphoribosyl	
pyrophosphate	(PRPP)	by	diphosphokinase	for	nucleotide	and	nucleic	acid	synthesis.		PRPP	is	also	used	
as	the	ribose	supplier	for	nicotinic		acid	and	quinolinic	acid	in	NAD+	biosynthetic	pathway.103	NAD+	is	
the	signaling	molecule	and	key	factor	in	the	poly	ADP	ribose	polymerase	(PARP)	and	Sirtuins	regulation	
process	which	means	NADH	analogs	could	be	used	as	drug	for	anti-aging	and	life	span	prolongation.104	
Thus	the	phosphate	group	not	only	 forms	the	backbone	of	genetic	material,	but	also	 impacts	gene	
expression.		
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Figure	3.1	Glucose	metabolic	pathway,	phosphorylation	is	present	in	most	of	its	pathway.	
After	the	discovery	of	inosityl	hexaphosphate	in	green	plants	in	1919105,	inositol	phosphates	(IPs)	and	
Phosphoinositides	(PIs,	inositol	phospholipids)	have	drawn	enormous	attention.	Inositol-3-phosphate	
synthase	(IPS),	a	putative	target	for	mood-stabilizing	drugs	such	as	lithium	and	valproate,	converts	G	
6-P	to	myo-inositol	1-phosphate	which	later	gets	dephosphorylated	to	give	inositol.	Altered	level	of	
inositol	 affects	 brain	 signaling	 events	 leading	 to	 severe	 psychiatric	 and	 neurological	 problems	 like	
Alzheimer,	suicide	and	stroke.106-108	Inositol	isomers	could	be	phosphorylated	at	different	levels	leading	
to	more	than	60	different	inositol	phosphates.	The	complexity	of	low	concentrations	of	IPs	hinders	the	
mapping	of	their	functions.109,	110		Nevertheless,	more	than	4000	references	have	contributed	in	the	
field	due	to	their	important	roles	in	cell	signaling	and	gene	expression.110		
Besides	 in	 the	 sugar	 metabolic	 pathway,	 phosphate	 also	 plays	 an	 important	 role	 in	 many	 other	
biomolecules’	biosynthetic	pathways	(See	Figure	3.1).	Choline,	which	serves	as	the	hydrophilic	head	in	
the	 cell	 membrane,	 is	 linked	 to	 fatty	 acids	 via	 a	 phosphate	 ester	 (Figure	 3.2).	 Choline	 and	 its	
metabolites	are	important	nutrients	for	humans,	and	they	play	a	great	role	in	structural	integrity,	cell	
signaling	 and	 cholinergic	 neurotransmission.	 They	 are	 rich	 in	 milk	 and	 egg	 as	 free	 choline,	
phosphocholine,	 glycerophosphocholine	 and	 phosphatidylcholine.	 Sufficient	 intake	 of	 choline	 is	
especially	important	for	pregnant	women	since	it	reduces	the	risk	of	neural	tube	defects	(spinal	cord	
or	brain	defects)	in	infants.111	It	is	also	a	major	biological	source	of	methyl	groups	through	its	role	in	S-
adenosylmethionine	(SAMe)	synthesis.		
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Figure	3.2	biosynthetic	pathway	of	phosphatidylcholine	
Triglyceride	is	the	main	component	of	body	fat.	Its	biosynthesis	starts	with	glycerol	3-phosphate.	So	
does	 steroids	 biosynthesis	 with	 phosphorylated	 terpene.	 Terpene	 pyrophosphate,	 also	 called	
terpenoid	serves	as	an	important	intermediate	in	this	process.	However	the	leaving	group	of	these	two	
biosynthetic	pathways	is	different	(See	Figure	3.3).	In	the	steroid	biosynthetic	way,	pyrophosphate	is	
the	good	leaving	group,	which	can	be	attacked	by	another	terpenoid.	For	body	fat	biosynthesis,	the	
alcohol	of	 the	glycerol	3-phsphate	attacks	the	fatty	acid	which	 is	already	activated	by	coenzyme	A.		
After	phosphatidic	acid	is	obtained,	the	phosphate	needs	to	be	removed	by	phosphatase	for	the	later	
steps.	Then	the	free	alcohol	of	the	diacylglyceride	can	attack	another	acyl-CoA	to	afford	triglyceride.	
Hence	in	the	triglyceride	pathway	the	phosphate	monoester	does	not	serve	as	a	good	leaving	group,	
but	rather	as	a	special	recruiting	signal	for	glycerol’s	binding	to	different	enzymes	in	the	triglyceride	
biosynthetic	pathway.		
Figure	3.3	pyrophosphate	as	the	nature	leaving	group	
Different	phosphate	esters	play	different	 roles	 in	biological	process.	 Purine	 tri-phosphates	are	well	
known	as	the	energy	currency.	Pyrophosphate	is	one	of	Nature’s	best	leaving	groups.	Phosphodiesters	
form	the	backbone	of	genetic	materials	in	all	organisms.	But	the	phosphate	monoester	has	a	role	in	
many	types	of	transformations	in	biology	(Figure	3.1).	Phosphate	installation	leads	to	such	a	dramatic	
change	 in	 chemical	 properties	 that	 it	 is	 often	 used	 as	 a	 chemical	 signal,	 for	 example	 in	 protein	
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phosphorylation.	 We	 have	 discussed	 how	 the	 phosphorylated	 form	 of	 glucose	 or	 glycerol	 is	 very	
important	in	interacting	with	enzymes	to	start	their	pathway.	Their	ubiquity	has	led	many	to	speculate	
as	to	why	nature	chose	phosphates	as	components	of	many	of	its	processes.112-114	
	
Figure	3.4	different	phosphate		group	in	chemical	biology	
	
3.1.1	Revealing	the	mysterious	of	reversible	protein	phosphorylation		
The	 first	 example	 of	 phosphorylation	was	 discovered	 in	 the	 late	 1930s.	 During	 the	 study	 of	 sugar	
metabolisms,	Carl	and	Gerty	Cori	discovered	G	6-P	as	the	first	intermediate	of	the	glycogen	breakdown	
process	 (glycogenolysis,	 not	 glucolysis).	 The	 enzyme	 that	 catalyzes	 this	 process	 was	 named	 as	
phosphorylase	since	it	added	a	phosphate	group	to	glucose.	They	found	there	were	two	forms	of	this	
phosphorylase	(A	form	and	B	form)	which	is	under	the	regulation	of	another	enzyme,	the	prosthetic-
group-removing'	(or	PR)	enzyme.115	They	believed	phosphorylase	a	containing	a	covalently	linked	5'-
AMP	 (incorrect)	 is	 the	 active	 form	 in	 glycogenolysis,	 PR	 enzyme	 releases	 5'-AMP	 and	 converts	
phosphorylase	A	to	phosphorylase	B.	They	were	awarded	the	Nobel	Prize	in	1947	for	discovering	the	
course	of	“the	catalytic	conversion	of	glycogen”.	However	many	years	passed,	the	Coris	were	stuck	in	
a	situation	that	they	could	show	no	formation	of	AMP	in	the	reaction	of	phosphorylase	A	to	B,	further	
more	they	could	show	no	AMP	in	phosphorylase	a.	The	problem	was	then	passed	to	Fischer	and	Krebs	
who	 later	discovered	 that	phosphorylase	b	 could	be	 converted	 to	a	 in	 the	presence	of	Mg-ATP	by	
phosphorylase	kinase.116	They	also	proved	that	prosthetic-group-removing'	(or	PR)	enzyme	is	actually	
a	 phosphate	 removing	 (PR)	 enzyme,	 not	 5’-AMP	 removing	 enzyme.	 The	 transformation	 of	
phosphorylase	A	to	B	established	the	concept	of	reversible	protein	phosphorylation	(Figure	3.5).	At	the	
same	time,	Sutherland	made	the	unexpected	observation	that	phosphorylase	activation	increased	with	
the	addition	of	5’-AMP,	which	is	a	precursor	of	3',5'-cyclic	AMP.117	That	was	why	Coris	logically	assumed	
5’-AMP	 linked	phosphorylase	 is	 the	active	 form	 in	1930s.	After	 two	decades	of	 strenuous	 trial	 and	
error,	 the	 isolation	 and	 purification	 of	 protein	 kinase	 A	 (PKA)	 by	 Fisher	 and	 Krebs118	 revealed	 the	
cascade	of	phosphorylation.119			
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Figure	 3.5	 The	 glycogenolytic	 cascade119:	 Adrenalin	 stimulates	 the	 production	 of	 (c-AMP)	 leading	 to	 the	 sequential	
activation	of	c-AMP-dependent	protein	kinase	and	phosphorylase	kinase.		
PKA	 is	 known	as	 cyclic	AMP-dependent	protein	kinase	which	phosphorylates	phosphorylase	kinase	
(they	called	it	kinase	kinase	when	they	sent	the	draft	to	the	editors).	Their	concept	of	reversible	protein	
phosphorylation	 in	 this	 phosphorylation	 cascade	 is	 embarrassingly	 simple	 according	 to	 their	 own	
humble	comments,	yet	today	this	theory	proves	to	be	an	absolute	crucial	phenomenon	in	every	aspect	
of	 cell	 life.	 Protein	 kinases	act	 like	 the	messengers	 in	 the	 signal	 transduction	pathways	where	one	
kinase	activates	a	second	kinase,	which	may	act	on	yet	another	kinase	(a	kinase	kinase	kinase	according	
to	Fisher	and	Krebs).	The	sequential	action	of	a	series	of	protein	kinases	can	transmit	a	signal	received	
at	the	cell	surface	to	target	proteins	within	the	cell	nucleus,	resulting	in	gene	expression	regulation,	
change	of	cell	behavior	 in	response	to	environmental	stimuli.	One	commonly	cited	estimate	 is	 that	
approximately	30%	of	proteins	are	phosphorylated,	with	tens	of	thousands	of	distinct	phosphorylation	
sites.119	In	HeLa	cells,	changes	in	6,600	phosphorylation	sites	on	2,244	proteins	were	detected	after	
stimulating	the	cell	with	epidermal	growth	factor	(EGF).120	This	sounds	formidable	to	non-experts	who	
would	 like	 to	 know	 how	 exactly	 the	 reversible	 phosphorylation	 (especially	 the	 phosphorylation	
stoichiometries	level)	regulates	cell	life.		
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Figure	3.6	Structure	and	regulation	of	Src	family	kinases	(SFKs).	[Reprinted	with	permission	from	Macmillan	Publishers	
Ltd:	[Nat	Rev	Neurosci]	(M.	W.	Salter	and	L.	V.	Kalia,	Nat	Rev	Neurosci,	2004,	5,	317-328),	copyright	(2004)].	
One	 of	 the	 oldest	 and	most	 investigated	 protein	 kinase,	 c-Src,	will	 be	 used	 here	 to	 exemplify	 the	
complexity	of	this	process.121-124	C-Src	(cellular	Src	kinase)	is	a	proto-oncogene	tyrosine-protein	kinase	
which	means	 it	 phosphorylates	 specific	 tyrosine	 residues	 in	 other	 proteins.	 A	 different	 protein	 C-
terminal	 Src	 kinase	 (CSK)	 phosphorylates	 c-Src	 at	 its	 C-terminal	 Y527	 position,	 the	 resulting	
phosphorylated	Y527	then	folds	over	and	binds	to	its	own	SH2	domain	(Figure	3.6,	left).		In	this	form,	
c-Src	is	folded	and	its	enzymatic	activity	is	turned	off.	C-Src	can	be	activated	by	many	transmembrane	
proteins	that	include:	adhesion	receptors,	receptor	tyrosine	kinases,	G-protein	coupled	receptors	and	
cytokine	receptors.	Once	the	stimuli	passes	down	to	turn	on	c-Src,	Y527	is	dephosphorylated	(Figure	
3.6	right)	and	the	catalytic	domain	(SH1	domain,	N-	and	C-lobes)	which	contains	a	conserved	tyrosine	
residue	 (Y416),	 will	 be	 autophosphorylated	 and	 the	 enzyme	 opens	 to	 its	 active	 conformation	 and	
passes	its	signal	to	a	downstream	receptor	like	epidermal	growth	factor	receptor	(EGFR).	Recently,	it	
has	been	reported	that	c-Src	also	defines	a	new	pool	of	EGFR	substrates	(like	Mig6	and	Shc1,	they	are	
signal	adapters	in	mitogen-activated	protein	kinase	pathway).	Peptides	containing	a	tandem	motif	of	
two	tyrosines	in	a	roll	(YY)	will	be	an	optimized	EGFR	substrate	when	the	second	tyrosine	is	primed	by	
c-Src	mediated	phosphorylation.	Because	the	primed	tyrosine	sits	 in	a	 'priming	pocket'	of	the	EGFR	
kinase	increasing	the	affinity	and	specificity	of	the	EGFR	kinase	for	binding	to	the	tandem	YY	motif,	the	
first	tyrosine	is	subsequently	efficiently	phosphorylated	by	EGFR	kinase.125		
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As	the	example	above	demonstrate,	protein	phosphorylation	stoichiometry	and	the	variety	of	diverse	
phosphate	 modification	 sites	 make	 characterization	 very	 difficult.	 Nevertheles,	 detection	 and	
sequencing	of	phosphorylated	proteins	(or	phosphoproteome)	has	made	a	significant	progress	after	a	
great	number	of	scientists	spent	tremendous	effort	working	on	this	problem.126-129	Sequencing	analysis	
could	be	done	by	tandem	MS	after	the	enrichment	of	phosphoprotein	or	phosphopeptide.	Enrichment	
of	the	phosphorylated	proteins	could	be	achieved	by	immunoprecipitation	(but	highly	dependant	on	
the	availability	of	antibodies).	Large	scale	enrichment	of	phosphopeptide	can	be	achieved	by	affinity	
chromatography	 purification.	 Immobilized	 metal	 affinity	 chromatography	 (IMAC)	 is	 the	 most	
extensively	used	method	for	global	phosphopeptide	enrichment.85	It	is	rather	“cheap	and	easy”,	but	
there	is	no	selectivity	compared	to	immunoprecipitation.	The	negatively	charged	phosphopeptide	is	
bound	on	the	positively	charged	immobilized	metal	ion.	A	review	of	recent	developments	of	different	
metal	 ligands	 in	 the	 IMAC	 technique	 indicates	 the	 state-of-the-art.130	 IMAC’s	 high	 sensitivity	 and	
selectivity	 for	 phosphopeptide	 over	 non-phosphorylated	 peptides	 have	 made	 measurement	 of	
absolute	protein	phosphorylation	stoichiometries	in	human	cells	possible	(Figure	3.7).131	Two	identical	
aliquots	of	tryptic	peptides	are	either	mock	or	phosphatase	treated	followed	by	isotopic	tagging.	Then,	
the	mixing	fraction	is	purified	by	IMAC.	In	the	flow	through	of	IMAC	purification,	the	dephosphorylated	
peptides	 from	 phosphatase-treated	 aliquot	 (blue,	 light	 isotope	 labelled)	 will	 represent	 the	 total	
peptides,	 while	 the	 unphosphorylated	 counterpart	 in	 the	 untreated	 aliquot	 (red,	 heavy	 isotope	
labelled)	 will	 represent	 the	 fraction	 of	 initial	 unphosphorylated	 amount.	 The	 mixture	 of	
dephosphorylated	and	unphosphorylated	peptides	in	the	flow	through	is	subjected	to	phosphorylation	
via	a	kinase	reaction.	Then	the	phosphopeptides	are	purified	by	 IMAC.	The	ratio	of	heavy/light	will	
represent	the	fraction	of	 initially	unphosphorylated	amount	and	the	phosphorylation	stoichiometry	
can	be	calculated	by	formula	a	as	shown	in	Figure	3.7a.		
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Figure	3.7	The	basic	principle	of	the	motif-targeting	quantitative	proteomic	approach.	[Reprinted	with	permission	from	
Macmillan	Publishers	Ltd:	[Nat	Commun]	(C.-F.	Tsai,	Y.-T.	Wang,	H.-Y.	Yen,	C.-C.	Tsou,	W.-C.	Ku,	P.-Y.	Lin,	H.-Y.	Chen,	A.	
I.	Nesvizhskii,	Y.	Ishihama	and	Y.-J.	Chen,	Nat	Commun,	2015,	6)	copyright	(2015)	]	
	
3.1.2	Limited	methods	of	chemical	labelling	of	phosphopeptides	
The	 chemical	 modification	 of	 the	 phosphoprotein	 or	 peptide	 has	 made	 little	 progress	 except	 for	
reports	by	Oda	and	Zhou	developed	a	parallel	of	chemical	derivatization	strategies	(Figure	3.8).	Oda’s	
protocol132	started	with	a	pool	of	protein,	then	serine	and	threonine	phosphate	could	be	eliminated	to	
alkenes,	making	them	susceptible	to	nucleophilic	attack	by	a	thiol,	biotin	could	then	be	linked	to	these	
modified	proteins.	Zhou	et	al133	started	with	a	pool	of	peptides,	then	they	first	protected	all	amines,	
then	carboxylic	acids,	then	released	phosphate	by	TFA	for	the	cystamine	attachment	via	carbodiimide-
catalyzed	condensation.	Reduction	of	the	internal	disulfide	of	cystamine	generated	a	free	sulfhydryl	
group	 which	 could	 be	 captured	 by	 iodoacetyl	 groups	 immobilized	 on	 glass	 beads.	 Both	 methods	
required	a	 series	of	 chemical	 reaction	 steps	 to	have	an	affinity	 tag	which	discourage	people	 to	 try	
chemical	modification.	In	comparison,	IMAC	is	two	steps	and	the	protocol	is	easy	to	implement.		
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Figure	3.8	The	chemical	enrichment	of	phosphoprotein.	
3.1.3	Previous	phosphate	modification		
The	 phosphate	 group	 and	 its	 esters	 are	 ubiquitous	 in	 nature,	 serving	 critical	 roles	 in	metabolism,	
nucleic	 acids	 and	 cell	membranes.	 Especially	 protein	 phosphorylation	 is	 the	most	 important	 post-
translation	modification	of	proteins,	and	yet,	despite	more	than	sixty	years	of	study,	it	remains	poorly	
understood	 since	 signal	 transduction	 networks	 in	 the	 phosphorylation	 cascade	 are	 complicated	 to	
trace.	Chemical	modification	of	phosphate	biomolecules	is	in	a	urgent	need	due	to	its	important	role	
in	biological	process.	There	are	a	handful	of	cases	of	phosphate	ester	alkylation	by	diazo	compounds	
as	 I	 discussed	 	 in	 Chapter	 1.	 For	 example,	 nucleotide	 monophosphates	 were	 first	 modified	 by	
phenyldiazomethane	 in	 1955.47	 Diazo-substituted	 coumarin	 has	 been	 employed	 to	 react	 with	 the	
phosphate	 moiety	 of	 the	 backbone	 of	 RNA,	 modifying	 approximately	 30	 sites	 on	 the	 phosphate	
moieties	per	1	kb	of	RNA	sequence.52	The	modification	of	seconD	messager	c-AMP	and	c-GMP	with	
diazo	 compounds	has	been	managed	albeit	 in	 low	yield	 (average	10-15%).134	 In	most	of	 the	 cases,	
DMSO	 or	 methanol	 is	 chosen	 rather	 than	 aqueous	 buffer	 for	 phosphate	 esterfication	 with	 diazo	
compounds	 since	 the	 non-ionized	 form	 of	 phosphoric	 acids	 woud	 dominante	 in	 organic	 solvents,	
whereas	most	of	the	phosphates	are	expected	to	be	ionized	in	aqueous	buffer	at	approximately	pH	7.	
However	no	detailed	look	at	the	reactivity	difference	between	phosphate	mono-	and	diesters	in	water	
has	been	attempted.	
3.2	Selective	modification	of	phosphate	in	aqeous	buffer	
Many	bioactive	molecules	have	both	 carboxylate	 and	phosphate	 group	 in	presence	of	many	other	
functional	groups	 like	amines	or	alcohols.	Selectively	modification	 	of	one	group	 inn	a	sea	of	other	
functional	groups	is	very	difficult.	Zhou	and	Oda’s	modification	of	phosphopeptide	also	showed	how	
complicated	it	is	to	modify	just	the	phosphate	group	in	a	peptide	(Figure	3.8).127	Despite	phosphate	
esters	and	carboxylates’	known	reactivity	with	diazo	compounds,	no	head-to-head	comparison	has	
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been	investigated.	In	our	own	work	on	metal-catalysed	DNA	and	RNA	alkylation	by	diazo	compounds,	
we	sometimes	found	low	levels	of	phosphate	alkylation	in	product	streams.	In	this	chapter	we	take	a	
close	look	at	phosphate	monoester	alkylation	and	compare	it	to	carboxylate	and	phosphate	diester	
alkyation	under	conditions	relevant	to	chemical	biologists.	
3.2.1	Competition	alkylation	between	carboxylic	acid	and	phosphate	
	
	
A	
	
B	
Figure	3.9	A:	Diazo	stability	in	water	is	controlled	by	its	pKa	(Path	A);	BrØnsted	acids	that	can	protonate	diazo	compounds	
lead	to	O-alkylation	(Path	B);	The	pKa	of	phosphates	(6-7)	should	facilitate	selective	reactions	with	diazo	compounds	at	
neutral	pH	(bottom).	B:	Competition	experiments	at	varying	pH	support	the	role	of	pKa	in	reactions	of	BrØnsted	acids	
with	diazo	compounds	
For	reactions	of	diazo	compounds	in	water	the	pKa	of	its	protonated	form	(the	diazonium	ion)	is	critical.	
If	 the	 conjugate	 base	 (3.1	 in	 Figure	 3.9A)	 is	 too	 basic	 it	 will	 be	 protonated	 quickly	 by	 water	 and	
decompose	 unselectively	 through	 hydrolysis	 (path	 A	 in	 Figure	 3.9A).	 When	 used	 to	 perform	
transformations	in	water	diazo	compounds	akin	to	diazomethane	must	therefore	be	used	in	enormous	
excess	since	hydrolysis	will	always	predominate	(for	example	diazomethane	has	a	pKa	of	10).	 If	too	
weakly	basic	diazo	compounds	will	not	deprotonate	the	BrØnsted	acids	(required	for	Path	B	in	Figure	
3.9)	 to	 initiate	 reaction	 –	 compounds	 in	 this	 class	 include	 diazomalonates	 and	 donor-acceptor	
substituted	diazo	esters.	These	stable	diazo	compounds	have	long	lifetimes	in	water	and	hence	can	be	
used	to	perform	aqueous	metal-carbene	reactions.	Their	weak	basicity,	however,	renders	them	of	little	
value	 in	 BrØnsted	 acid	 alkylation.	 Quantifying	 the	middle	 ground	 between	 these	 two	 extremes	 is	
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essential	 for	controlling	selectivity	 in	diazo-type	esterifications.	The	first	step	 in	a	productive	diazo-
type	O-alkylation	 is	protonation	by	the	BrØnsted	acid	(see	Path	B	 in	Figure	3.9A).	 It	should	then	be	
possible	 to	 exploit	 pKa	 differences	 between	 acids	 to	 control	 O-alkylation	 selectivity.	 To	 test	 this	
hypothesis	we	examined	product	 ratios	of	CMP	versus	benzoic	acid	alkylation	 in	aqueous	buffer	at	
different	pHs	using	commercially	available	trimethylsilyldiazomethane	3.1c	as	the	diazo	compound.	
Indeed	at	 low	pH	benzoic	acid	alkylation	 is	preferred,	but	as	 the	pH	 is	 raised	phosphate	alkylation	
begins	to	dominate	(see	Figure	3.9B).	This	is	consistent	with	benzoic	acid	being	largely	benzoate	at	pHs	
higher	 than	 6,	 while	 a	 large	 fraction	 of	 the	 phosphate	 remains	 protonated.	 Although	 3.1c	 was	 a	
convenient,	 highly	basic,	 diazo	 compound	 for	preliminary	hypothesis	 testing,	 its	 extreme	 reactivity	
(comparable	to	diazomethane)	would	limit	its	practical	application.	The	ideal	diazo	compound	would	
have	pKb	that	matches	the	pKa	of	the	Bronsted	acid.	Unfortunately	there	has	been	no	tabulation	of	
pKas	for	diazo	compounds.	Raines135	selected	the	pKa	of	the	parent	alkyl	group	as	a	proxy	for	diazo	
acidity	 in	 their	discussion	of	ester	alkylation	 (See	Figure	3.10	 right).	 In	 the	measurement	of	pKa	of	
diazomethane,	McGarrity136	found	the		acidity		of	methanediazonium	ion		in		THF-water		is		similar		to		
that		of		nitromethane		in		water		(pKa	=	10.2).	So	we	could	have	a	better	idea	of	the	acidity	of	diazo	
compounds	 using	 McGarrity’s	 result	 (Figure	 10	 left)	 than	 Raines	 theory.	 In	 this	 manner,	 phenyl	
diazomethane	 (3.1d)	 and	 2-nitro-phenyl	 diazomethane	 (3.1e)	 with	 increase	 acidity	 will	 be	 good	
substrates	for	O-alkylation	of	BrØnsted	acids.		
	
Figure	3.10	pKa	of	relevent	diazo	parent	alkyl	compounds,	pKa	(in	DMSO)	is	from	Bordwell	pKa	Table	
a	pKa	calculated	using	Advanced	Chemistry	Development	(ACD/Labs)	Software	V11.02	(©	1994-2016	ACD/Labs),	b	pKa	
in	THF/water	
3.2.2	Substrate	scope	of	modification	of	bioactive	phosphate	compound	
We	next	selected	a	range	of	biologically	relevant	monophosphates	and	looked	at	their	reaction	with	
diazo	compounds	3.1d	and	3.1e.	Although	yields	are	moderate	(21-74%	depending	on	the	substrate),	
the	ability	to	obtain	milligram	quantities	of	each	compound	from	simple	starting	materials	is	a	valuable	
innovation.	The	yields	could	likely	be	improved	further	if	necessary	by	examining	cosolvents	(limited	
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solubility	is	one	of	the	causes	of	low	conversion)	or	by	tweaking	the	structure	of	the	diazo	compound	
to	make	 it	more	 stable	 in	water.	 The	modification	 of	 serine	 and	 tyrosine	 phosphate	 only	 give	 the	
phosphate	product	as	we	desired.	But	in	the	case	of	serine	phosphate	(3.6f),	side	product	carboxylic	
esterfication	was	observed	when	diazo	 is	 increase	 to	10	equivalents.	This	 could	be	 	a	 result	of	 the	
proximity	of	the	serine	carboxylate	to	the	formed	tight	ion	pair	intermediate.	In	general	we	consider	
3.1e	 the	 superior	 reagent	 because	 it	 is	 more	 stable	 and	 the	 adduct,	 ortho-nitrobenzyl	 (ONB),	 is	
photolabile.	
	
Figure	3.11	Alkylations	of	diverse	naturally	occurring	monophosphates	
Modifications	 of	 phosphates	 within	 large	 biopolymers	 would	 be	 a	 valuable	 application	 of	 diazo	
alkylation.	 This	 reaction	 has	 previously	 been	 employed	 in	 the	 alkylation	 of	 nucleoside	
monophosphates47	 and	 nucleic	 acid	 oligomers48	 but	 in	 those	 cases	 substantial	 amounts	 of	 diester	
alkylation	were	observed.	It	is	likely	that	pH	buffering	is	the	decisive	difference	for	selectivity	and	hence	
we	examined	the	reactivity	of	two	common	phosphate	diesters	c-AMP	and	c-di-GMP	under	the	same	
conditions	employed	in	monophosphate	alkylation.	As	shown	in	Figure	3.12A	,	both	show	very	limited	
reactivity	with	the	diazo	compound	under	conditions	that	deliver	smooth	reaction	of	the	molecules	
shown	in	Figure	3.11A.	There	are	cases	where	phosphate	diester	alkylation	has	been	used	in	practice,	
but	an	enormous	excess	is	always	employed	in	DMSO.	With	30	equivalents	of	3.1e	we	begin	to	see	
phosphate	 diester	 alkylation,	 but	 under	 these	 forcing	 conditions	 substantial	 amounts	 of	 sulfonate	
alkylation	 of	 the	MES	 buffer	 salt	 were	 also	 observed	 (experimental	 part).	 The	 dramatic	 reactivity	
difference	between	mono-	and	diesters	augured	well	for	a	selective	5’-phosphate	alkylation	in	larger	
oligonucleotides.	 Oligonucleotides	 bearing	 terminal	 phosphates	 are	 alkylated	 selectively.	 A	 simple	
hexanucleotide	 (8,	 see	 trace	 a	 in	 Figure	 3.12B)	 bearing	 a	 5’-phosphate	was	 treated	with	 the	diazo	
compound	3.1d	in	varying	amounts	at	pH	7	(see	traces	b-g	in	Figure	3.12B).	Optimal	conversion	was	
observed	at	20	equivalents	of	3.1e	with	further	increases	leading	to	little	improvement.	The	reactions	
are	 clean	with	most	 by-products	 derived	 from	 side-reactions	of	 the	diazo	 compound	with	 itself	 or	
77	
	
water	(see	trace	j	for	control	sample	where	oligo	8	is	not	added	to	reaction)	and	not	with	the	backbone	
or	 the	 bases	 of	 the	 oligonucleotide	 (see	 trace	 h	 for	 control	 experiment	 of	 3.1e’s	 reaction	 with	
dephosphorylated	oligo	8,	figure	3.12B).	
Figure	3.12	A:	phosphate	diesters	are	poorly	alkylated	in	aqueous	buffer,	B:	5’-phosphates	in	DNA	are	alkylated	cleanly	
by	diazo	compound	3.1e.	
3.2.3	Src	(521-533)	and	its	inhibitor	5mer-peptide	modification	
Protein	 phosphorylation	 is	 a	 widespread	 post-translational	 modification	 that	 regulates	 numerous	
functions.	The	ability	to	selectively	modify	phosphates	in	a	native	protein	would	be	a	powerful	tool	for	
studying	 protein	 phosphorylation	 networks.	 In	 Zhou’s	 work	 (left	 side	 of	 Figure	 3.13),	 phosphate	
labeling	requires	multi-step	synthesis.	We	are	tempted	to	try	selective	alkylation	of	phosphate	group	
in	the	phosphopeptide	based	on	the	competition	reaction	of	carboxylate	and	phosphate	(Figure	3.10),	
even	though	Raines	group	employed	diazo	compound	for	labelling	of	carboxylate	groups	in	proteins.135	
Alkylation	to	create	products	3.6f	and	3.6g	in	Figure	3.11	already	suggested	that	a	selective	phosphate	
alkylation	in	a	peptide	or	protein	might	be	feasible.	
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Figure	3.13	selective	alkylation	of	phosphopeptide	
Although	whole	proteins	with	a	precisely	defined	phosphorylation	state	are	difficult	to	obtain,	many	
phosphorylated	model	peptides	are	commercially	available.	Phosphorylation	of	Y527	in	the	C-terminal	
region	of	c-Src	causes	this	domain	to	fold	over	on	its	SH2	domain,	holding	the	protein	in	an	inactive	
state.	A	13-mer	phosphorylated	peptide	of	the	Src	C-terminal	domain	(residues	521-533,	see	3.10	in	
Tabel	 3.1)	 has	 therefore	 become	 an	 important	 model	 peptide	 in	 studying	 Src	 signalling.	 If	 the	
commercially	available	TFA	salt	of	phosphopeptide	3.10	is	dissolved	in	unbuffered	water	(final	pH	4.2)	
and	treated	directly	with	diazo,	alkylation	of	glutamic	acid	531	(E531)	is	the	major	product	(see	table	
3.1,	entry	2).	Consistent	with	the	pKas	controlling	selectivity,	performing	the	same	reaction	 in	pH	7	
MOPS	buffer	switches	the	alkylation	preference	to	Y527	(table	3.1,	entries	2	&	3).	Although	there	are	
three	carboxylates	available	 for	alkylation	(C-terminus,	E524	and	E531),	phosphate	alkylation	 is	 the	
major	product	along	with	a	small	amount	of	carboxylate	alkylation	(3.13a	&	3.13b,	sites	of	alkylation	
are	determined	by	MS/MS	sequencing,	see	the	experimental	part	 for	details).	 In	addition,	while	10	
equivalents	of	3.1e	leads	to	75%	conversion	of	phosphopeptide	3.10,	dephosphorylated	peptide	3.11	
is	 only	 partially	 converted	 (approximately	 30%)	 to	 alkylated	 products	 under	 the	 same	 conditions.	
Entries	3-7	of	table	3.1	investigate	the	effect	of	adding	more	diazo	compound	and	the	ideal	seems	to	
be	3	equivalents;	Further	addition	of	3.1e	 increases	consumption	of	phosphopeptide	3.10,	but	also	
leads	to	substantial	amounts	of	double	alkylation,	thereby	reducing	the	yield	of	3.12	(see	number	in	
parenthesis	in	the	conversion	column	of	Tabel	3.1).		
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Tabel	3.	1	selective	alkylation	of	phosphopeptide	Src	
	
entry	 substrate	 pHa	
equiv.	
diazo	
Major		
product	 conv.b	
Y527:	
(E524+531)c	
1	 3.10	 4	 20	 3.13a	 40	 1:9d	 	
2	 3.10	 7	 2	 3.12	 43	(35)	 13:1	 	
3	 3.10	 7	 3	 3.12	 52	(42)	 15:1	 	
4	 3.10	 7	 5	 3.12	 68(44)	 11:1	 	
5	 3.10	 7	 10	 3.12	 75(47)	 11:1	 	
6	 3.10	 7	 15	 3.1	 95	 11:1	 	
7	 3.11	 7	 10	 3.14	 30	 n.	a.	 	
aRun	in	5mM	MOPS	buffer	at	pH	7,	pH	4	experiment	is	run	in	unbuffered	water	and	the	pH	is	measured	after	the	
reaction;	 bfirst	 number	 is	 conversion	 of	 starting	 peptide;	 number	 in	 parenthesis	 refers	 to	 amount	 of	 alkylated	
phosphate;	cratios	are	determined	by	HPLC	ion	extraction	intergration;	da	small	side	product	obscures	phosphate	
slakyltion	hence	we	can	only	report	in	a	lower	limit.		 	
	
A	second	study	on	a	model	5-mer	phosphorylated	peptide	supports	the	generality	of	the	observations	
with	 13mer	 peptide.	 This	 results	 again	 indicate	 how	 pH	 can	 be	 exploited	 to	 control	 selectivity	 in	
BrØnsted	acid	alkylation,	even	in	the	presence	of	competing	acids.	
Tabel	3.	2	selective	alkylation	of	5-mer	phosphopeptide		
	
entry	 substrate	 pH	
eq.	
diazo	
Major		
protduct	 conv.a	 Y:Eb	
1	 3.15	 7	 3	 3.17	 43	(43)	 99:1	
2	 3.15	 7	 10	 3.17	 70	(56)	 5:1	
3	 3.15	 7	 100	 3.17	 81	(56)	 3:1	
4	 3.16	 7	 20	 3.16	 0	 	
afirst	number	 is	conversion	of	 starting	peptide;	number	 in	parenthesis	 refers	 to	amount	of	alkylated	phosphate;	
bratios	are	determined	by	HPLC	intergration	
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3.2.4	Photo-cleavage	of	modified	product	
2-Nitro	benzyl	ester	is	a	photolabile	tag.	The	alkylated	tyrosine	phosphate	and	phosphopeptide	can	be	
removed	by	shining	366nm	UV	light	overnight.	Tyrosine	phosphate	2-nitro	benzyl	ester	was	dissolved	
in	D2O	in	the	NMR	tube.	NMR	spectrum	was	measured	before	and	after	the	photo	cleavage	reaction	
(Figure	3.14).	The	reaction	mixture	was	spiked	with	another	5	mg	of	tyrosine	phosphate	to	confirm	the	
photo	cleavage	result.	Triethyl	amine	salt	inside	of	phosphate	2-nitro	benzyl	ester	was	there	from	the	
purification	buffer	and	here	it	could	be	used	as	internal	standard.	The	photo-cleavage	side	product	is	
insolvable	in	water,	and	thus	is	not	visible	in	the	NMR	spectrum.	
Figure	3.14	photo-cleavage	of	alkylated	tyrosine	phosphate  
The	 alkylated	 peptide	 Src	 (527)	 	 3.12	 recoveried	 89%	 original	 phosphorylated	 peptide	 with	 11%	
dephosphorylated	peptide	after	photo	cleavage	by	UV	radiation	The	reaction	was	monitored	by	UPLC-
MS	(Figure	3.15). 
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Figure	3.15		photocleavage	of	caged	phosphopeptide	3.12	
	
3.3	Conclusion	
We	have	validated	and	extended	the	classical	mechanistic	view	of	how	diazo	compounds	accomplish	
O-alkylation.	The	accepted	mechanism	predicts	that	the	pH	of	the	medium	could	be	used	to	steer	O-
alkylation	preference	among	BrØnsted	acids.	We	have	validated	this	prediction	and	shown	how	this	
property	can	be	used	to	selectively	target	phosphates	in	a	mixture	of	other	BrØnsted	acids	including	
carboxylic	acids	and	sulfonic	acids.	
In	its	present	form	the	method	is	most	useful	for	creating	photo-caged	variants	of	peptides,	nucleic	
acids,	 and	 phosphate	 bearing	metabolites.	 Perhaps	 the	most	 exciting	 future	 application,	 however,	
would	 be	 in	 global	 phosphoproteomics,	 an	 area	 that	 suffers	 from	 a	 lack	 of	 selective	 pull-down	
reactions.	While	 there	 remain	 a	number	of	 challenges	 to	be	 addressed	before	 the	method	 can	be	
applied	in	phosphoproteomics,	a	critical	hurdle	has	been	overcome:	a	phosphate	selective	chemical	
reaction	that	works	under	biological	conditions.			
The	future	work	on	selective	esterification	of	peptide	could	be	continued	in	two	directions:	
a) Adding	biotin	tag	to	the	diazo	precursor	to	pull	down	phosphopeptides	for	sequencing;	
b) Esterification	of	 phosphopeptides	 in	 the	 cell	 lysate	 (with	phosphatase	 inhibitor)	where	 the	
carboxylic	ester	could	be	hydrolyzed	by	esterase,	then	pull	down	the	peptide	phosphate	ester	
by	affinity	assay.		
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3.4	Experimental	part	
3.4.1	General	Methods	
All	reagents	and	solvents	used	were	of	analytical	grade.	Buffers	were	prepared	with	nanopure	water.	
All	 chemicals	 were	 purchased	 from	 Sigma-Aldrich	 or	 TCI	 and	 used	 as	 received.	 Peptides	 were	
purchased	 from	 Bachem,	 oligonucleotides	 from	Microsynth	 and	 used	 as	 received	 without	 further	
purification.	1H	and	13C	NMR	were	acquired	on	a	Bruker	400	MHz,	500	MHz	or	AvanceIII+	600	MHz	
depending	on	availability	of	 the	machine	because	photolabile	 compounds	needed	 to	be	measured	
once	obtained.	Chemical	shifts	relative	to	TMS	were	referenced	to	the	solvent’s	residual	peak	and	are	
reported	in	ppm.	ESI	and	ESI-MS-MS	spectra	were	obtained	on	a	Bruker	Esquire3000+	spectrometer	
by	direct	injection	in	positive	or	negative	polarity	of	the	ion	trap	detector.	High	resolution	mass	spectra	
were	acquired	on	a	Bruker	maXis	4G	QTOF	ESI	mass-spectrometer.	MALDI	TOF	analyses	were	carried	
out	on	a	Bruker	Microflex	mass-spectrometer	in	linear	negative	mode	using	trihydroxyacetophenone	
as	matrix.	Shimadzu	preparative	HPLC	(LC-20AP)	equipped	with	phenomenex	column	(Gemini®	10	µm	
C18	 110	 Å,	 LC	 Column	 250	 x	 21.2	 mm,	 AXIA™	 Packed)	 was	 employed	 for	 purification.	 100	 mM	
triethylammonium	acetate	 (pH	7.2-7.3)	and	acetonitrile	were	used	as	mobile	phases.	Flow	rate:	20	
mL/min,	 0%	 acetonitrile	 in	 2	 min,	 0-30	 %	 acetonitrile	 in	 22	 min.	 Detection	 was	 carried	 out	 by	
monitoring	the	absorbance	of	the	column	effluent	at	254	nm.	The	identity	of	the	product	peaks	was	
confirmed	by	ESI-MS.	The	UV	photocleavage	reaction	was	carried	out	with	a	CAMAG	TLC	UV	lamp	at	
366	nm	with	a	sample-lamp	distance	of	~2	cm.	Alkylation	of	oligonuceotides	was	purified	and	analyzed	
by	 HPLC	 (Agilent	 1100	 LC	 system	 equipped	 with	 phenomenex	 ®Jupiter	 3µ	 C18	 300Å,	 150x4.6mm	
column)	using	100	mM	triethylammonium	acetate	(pH	7.2-7.3)	and	acetonitrile	as	the	mobile	phase.	
Flow	rate:	1	mL/min.	0-35	%	acetonitrile	in	12	min,	15	min	80	%.	The	fractions	were	analyzed	by	ESI-
MS.	Compeptition	alkylations	of	CMP	and	benzoic	acid	was	analyzed	by	UPLC-MS	(method	A).	Peptide	
alkylation	experiments	were	analyzed	by	UPLC-MS	(method	B)	using	an	Agilent	1290	Infinity	system,	
equipped	with	 a	 Zorbax	 Eclipse	 Plus	 C18	 2.1x50	mm	column	 (Agilent),	 coupled	 to	 an	Agilent	 6130	
Quadrupole	LC/MS.	Elution	was	performed	using	0.1	%	formic	acid	in	water/acetonitrile.	Method	A:	
flow	rate	0.45	mL/min,	5-95	%	acetonitrile	in	3.5	min;	method	B:	0%	acetonitrile	for	0.2	min,	0-54	%	
acetonitrile	in	4	min,	54-95	%	acetonitrile	in	1	min.		
3.4.2	Synthesis	of	diazo	compounds	
Diazo	substrates	were	synthesized	according	 to	published	procedures.137-139	The	corresponding	aryl	
aldehyde	was	first	converted	into	a	hydrazone	which	was	then	oxidized	to	the	final	diazo	compound.	
We	 tested	 two	 oxidation	 methods:	 Swern	 Oxidation	 and	 MnO2	 oxidation.	 They	 both	 work	 well.	
Oxidations	 using	MnO2	 are	 fast	 and	 simple	 (~20	min),	 however	 during	work	 up	 the	 reactive	 diazo	
product	was	found	to	decompose	easily.	Swern	Oxidation	was	carried	out	at	-78	°C,	and	there	is	less	
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decomposition	afterwards,	especially	 for	benzyl	diazo	which	 is	very	unstable	at	 room	temperature.	
Once	formed,	benzyl	diazo	is	used	for	modification	reactions	directly	after	work	up	and	without	further	
purification.	2-nitro-phenyl	diazomethane	was	 found	 to	have	a	higher	 stability	compared	 to	benzyl	
diazo	and	thus	can	be	stored	for	two	weeks	at	-20°C.	
	
In	a	round-bottomed	flask	containing	12	mL	of	N2H4	(1	M	in	THF,	12	mmol),	a	solution	of	aldehyde	(1	
M	in	THF,	10	mmol)	was	slowly	added.	The	mixture	was	stirred	for	30	min	at	room	temperature.	The	
mixture	was	evaporated	under	reduced	pressure	to	affording	the	desired	hydrazone	(>95%	yield).	All	
hydrazones	were	used	without	further	purification	for	the	generation	of	diazo	compounds.	
	
Under	a	nitrogen	atmosphere	oxalyl	chloride	(0.225	mL,	1.05	equiv.)	was	added	drop	wise	to	a	stirred	
solution	of	Et2O	(21	mL)	containing	DMSO	(0.195,	1.10	equiv.)	at	-55°C.	After	gas	evolution	ceased	(~20	
min),	the	reaction	was	cooled	down	to	-78°C.	Behind	a	blast	shield,	a	mixture	of	Et3N	(0.732	mL,	2.10	
equiv.)	and	hydrazone	(2.50	mmol,	1.00	equiv.)	in	THF	(6	mL)	was	added	drop	wise	over	a	period	of	5-
7	min	to	the	activated	DMSO	solution.	An	immediate	color	change	and	concomitant	formation	of	a	
white	precipitate	were	observed.	The	reaction	mixture	was	maintained	at	-78°C	for	~1	h	and	allowed	
to	gradually	warm	up	to	0°C	followed	by	the	addition	of	and	ice	cold	half	saturated	NH4Cl	solution	(20	
mL)	was	added.	The	reaction	mixture	was	extracted	with	cold	Et2O	(dry	ice	was	added	to	reach	-30°C,	
2	 x	 50	 mL),	 and	 the	 combined	 organic	 layers	 were	 dried	 over	 magnesium	 sulfate,	 filtered	 and	
concentrated	at	15	°C	under	reduced	pressure.	
	
In	a	100	mL	round	bottom	flask,	Hydrazone	(661	mg,	4.0	mmol,	1.00	eq.)	dissolved	in	50	mL	of	CHCl3,	
was	stirred	with	MnO2,	(2.85	g,	33	mmol,	8.25	equiv.)	for	5	min	in	the	dark.	In	the	absence	of	light	the	
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mixture	was	filtered	over	celite	and	the	filtrate	washed	with	0.1	M	NaHCO3	until	pH	7	was	reached,	
dried	over	MgSO4,	filtered	and	stored	at	-20	°C	in	a	brown	glass	vial	wrapped	in	black	foil.	
3.4.3	CMP	methylation			
All	aqueous	buffers	were	prepared	freshly	with	final	concentrations	of	200	mM.	Buffer	pH	4	and	5:	
CH3COOH/CH3COONa,	pH	6:	MES/NaOH,	pH	7	and	8:	MOPS/NaOH.	
CMP	(20	mg,	54	µmol)	was	dissolved	in	the	appropriate	buffer	(2.72	mL)	to	give	a	20	mM	stock	solution.	
Then,	different	equivalents	of	TMSCHN2	(2.0	M	in	hexane)	were	added.	Upon	disappearance	of	the	
yellow	layer,	UPLC-MS	analysis	(Method	A)	was	performed.	The	results	are	summarized	in	table	S	3.1.	
Table	S3.1	CMP	methylation	conversions	at	different	pH	with	TMSCHN2	
pH	 Equiv.	
Diazo	
Conv.	
5	
1	 2%	
5	 4%	
10	 9%	
20	 27%	
6	
1	 21%	
5	 9%	
10	 16%	
20	 36%	
25	 37%	
35	 46%	
	7	
1	 41%	
5	 16%	
10	 31%	
20	 57%	
25	 64%	
8		
1	 41%	
5	 16%	
10	 19%	
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20	 49%	
3.4.4	Methylation	selectivity	towards	CMP	and	benzoic	acid	with	TMSCHN2	
	
CMP	(20	µL,	100	mM	in	water),	benzoic	acid	(20	µL,	100	mM	in	CH3CN),	buffer	(60	µL,	200	mM)	were	
added	into	an	Eppendorf	vial.	The	vial	was	closed,	vortexed	for	5	s	and	then	centrifuged	for	10	s.	Then	
TMSCHN2	(2.0	M	in	hexane,	20	µL)	was	added	and	the	mixture	allowed	to	react	without	agitation	at	
room	 temperature.	 After	 the	 yellow	 color	 disappeared,	 the	 reaction	 was	 analyzed	 by	 UPLC-MS	
(method	A).	The	peak	areas	of	CMP	and	methylated	CMP	were	measured	at	254	nm.	The	peak	areas	
of	benzoic	acid	and	methyl	benzoate	were	measured	at	220	nm.	The	results	are	summarized	in	Table	
S3.2.		
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Table	S3.2	Competition	experiments	at	varying	pH	towards	diazo	compounds	
pH	 CMP	
conv.		
	
ø	
	
SD	
BA	
conv.	
	
ø	
	
SD	
	 [%]	
	 16.1	
15.2	 0.767	
33.0	
34.3	 1.490	4	 15.2	 34.9	
	 14.5	 33.9	
	 31.0	
30.9	 0.154	
23.4	
25.9	 2.370	5	 31.1	 26.2	
	 30.8	 28.1	
	 41.8	
41.6	 0.321	
07.7	
08.1	 0.860	6	 41.4	 07.6	
	 41.4	 09.1	
	 50.9	
51.0	 4.930	
10.1	
10.6	 0.356	7	 56.0	 10.9	
	 46.1	 10.7	
	 53.8	
54.9	 6.050	
06.5	
06.5	 0.056	8	 61.4	 06.4	
	 49.2	 06.6	
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3.4.5	Modification	of	bioactive	phosphate	compounds	
In	a	round	bottomed	flask	a	50	mM	stock	solution	of	phosphate	derivative	(~50	mg	dissolved	in	250	
mM	MES	buffer	pH	6)	was	prepared.	To	the	solution	was	added	freshly	prepared	phenyl	diazomethane	
(as	a	solid,	10	equiv.)	whereupon	gas	bubbles	were	formed	immediately.	The	reaction	mixture	was	left	
for	30	min	at	room	temperature	until	gas	evolution	ceased.	The	side-products	were	very	sticky	to	the	
glass	wall	and	the	clear	solution	was	purified	by	preparative	HPLC	to	afford	the	pure	product.		
In	some	cases,	the	starting	material	phosphate	monoester	was	only	supplied	as	RPO4-xH2O	hydrate	
compounds.	The	amount	of	water	 is	unclear.	 They	were	co-evaporated	with	CH3CN	 three	 times	 to	
remove	the	water	(100	mg	phosphate	monoester	in	10	mL	CH3CN),	afterwards	they	were	used	directly	
as	anhydrous	pure	products.		
	
40	mg	ATP	sodium	salt	was	dissolved	in	1.45	mL	of	250	mM	MES	buffer	pH	6,	and	freshly	prepared	
benzyl	diazo	(90	mg)	was	added	to	the	reaction	solution.	Gas	was	formed	immediately.	The	reaction	
mixture	was	left	for	30	min	until	the	gas	formation	ceased.	The	side-products	stuck	to	the	glassware	
and	the	clear	solution	was	purified	by	preparative	HPLC.	The	desired	product	eluted	at	15	min.	The	
product	fractions	were	combined	and	lyophilized	to	afford	the	desired	product	(43	mg,	46%).	1H	NMR	
(500	MHz,	DMSO-d6)	δ	10.84	(s,	2H),	8.48	(s,	1H),	8.14	(s,	1H),	7.37	–	7.26	(m,	6H),	7.24	(m,	1H),	5.91	
(d,	JHH	=	5.1	Hz,	1H),	4.88	(dd,	JHP	=	6.3,	1.9	Hz,	2H),	4.58	(t,	JHH	=	5.0	Hz,	1H),	4.34	(dd,	JHH	=	17.7,	13.4	
Hz,	1H),	4.10	–	3.99	(m,	3H),	3.04	–	2.88	(m,	16H),	1.12	(t,	JHH	=	7.2	Hz,	25H).	31P	NMR	(202	MHz,	DMSO-
d6)	δ	-12.33,	-12.43,	-23.47.	13C	NMR	(101	MHz,	DMSO-d6)	δ	155.94,	152.56,	149.51,	139.23,	127.95,	
127.03,	118.79,	86.97,	83.35	(d,	3JCP	=	8.08	Hz),	73.92,	69.97,	66.28	(d,	2JCP	=	5.35	Hz),	64.42	(d,	2JCP	=	
3.23	Hz),	45.00,	8.61.		HR-ESI	(Et3N	salt):	Exact	Mass	calcd.	for	C23H37N6O13P3	[M.NEt3+H]+:	699.1631,	
found:	699.1701.	
	
	
50	mg	Deoxyguanosine	monophosphatephospahte	disodium	salt	was	dissolved	in	2.5	mL	of	250	mM 
MES	buffer	pH	6,	and	freshly	prepared	benzyl	diazo	(151	mg)	was	added	to	the	reaction	solution,	and	
gas	was	formed	immediately.	The	reaction	mixture	was	left	for	half	an	hour	until	the	gas	formation	
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ceased.	The	side-products	stuck	to	the	glassware	and	the	clear	solution	was	purified	by	preparative	
HPLC.	The	desired	product	eluted	at	15	min.	The	product	fractions	were	combined	and	lyophilized	to	
afford	the	desired	product	(30	mg,	51%).	1H	NMR	(500	MHz,	DMSO-d6)	δ	10.69	(s,	1H),	7.92	(s,	1H),	
7.36-7.27	(m,	4H),	7.24	–	7.20	(m,	1H),	6.60	(s,	2H),	6.12	(t,	JHH	=	6.9	Hz,	1H),	5.49	(d,	JHH	=	2.8	Hz,	1H),	
4.71	(d,	JHP	=	6.6	Hz,	2H),	4.42	(s,	1H),	3.89-3.92	(m,	2H),	3.83	–	3.72	(m,	1H),	2.90	(s,	7H),		2.61	–	2.52	
(m,	1H),	2.19	(ddd,	JHH	=	13.0,	6.1,	3.1	Hz,	1H),	1.11	(t,	JHH	=	7.0	Hz,	11H).	31P	NMR	(202	MHz,	DMSO-d6)	
δ	-0.70	(s).	13C	NMR	(101	MHz,	DMSO-d6)	δ	156.77,	153.67,	150.88,	139.44	(d,	3JCP	=	7.57	Hz)		,	135.45,	
128.01,	126.98,	116.68,	86.07	(d,	3JCP	=	7.37	Hz)	82.77,	71.22,	65.90	(d,	2JCP	=	5.35	Hz),	64.80	(d,	2JCP	=		
5.15	 Hz),	 45.36,	 8.78.	 HR-ESI	 (Et3N	 salt):	 Exact	Mass	 calcd.	 for	 C23H36N6O7P	 [M.Et3N+H]+:	 539.2378,	
found:	539.2378.		
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CMP	(22	mg,	60	µmol)	was	dissolved	in	1.2	mL	of	250	mM	MES	buffer	pH	6.	TMS	diazomethane	was	
added	(100	µL,	200	µmol,	2	M	in	hexane,	3.33	equiv.).	It	was	stirred	for	20	min	at	room	temperature.	
According	to	HPLC,	only	a	minor	amount	of	product	has	formed.	Additional	TMS-diazomethane	was	
added	(200	µL,	400	µmol,	2	M	in	hexane,	6.67	equiv.)	and	the	reaction	was	stirred	until	the	yellow	
diazo	color	disappeared.	The	reaction	mixture	was	lyophilized	and	purified	by	preparative	HPLC.	The	
product	fractions	were	combined	and	lyophilized	to	afford	the	desired	methylated	product	(5	mg,	25%)	
as	a	white	solid.	1H-NMR	(500	MHz,	D2O)	δ	=	7.83	(d,	J	=	7.6Hz,	1H),	6.01	(d,	J	=	7.6Hz,	1H),	5.90	(d,	J	=	
3.9Hz,	1H),	4.25	to	4.19	(m,	2H),	4.19	–	4.13	(m,	1H),	4.09	(ddd,	J	=	4.3,	12.0,	2.3Hz,	1H),	3.99	(ddd,	J	=	
5.1,	12.1,	3.1Hz,	1H),	3.51	(d,	J	=	11.0Hz,	3H).	13C-NMR	(125	MHz,	D2O)	δ	166.2,	157.70,	141.22,	96.43,	
89.42,	82.52,	74.11,	69.22,	64.17,	52.87.	31P-NMR	(202	MHz,	D2O)	δ	1.47.	HR-ESI:	Exact	mass	calcd.	for	
C10H15N3O8P	[M]-:	336.0602,	found:	336.0605.		
	
	
50	mg	glycerol	phosphate	disodium	salt	was	dissolved	in	4.6	mL	of	250	mM	MES	buffer	pH	6	followed	
by	the	addition	of	freshly	prepared	benzyl	diazo	(90	mg).	The	reaction	mixture	was	left	for	30	min	until	
the	gas	formation	ceased.	The	side-products	were	stuck	to	the	glassware	and	the	clear	solution	was	
purified	 by	 preparative	 HPLC.	 The	 desired	 product	 eluted	 at	 15	 min.	 The	 product	 fractions	 were	
combined	and	lyophilized	to	afford	the	desired	product	(30	mg,	49%).	1H	NMR	(500	MHz,	DMSO-d6)	δ	
9.85	(s,	0.5H),	7.42	–	7.32	(m,	4H),	7.30	(m,	1H),	4.85	(d,	JHP	=	6.3	Hz,	2H),	4.04	(m,	1H),	3.46	(dd,	JHH	=	
5.4,	2.0	Hz,	4H),	3.05	(dd,	JHH	=	7.5,	3.2	Hz,	3H),	1.17	(t,	JHH	=	7.3	Hz,	4H).	31P	NMR	(202	MHz,	DMSO-d6)	
δ	-0.71.	13C	NMR	(101	MHz,	DMSO-d6)	δ	138.44	(d,	3JCP	=	8.48	Hz),		128.16,	127.44,	127.26,	77.91	(d,	
2JCP	=	5.76	Hz),	66.60	(d,	2JCP	=	5.35	Hz),	61.66	(d,	3JCP	=	4.64	Hz),	45.49,	8.50.	HR-ESI:	Exact	mass	calcd.	
for	C10H14Na2O6P	[M-H+2Na]+:	307.0318,	found:	307.0320.		
			
	
53	mg	tyrosine	phosphate	was	dissolved	in	250	mM	of	MES	buffer	pH	6	followed	by	the	addition	of	2-
nitro-phenyl	 diazomethane	 (350	mg).	 CH3CN	 (1	mL)	was	 added	 to	 rinse	 down	 the	 remaining	 solid	
particles.	After	40	min	the	gas	formation	ceased	and	the	aqueous	solution	was	purified	by	preparative	
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HPLC.	The	desired	product	eluted	at	17	min.	The	product	fractions	were	combined	and	lyophilized	to	
afford	the	desired	product	(25	mg,	37%).	1H	NMR	(500	MHz,	DMSO-d6)	δ	8.07	(dd,	J	HH=	8.2,	0.9	Hz,	
1H),	7.82	(d,	JHH	=	7.6	Hz,	1H),	7.79	–	7.73	(m,	1H),	7.54	(t,	JHH	=	7.2	Hz,	1H),	7.10	(d,	JHH	=	8.5	Hz,	2H),	
7.01	(d,	JHH	=	8.4	Hz,	2H),	5.16	(d,	JHP	=	7.3	Hz,	2H),	3.39	(dd,	JHH	=	7.7,	4.8	Hz,	1H),	3.05	(d,	JHH	=	4.7	Hz,	
1H),	2.87	(q,	JHH	=	7.2	Hz,	7H),	2.83	–	2.78	(m,	1H),	1.10	(t,	JHH	=	7.2	Hz,	10H).	31P	NMR	(202	MHz,	DMSO-
d6)	δ	-6.07	(s).	13C	NMR	(101	MHz,	DMSO-d6)	δ	170.14,	152.64	(d,	2JCP	=	6.46	Hz),	146.47,	135.51	(d,	3JCP	
=	7.58	Hz),	133.97,	130.30,	129.77,	128.47,	128.08,	124.35,	119.70-119.65	88	(d,	3JCP	=	4.75	Hz),	63.25	
(d,	2JCP	=	4.75	Hz),	55.19,	45.31,	35.99,	8.75.	HR-ESI:	Exact	mass	calcd.	for	C16H15N2Na2O8P	[M-H+2Na]+:	
441.0361,	found:441.0432.		
	
	
The	reaction	for	serine	phosphate	modification	at	50	mM	resulted	in	the	formation	of	a	carboxylate	
ester	 as	 a	 side	product.	 Therefore	 the	 reaction	was	 carried	out	at	10	mM	serine	phosphate	which	
resulted	only	in	phosphate	modification.	The	freshly	prepared	2-nitro	phenyl	diazomethane	(220	mg,	
5	equiv.)	was	immediately	added	to	the	serine	phosphate	solution	(50	mg	in	27	mL	100	mM	MES	buffer	
pH	6).	After	30	min	the	gas	formation	ceased.	The	side-products	stuck	to	the	glassware	and	the	clear	
solution	was	purified	by	preparative	HPLC.	The	desired	product	eluted	at	14	min.	The	product	fractions	
were	combined	and	lyophilized	to	afford	the	desired	product	(18	mg,	21%).	1H	NMR	(500	MHz,	DMSO-
d6)	δ	8.08	(d,	J	=	8.1	Hz,	1H),	7.90	–	7.73	(m,	2H),	7.56	(t,	J	=	7.5	Hz,	1H),	5.09	(d,	JHP	=	6.8	Hz,	2H),	4.04	
(t,	JHH	=	12.1	Hz,	JHP	=	12.1	Hz,	1H),	3.89	(dd,	JHP	=	11.0	Hz,	JHH	=	7.5	Hz,	1H),	3.41	(d,	JHH	=	5.4	Hz,	1H),	
3.00	(q,	JHH	=	7.2	Hz,	5H),	1.15	(t,	JHH	=	7.0	Hz,	8H).	31P	NMR	(202	MHz,	DMSO-d6)	δ	0.61.13C	NMR	(101	
MHz,	DMSO-d6)	δ	167.77,	146.68,	135.21,	135.17	(d,	3JCP	=	8.08	Hz),	134.00,	128.63,	128.28,	124.42,	
64.10	(d,	2JCP	=	5.45	Hz),	63.17	(d,	2JCP	=	4.04	Hz),	55.73,	45.31,	8.67.	
	
	
66	mg	of	choline	phosphate	chloride	salt	was	dissolved	in	4	mL	of	MES	buffer	pH	6.	Then	327	mg	of	2-
nitro-phenyl	 diazomethane	 was	 added	 to	 phosphate	 aqueous	 solution.	 The	 reaction	 proceeded	
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smoothly	and	the	aqueous	solution	was	purified	by	preparative	HPLC.	The	desired	product	eluted	at	
15	min.	The	product	fractions	were	combined	and	lyophilized	to	afford	the	desired	product	(22	mg,	
31%).	1H	NMR	(400	MHz,	DMSO-d6)	δ	8.07	(d,	JHH	=	8.0	Hz,	1H),	7.86	(d,	JHH	=	7.5	Hz,	1H),	7.79	(t,	JHH	=	
7.4	Hz,	1H),	7.55	(t,	 JHH	=	7.5	Hz,	1H),	5.07	(d,	 JHP	=	7.0	Hz,	2H),	4.06	(m,	2H),	3.52	(m,	2H),	3.13	(s,	
9H).	31P	NMR	(202	MHz,	DMSO-d6)	δ	-0.99.	13C	NMR	(101	MHz,	DMSO-d6)	δ	146.62,	135.89	(d,	3JCP	=	
7.37	Hz),	133.94,	128.58,	128.09,	124.34,	65.46,	62.92	(d,	2JCP	=	4.44	Hz),	58.36	(d,	2JCP	=	5.25	Hz),	53.10,	
53.07,	 53.04,	 39.94,	 39.73,	 39.52,	 39.31,	 39.10.	HR-ESI:	 Exact	mass	 calcd.	 for	 C12H20N2O6P+	 [M-Cl]+:	
319.1053,	found:	319.1056.	
	
	
	
48	mg	 of	 glucose	monophosphate	 dipotassium	 salt	 was	 dissolved	 in	 2.85	mL	 of	MES	 buffer	 pH	 6	
followed	by	the	addition	of	233	mg	of	2-nitro-phenyl	diazomethane.	The	reaction	proceeded	smoothly	
and	the	aqueous	solution	was	purified	by	preparative	HPLC.	The	desired	product	eluted	at	17	min.	The	
product	 fractions	were	 combined	 and	 lyophilized	 to	 afford	 the	desired	product	 (42	mg,	 74%).	 The	
glucose	 modified	 product	 is	 a	 mixture	 of	 antomer	 (ratio=1:1.2),	 but	 some	 of	 the	 NMR	 peaks	 are	
overlapped.	1H	NMR	(400	MHz,	D2O)	δ	8.19	(d,	JHH	=	8.1	Hz,	1H),	7.95	–	7.75	(m,	2H),	7.60	(t,	JHH	=	7.6	
Hz,	1H),	5.35	(d,	JHP	=	7.3	Hz,	2H),	5.14	(d,	JHH	=	3.7	Hz,	0.49H),	4.61	(d,	JHH	=	8.0	Hz,	0.59H),	4.20	–	4.00	
(m,	2H),	3.88	(d,	JHH	=	9.6	Hz,	0.5H),	3.69	(t,	JHH	=	9.5	Hz,	0.5H),	3.57	–	3.39	(m,	3H),	3.22	(q,	JHH	=	7.3	Hz,	
6H),	1.29	(t,	JHH	=	7.3	Hz,	9H).	13C	NMR	(101	MHz,	D2O)	δ	146.56,	146.51,	134.54,	133.72-133.65	(d,	3JCP	
=	7.37	Hz),	133.62-133.54(d,	 3JCP	=	7.77	Hz),	128.73,	128.70,	128.68,	128.61,	124.96,	124.92,	95.95,	
92.08,	75.54,	74.67-74.59	(d,	2JCP	=	7.77	Hz),	74.03,	72.54,	71.40,	70.35-70.28	(d,	2JCP	=	7.67	Hz),	69.18,	
64.57,	64.53	(d,	2JCP	=	3.23	Hz),	64.49-64.44	(d,	2JCP	=	4.84	Hz),	46.66,	8.21.	31P	NMR	(202	MHz,	D2O)	δ	
0.61,	 0.53.	 HR-ESI	 (Et3N	 salt):	 Exact	 mass	 calcd.	 for	 C19H34N2O11P+	 	 [M.NEt3+H]+:	 497.1900,	 found:	
497.1902.	
	
	
Because	MES	salt	was	used	as	the	buffer,	it	is	ten	times	concentrated	than	phosphate	monoester,	so	
there	is	also	MES	esterification	reaction	observed	as	the	side	reaction.	But	the	conversion	is	very	low	
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(Conv.	<	5%).	In	the	next	chapter,	when	diazo	was	tested	with	phosphodiester	(c-AMP	and	c-di-GMP),	
since	 there	 is	no	phosphate	monoester	available,	 thus	 the	MES	 reacted	with	diazo	and	 the	 sulfate	
esterification	product	could	be	purified.	(in	the	c-di-GMP	reaction,	MES	ester,	 isolated	yield	3%).	1H	
NMR	(600	MHz,	DMSO-d6)	δ	8.21	(dd,	J	=	7.9,	1.2	Hz,	1H),	7.97	–	7.81	(m,	3H),	5.04	(s,	2H),	3.97	–	3.89	
(m,	2H),	3.85	(dd,	J	=	14.5,	9.2	Hz,	4H),	3.54	(d,	J	=	12.5	Hz,	2H),	3.30	–	3.26	(m,	2H),	3.16	–	3.08	(m,	
2H).13C	NMR	 (151	MHz,	DMSO-d6)	 δ	 150.74,	 136.81,	 133.95,	 132.45,	 126.06,	 120.49,	 60.71,	 59.91,	
56.31,	53.54,	43.41.	HR-ESI	(Et3N	salt):	Exact	mass	calcd.	for	C19H34N3O6S		[M.Et3N+H]+:	432.2163,	found:	
432.2170.	
3.4.6	Photo	cleavage	of	Tyrosine	phosphate	2-nitro	benzyl	ester	
0.8	mg	of	tyrosine	phosphate	2-nitro	benzyl	ester	was	dissolved	in	D2O	in	a	NMR	tube	and	kept	in	the	
dark	for	measuring	NMR	spectrum,	then	it	was	put	under	366	nm	UV	lamp	overnight	(NMR	spectrum	
was	measured	in	between).	After	15	h,	the	phosphate	2-nitro-benzyl	ester	was	found	to	be	cleaved	
according	to	1H-NMR	spectral	data.	Afterwards	5	mg	of	tyrosine	phosphate	were	added	to	the	NMR	
tube	in	order	to	confirm	the	product	peaks.	The	photo-cleaved	side	product	of	the	reaction	is	insoluble	
in	water	and	therefore	not	visible	in	the	1H-NMR	spectrum.	Please	note	the	presence	of	triethylamine	
salt	which	resulted	from	the	HPLC	purification	buffer	of	the	phosphate	2-nitro	benzyl	ester.	In	these	
experiments	it	was	used	as	an	internal	standard.	
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3.4.7	Alkylation	of	phosphate	monoester	vs	phosphodiester		
The	c-AMP	and	c-di-GMP	were	tested	under	the	same	condition	as	before,	pH	6,	MES	buffer.	It	was	
found	 that	 phosphodiesters	 remained	 unconverted	 employing	 10	 equiv.	 of	 diazo	 substrate,	 low	
conversion	 with	 30	 equiv.	 diazo.	 The	 5’-phosphorylated	 hexanucleotide	 is	 alkylated	 with	 high	
conversion	 compared	 to	 non-phosphorylated	 hexanucleotide	 (table	 S3.3).	 Hexanucleotides	 with	
various	amount	of	diazo	were	also	tested	later	at	pH	7	and	summarized	in	table	S3.	4.		
Table	S3.3	screening	of	alkylation	of	phosphodiester		
	 	 Conversion	of	nulceic	acid	
	 Reaction	concentration	 10	equiv.	diazo	 30	equiv.	diazo	
c-AMP	 50	mM	 0	 5%	
c-di-GMP	 50	mM	 0	 12%	
TACTGC	 100	µM	 0	 0	
pTACTGC	 100	µM	 42%	 52%	
	
	
c-AMP	
70	mg	c-AMP	was	dissolved	in	4	mL	of	250	mM	MES	buffer	pH	6	to	give	a	50	mM	c-AMP	stock	solution.	
Then	 0.5	 mL	 of	 this	 stock	 solution	 was	 incubated	 with	 10	 equiv.	 of	 2-nitro-phenyldiazomethane	
whereupon	gas	bubbles	formed	slowly.	After	1.5	h	the	gas	formation	ceased	and	UPLC-MS	analysis	
(Method	A)	indicated	no	conversion	of	c-AMP.	Another	0.5	mL	of	c-AMP	solution	was	treated	with	30	
equiv.	of	2-nitro-phenyldiazomethane,	however	due	to	the	large	excess	of	diazo	the	reaction	became	
heterogeneous.	 Although	 the	 reagent	 couldn’t	 interact	with	 all	 the	 c-AMP	 solution,	 gas	 formation	
stopped	after	2	h.	The	aqueous	solution	was	transfer	to	a	new	flask	and	washed	with	diethyl	ether	(2	
mL)	 to	 remove	 diazo	 side	 products.	 The	 aqueous	 solution	 was	 submitted	 to	 UPLC-MS	 analysis	
indicating	5%	c-AMP	conversion	 to	 the	corresponding	product.	When	using	a	huge	excess	of	diazo	
reagent	(50	equiv.)	for	c-AMP	modification,	conversion	didn’t	exceed	6%.		
		
c-di-GMP	
22	mg	c-di-GMP	was	dissolved	in	1	mL	of	250	mM	MES	buffer	pH	6	to	give	a	50	mM	stock	solution.	
Then	 0.5	mL	 of	 this	 stock	 solution	 was	 incubated	 with	 10	 equiv.	 of	 2-nitro-phenyldiazomethane,	
whereupon	gas	bubbles	formed	slowly.	After	1.5	h	the	gas	formation	ceased	and	UPLC-MS	analysis	
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indicated	no	conversion	of	c-di-GMP.	Another	0.5	mL	of	c-di-GMP	solution	was	treated	with	30	equiv.	
diazo	 and	 gas	 formation	 stopped	 after	 2	 h.	 The	 aqueous	 solution	was	 transfer	 to	 a	 new	 flask	 and	
washed	with	diethyl	ether	to	remove	the	diazo	side	products.	The	aqueous	solution	was	submitted	to	
UPLC-MS	analysis	where	12%	of	modified	product	was	observed.	
	
Hexanucleotide	TACTGC	
The	purchased	oligomers	were	dissolved	 in	water	to	give	approximately	2	mM	stock	solutions.	The	
amount	 of	 water	 was	 calculated	 according	 to	 Microsynth’s	 quality	 certification.	 The	 accurate	
concentration	was	determined	by	NanoDrop	measurements.	5’-Phosphorylated	oligo	(pTACTGC)	was	
determined	to	be	at	1.4	mM	and	TACTGC	to	be	at	1.7	mM.	10	mg	of	2-nitro-phenyl	diazomethane	was	
dissolved	in	CH3CN	to	form	a	10	mM	stock	solution.	
	
Reactions	
Oligonucleotide	alkylations	were	tested	at	100	µM	concentration.	The	oligomer	was	first	mixed	with	
buffer	(MOPS,	pH	7.15,	5	mM),	diluted	with	water	followed	by	the	addition	of	the	diazo.	The	reaction	
details	and	results	are	summarized	in	Table	S3.4.	The	5’-phospharylated	oligomer	pTACTGC	was	found	
to	give	a	decent	conversion	using	5	equivalents	of	diazo	and	can	be	increased	to	50%	using	up	to	20	
equivalents	 of	 diazo.	 Further	 increase	 of	 the	 stoichiometry	 didn’t	 have	 a	 positive	 effect	 on	 the	
conversion.	The	modification	of	5’-phospharylated	oligomer	pTACTGC	at	50	µM	was	also	tested	with	
various	 amounts	of	 diazo	 compound.	Once	 the	diazo	 stoichiometry	was	 above	10	equivalents,	 the	
reaction	gave	similar	conversions	when	compared	to	the	modification	at	100	µM.	With	the	normal	
synthetic	oligo	TACTGC,	no	conversion	was	noted	even	when	using	40	equiv.	of	diazo	as	determined	
by	HPLC	analysis.		
In	general	the	major	HPLC	peaks	were	collected	manually	and	subjected	to	ESI-MS	and	MS/MS	analysis.	
The	desired	alkylated	oligo	was	further	confirmed	by	HR-ESI:	exact	mass	calcd.	for	C65H79N21O4P62-,	[M]2-
:	989.6687,		found:	989.6603.	Using	MS-MS	the	exact	alkylation	site	could	not	be	determined	due	to	
the	limitation	of	the	MS-MS	method.	The	reaction	mixture	was	also	submitted	to	MALDI	TOF	analysis.	
The	pTACTGC	modification	 showed	mainly	mono-alkylation	product	 and	a	 small	 fraction	of	double	
modification.	 This	 result	 is	 in	 good	 agreement	 with	 the	MS-MS	 data	 (Figure	 S4).	 The	minor	 peak	
observed	(MS	867.07,	I/Imax	10%)	may	be	[T*.A.C-b(T)]-,	[T.A*.C-b(T)]-	or	[T.A.C*-b(T)]-,	where	*	is	the	
site	of	modification,	.		is	the	phosphate	linkage	and	-b(T)	is	the	ribose	without	base.	For	the	TACTGC,	
no	modification	was	observed	by	HPLC	analysis.	Instead	MALDI	TOF	analysis	indicated	that	besides	the	
major	oligo	peak,	a	less	intense	mass	peak	for	the	mono-modified	oligomer	could	be	identified.	This	
states	that	a	very	small	portion	of	oligo	is	alkylated	which	could	only	be	observed	by	MALDI	TOF	since	
a	new	HPLC	peak	could	not	be	detected	under	these	conditions.		
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Table	S3.4	Reaction	details	and	alkylation	results	of	5’-phospahte	hexanucleotide	
pTACTGC	
[mM]	
TACTGC	
[mM]	
Buffer	
[mM]	
Diazo	
[mM]	
Total	
[µL]	
ACN	
[%]	 equiv.	
Conversion	
[%]	
0.10	 	 1	 0.10	 30	 01.0	 1	 03.1	
	 0.10	 1	 0.10	 30	 01.0	 	 00.0	
0.10	 	 1	 0.50	 30	 05.0	 5	 26.9	
0.05	 	 1	 0.25	 30	 02.5	 	 19.3	
	 0.10	 1	 0.50	 30	 05.0	 	 0.0	
0.10	 	 1	 1.00	 30	 10.0	 10	 42.3	
0.05	 	 1	 0.50	 30	 05.0	 	 38.1	
	 0.10	 1	 1.00	 30	 10.0	 	 00.0	
0.10	 	 1	 1.50	 30	 15.0	 15	 49.5	
0.05	 	 1	 0.75	 30	 07.5	 	 49.6	
	 0.10	 1	 1.50	 30	 15.0	 	 00.0	
0.10	 	 1	 2.00	 30	 20.0	 20	 56.3	
0.05	 	 1	 1.00	 30	 10.0	 	 54.3	
	 0.10	 1	 2.00	 30	 20.0	 	 00.0	
0.10	 	 1	 2.50	 30	 25.0	 25	 49.2	
0.05	 	 1	 1.25	 30	 12.5	 	 60.0	
	 0.10	 1	 2.50	 30	 25.0	 	 00.0	
0.10	 	 1	 3.00	 30	 30.0	 30	 52.7	
0.05	 	 1	 1.50	 30	 10.0	 	 52.7	
	 0.10	 1	 3.00	 30	 30.0	 	 00.0	
0.10	 	 1	 4.00	 30	 40.0	 40	 47.6	
	 0.10	 1	 4.00	 30	 40.0	 	 00.0	
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Figure	S3.1	HPLC	trace	of	0.1	mM	5’-phospahte	hexanucleotide	modification	
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Figure	S3.2	Alkylation	of	5’-phospahte	hexanucleotide	with	varying	equiv.	of	diazo	reagent	
	
	
Figure	S3.3	5’-PO4-TACTGC	modification	
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Figure	S3.4	MALDI	TOF	spectrum	of	5’-PO4-TACTGC	modification	with	40	equiv.	of	diazo	reagent	
 
	
Figure	S3.5	MALDI	TOF	spectrum	of	TACTGC	modification	with	40	equiv.	of	diazo	reagent	
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3.4.8	Modification	of	phosphopeptide		
All	the	reactions	were	carried	out	by	adding	the	diazo	compound	to	the	peptide	aqueous	solution.	The	
yellow	reaction	mixture	turned	colorless	upon	complete	diazo	consumption.	It	took	15-30	min	for	the	
following	reactions.	Since	the	diazo	side	products	were	found	to	be	insoluble	in	water,	diethyl	ether	(2	
x	0.2	mL)	was	added	to	wash	away	the	side	products.	Afterwards	the	aqueous	solution	was	subjected	
to	a	gentle	nitrogen	flow	for	a	minute	to	remove	residual	diethyl	ether	followed	by	UPLC-MS	analysis	
(Method	B)	of	the	aqueous	reaction	mixture.	The	modification	position	was	confirmed	by	collecting	
the	corresponding	HPLC	peaks	followed	by	MS-MS	analysis.	The	collected	fractions	were	resubmitted	
to	UPLC-MS	 to	 confirm	 the	 identity	 of	 the	 purified	 peak.	 Sequencing	 of	 the	modified	 peptide	was	
carried	 out	 by	 standarded	 MS/MS	 method.140	 The	 calculation	 was	 done	 by	 mMass	 software	
(http://www.mmass.org/).			
 
13mer	peptide	pp60	Src	(521-533)		
	
Phosphorylated	peptide	pp60	Src	(521-533)	was	purchased	from	Bachem	as	TFA	salt.	It	was	dissolved	
in	water	to	give	a	5	mM	stock	solution	(pH	=	3.3).		
The	 modification	 of	 the	 peptide	 is	 carried	 out	 at	 pH	 6,	 however	 it	 didn’t	 show	 selectivity	 of	 the	
phosphate	modification.	So	the	reaction	was	investigated	at	different	pH.	
Stock	solution:	5	mM	peptide	in	water,	50	mM	diazo	in	CH3CN,	5	mM	MES	buffer	pH	6.05,	5	mM	MOPS	
buffer	pH	7.05.	
1:	190	µL	water,	50	µL	MES	buffer,	pH	6.05,	5	µL	peptide,	5	µL	diazo	
2:	190	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	5	µL	diazo	
3:	240	µL	water,	5	µL	peptide,	5	µL	diazo,	(pH	=	4.2	due	to	TFA	salt	of	the	peptide)	
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Figure	S3.6	UPLC	trace	of	the	Src	(521-533)	modification	at	different	pH 
 
If	the	commercially	available	Src(521-533)	TFA	salt	is	dissolved	in	unbuffered	water	(final	pH	4.2)	and	
treated	directly	with	diazo,	alkylation	of	glutamic	acid	531	(E531)	was	found	to	be	the	major	product	
(see	Figure	S3.7).	Consistent	with	the	pKa’s	controlling	selectivity,	performing	the	same	reaction	at	pH	
6	 and	 7,	 the	 alkylation	 preference	 switches	 to	 tyrosine	 527	 (Y527).	 However	 the	 addition	 of	 15	
equivalents	diazo	reagent	leads	to	substantial	amounts	of	double	alkylation,	thereby	reducing	the	yield	
of	the	desired	alkylation.	The	reaction	was	re-investigated	with	less	equivalents	of	diazo	reagent.	(The	
sites	of	alkylation	have	been	determined	by	MS/MS	sequencing,	see	Table	S3.9-S3.11	for	details).	
	
Stock	solutions:	5	mM	peptide	in	water,	10	mM	diazo	in	CH3CN,	5	mM	MOPS	buffer	pH	7.05.	
Final	reaction	mixture:	100	µM	peptide,	1	mM	MOPS	pH	7.05,	and	diazo	were	added	into	the	peptide	
solution	one	equiv.	per	time	for	the	first	5	reactions.	
1:	192	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	2.5	µL	10	mM	diazo	
2:	190	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	5	µL	10	mM	diazo	
3:	188	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	7.5	µL	10	mM	diazo	
4:	185	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	10	µL	10	mM	diazo	
5:	182	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	12.5	µL	10	mM	diazo	
6:	190	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	5	µL	50	mM	diazo	
7:	188	µL	water,	50	µL	MOPS	buffer,	pH	7.05,	5	µL	peptide,	7.5	µL	50	mM	diazo	
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Table	S3.5	Src	(521-533)	alkylation	with	varying	equivalents	of		diazo	reagent		
Entry	
		
Diazo	
Equiv.	
Phosphate	
modification	
Conv.	
	
1	 1	 19%	 23%	
2	 2	 35%	 43%	
3	 3	 42%	 52%	
4	 4	 47%	 73%	
5	 5	 44%	 68%	
6	 10	 47%	 75%	
7	 15	 40%	 95%	
	
	
	
Figure	S3.7	UPLC	trace	of	the	Src	(521-533)	modification	with	varying	equiv.	of	diazo	reagent	
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Table	S3.6	summary	of	selective	phosphopeptide	modification	
	
	
entry	 substrate	 pHa	
equiv.	
diazo	
Major		
protduct	 conv.b	
Y527:	
(E524+531)c	
1	 10	 4.3	 20	 13	 40	 1:9d	 	
2	 10	 7	 2	 12	 43(35)	 13:1	 	
3	 10	 7	 3	 12	 52(42)	 15:1	 	
4	 10	 7	 5	 12	 68(44)	 11:1	 	
5	 10	 7	 10	 12	 75(47)	 11:1	 	
6	 10	 7	 15	 12	 95(40)	 11:1	 	
7	 11	 7	 10	 14	 30	 n.d.	 	
aRun	in	5	mM	MOPS	buffer	at	pH	7,	pH	4	experiment	is	run	in	unbuffered	water	and	the	pH	is	
measured	 after	 the	 reaction;	 bfirst	 number	 is	 conversion	 of	 starting	 peptide;	 number	 in	
parenthesis	 refers	 to	 amount	 of	 alkylated	 phosphate;	 cratios	 are	 determined	 by	 HPLC	
intergration;	da	small	side	product	obscures	phosphate	alkylation	hence	we	can	only	report	in	
a	lower	limit.		 	
	
	
The	result	of	peptide	modification	with	lower	amount	of	diazo	reagent	is	very	interesting.	With	one	
equivalent	 diazo,	 only	 phosphate	 modification	 was	 achieved.	 Using	 three	 equivalents	 of	 diazo,	 it	
mainly	modifies	 the	phosphate	of	Y527	with	minor	double	modification	 (see	Figure	S3.7	and	Table	
S3.6).	Although	there	are	three	carboxylates	available	for	potential	alkylation	(C-terminal,	E524	and	
E531),	phosphate	alkylation	is	the	major	product	along	with	small	portions	of	carboxylate	modification	
(Y527:	E=15:1,	Table	S3.6	entry	2-6).	Since	the	pKa	of	the	C-terminal	carboxylic	acid	is	around	2-3,	no	
alkylation	of	this	position	was	observed.	The	increase	of	diazo	equivalents	leads	to	double	alkylation	
as	we	 observed	 before.	 The	 selectivity	 of	 phosphate	 and	 carboxylic	 acid	 alkylation	was	 calculated	
according	to	the	extracted	ion	abundance	(See	Figure	S3.9-S3.13).		
In	addition,	while	10	equiv.	of	diazo	reagent	leads	to	75%	conversion	of	the	phosphorylated	peptide	
the	non-phosphorylated	peptide	is	only	partially	modified	under	the	same	conditions	(table	S3.7).		
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Figure	S3.8	ion	extraction	of	the	reaction	of	Src	(521-533)	with	2	equiv.	of	diazo	reagent	
	
104	
	
	
Figure	S3.9	ion	extraction	of	the	reaction	of	Src	(521-533)	with	3	equiv.	of	diazo	reagent	
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Figure	S3.10	ion	extraction	of	the	reaction	of	Src	(521-533)	with	5	equiv.	of	diazo	reagent	
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Figure	S3.11	ion	extraction	of	the	reaction	of	Src	(521-533)	with	10	equiv.	of	diazo	reagent	
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Figure	S3.12	ion	extraction	of	the	reaction	of	Src	(521-533)	with	15	equiv.	of	diazo	reagent	
	
	
Peptide	pp60	Src	(521-533)	non-phosphorylated		
	
	
The	 original	 peptide	without	 phosphate	 group	was	 also	 investigated.	 The	 13mer	 peptide	 could	 be	
modified	with	10	equiv.	of	diazo	reagent.	The	reaction	was	carried	out	as	described	before,	100	µM	
peptide,	1	mM	MOPS	buffer	pH	7.05	followed	by	the	addition	of	the	diazo.	
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Figure	S3.13	UPLC	trace	of	Src	(521-533)	of	modification	
	
Table	S3.7	Src	(521-533	non	phosphorylated	form)	modification	
Entry	
	
equiv.			
diazo		
Conv.	
	
1	 2	 0	
2	 10	 30%	
3	 20	 44%	
	
	
	
	
	
	
	
MS-MS	of	modified	pp60	Src	products	
The	MS-MS	was	the	fragmentation	of	the	double	charged	products.	In	the	following	table,	red	is	the	
observed	MS	which	matches	the	theory	MS/MS,	the	black	is	the	caculated	value.		
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Table	S3.8	MS-MS	fragments	of	phosphate	modification	TSTEPQYQPGENL	
	
ion	 slice	 m/z	 z	 sequence	
M	 [1-13]	 1678.663	 1	 .TSTEPQYQPGENL.	[1x	NO2-Benzyl	phosphate]	
b2	 [1-2]	 189.087	 1	 .TS.t	 	 	 	
b3	 [1-3]	 290.1347	 1	 .TST.e	 	 	 	
b4	 [1-4]	 419.1773	 1	 .TSTE.p	 	 	 	
b5	 [1-5]	 516.23	 1	 .TSTEP.q	 	 	 	
b6	 [1-6]	 644.2886	 1	 .TSTEPQ.y	 	 	
b7	 [1-7]	 1022.35	 1	 .TSTEPQY.q	[1x	NO2-Benzyl	phosphate]	
b8	 [1-8]	 1150.409	 1	 .TSTEPQYQ.p	[1x	NO2-Benzyl	phosphate]	
b9	 [1-9]	 1247.462	 1	 .TSTEPQYQP.g	[1x	NO2-Benzyl	phosphate]	
b10	 [1-10]	 1304.483	 1	 .TSTEPQYQPG.e	[1x	NO2-Benzyl	phosphate]	
b11	 [1-11]	 1433.526	 1	 .TSTEPQYQPGE.n	[1x	NO2-Benzyl	phosphate]	
b12	 [1-12]	 1547.569	 1	 .TSTEPQYQPGEN.l	[1x	NO2-Benzyl	phosphate]	
y12	 [2-13]	 1577.616	 1	 t.STEPQYQPGENL.	[1x	NO2-Benzyl	phosphate]	
y11	 [3-13]	 1490.584	 1	 s.TEPQYQPGENL.	[1x	NO2-Benzyl	phosphate]	
y10	 [4-13]	 1389.536	 1	 t.EPQYQPGENL.	[1x	NO2-Benzyl	phosphate]	
y9	 [5-13]	 1260.493	 1	 e.PQYQPGENL.	[1x	NO2-Benzyl	phosphate]	
y8	 [6-13]	 1163.441	 1	 p.QYQPGENL.	[1x	NO2-Benzyl	phosphate]	
y7	 [7-13]	 1035.382	 1	 q.YQPGENL.	[1x	NO2-Benzyl	phosphate]	
y6	 [8-13]	 657.3202	 1	 y.QPGENL.	 	 	
y5	 [9-13]	 529.2617	 1	 q.PGENL	 	 	 	
y4	 [10-13]	 432.2089	 1	 p.GENL.	 	 	 	
y3	 [11-13]	 375.1874	 1	 g.ENL.	 	 	 	
y2	 [12-13]	 246.1448	 1	 e.NL.	 	 	 	
y1	 [13-13]	 132.1019	 1	 n.L.	 	 	 	
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Table	S3.9	MS-MS	of	glutamic	acid	modification	TSTEPQYQPGENL	
	
ion	 slice	 m/z	 z	 sequence	
M	 [1-13]	 1678.663	 1	 .TSTEPQYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
b2	 [1-2]	 189.087	 1	 .TS.t	 	 	 	 	
b3	 [1-3]	 290.1347	 1	 .TST.e	 	 	 	 	
b4	 [1-4]	 419.1773	 1	 .TSTE.p	 	 	 	 	
b5	 [1-5]	 516.23	 1	 .TSTEP.q	 	 	 	 	
b6	 [1-6]	 644.2886	 1	 .TSTEPQ.y	 	 	 	
b7	 [1-7]	 887.3183	 1	 .TSTEPQY.q	[1xPhosphate]	 	 	
b8	 [1-8]	 1015.377	 1	 .TSTEPQYQ.p	[1xPhosphate]	 	 	
b9	 [1-9]	 1112.43	 1	 .TSTEPQYQP.g	[1xPhosphate]	
b10	 [1-10]	 1169.451	 1	 .TSTEPQYQPG.e	[1xPhosphate]	
b11	 [1-11]	 1433.526	 1	 .TSTEPQYQPGE.n	[1xPhosphate;	1x	NO2-benzyl]	
b12	 [1-12]	 1547.569	 1	 .TSTEPQYQPGEN.l	[1xPhosphate;	1x	NO2-benzyl]	
y12	 [2-13]	 1577.616	 1	 t.STEPQYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
y11	 [3-13]	 1490.584	 1	 s.TEPQYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
y10	 [4-13]	 1389.536	 1	 t.EPQYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
y9	 [5-13]	 1260.493	 1	 e.PQYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
y8	 [6-13]	 1163.441	 1	 p.QYQPGENL.	[1xPhosphate;	1x	NO2-benzyl]	
y7	 [7-13]	 1035.382	 1	 q.YQPGENL.	[1xPhosphate;	1xNO2-benzyl]	
y6	 [8-13]	 792.3523	 1	 y.QPGENL.	[1x	NO2-benzyl]	 	 	
y5	 [9-13]	 664.2937	 1	 q.PGENL.	[1x	NO2-benzyl]	 	 	
y4	 [10-13]	 567.2409	 1	 p.GENL.	[1x	NO2-benzyl]	 	 	
y3	 [11-13]	 510.2195	 1	 g.ENL.	[1x	NO2-benzyl]	 	 	
y2	 [12-13]	 246.1448	 1	 e.NL.	 	 	 	 	
y1	 [13-13]	 132.1019	 1	 n.L.	 	 	 	 	
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Table	S3.10				MS-MS	of	double	modification	TSTEPQYQPGENL	
	
ion	 slice	 m/z	 z	 sequence	
M	 [1-13]	 1813.695	 1	 .TSTEPQYQPGENL.	[1xBenzyl	phosphate;	1x	NO2-benzyl]	
b2	 [1-2]	 189.087	 1	 .TS.t	 	 	 	 	 	
b3	 [1-3]	 290.1347	 1	 .TST.e	 	 	 	 	 	
b4	 [1-4]	 419.1773	 1	 .TSTE.p	 	 	 	 	 	
b5	 [1-5]	 516.23	 1	 .TSTEP.q	 	 	 	 	 	
b6	 [1-6]	 644.2886	 1	 .TSTEPQ.y	 	 	 	 	
b7	 [1-7]	 1022.35	 1	 .TSTEPQY.q	[1x	NO2-Benzyl	phosphate]	 	 	
b8	 [1-8]	 1150.409	 1	 .TSTEPQYQ.p	[1x	NO2-Benzyl	phosphate]	
b9	 [1-9]	 1247.462	 1	 .TSTEPQYQP.g	[1x	NO2-Benzyl	phosphate]	
b10	 [1-10]	 1304.483	 1	 .TSTEPQYQPG.e	[1x	NO2-Benzyl	phosphate]	
b11	 [1-11]	 1568.558	 1	 .TSTEPQYQPGE.n	[1x	NO2-Benzyl	phosphate;	1xNO2-benzyl]	
b12	 [1-12]	 1682.601	 1	 .TSTEPQYQPGEN.l	[1x	NO2-Benzyl	phosphate;1xNO2benzyl]	
y12	 [2-13]	 1712.648	 1	 t.STEPQYQPGENL.	[1x	NO2-Benzyl	phosphate;1xNO2-benzyl]	
y11	 [3-13]	 1625.616	 1	 s.TEPQYQPGENL.	[1x	NO2-Benzyl	phosphate;	1x	NO2-benzyl]	
y10	 [4-13]	 1524.568	 1	 t.EPQYQPGENL.	[1x	NO2-Benzyl	phosphate;	1x	NO2-benzyl]	
y9	 [5-13]	 1395.525	 1	 e.PQYQPGENL.	[1x	NO2-Benzyl	phosphate;	1x	NO2--benzyl]	
y8	 [6-13]	 1298.473	 1	 p.QYQPGENL.	[1x	NO2-Benzyl	phosphate;	1x	NO2-benzyl]	
y7	 [7-13]	 1170.414	 1	 q.YQPGENL.	[1x	NO2-Benzyl	phosphate;	1x	NO2-benzyl]	
y6	 [8-13]	 792.3523	 1	 y.QPGENL.	[1x	NO2-benzyl]	 	 	 	
y5	 [9-13]	 664.2937	 1	 q.PGENL.	[1x	NO2-benzyl]	 	 	 	
y4	 [10-13]	 567.2409	 1	 p.GENL.	[1x	NO2-benzyl]	 	 	 	
y3	 [11-13]	 510.2195	 1	 g.ENL.	[1x	NO2-benzyl]	 	 	 	
y2	 [12-13]	 246.1448	 1	 e.NL.	 	 	 	 	 	
y1	 [13-13]	 132.1019	 1	 n.L.	 	 	 	 	 	
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Photo-cleavage	of	modified	pp60	Src	(527)	
The	purified	Y527	alkylation	product	(which	 is	manually	collected	by	HPLC	from	a	50	nmol	reaction	
setup)	was	re-dissolved	in	100	µL	water	in	an	Eppendorf	tube.	The	sample	was	irradiated	with	a	UV	
lamp	(366	nm)	over	night.	Under	this	condition	the	modified	product	was	cleaved	affording	the	original	
phosphorylated	 Src	 (521-533)	 along	 with	 11%	 of	 dephosphorylated	 peptide.	 The	 reaction	 was	
monitored	by	UPLC-MS	(method	B).	
	
Figure	S3.14		Photocleavage	of	caged	Src	(521-533)	
	
5mer	peptide	
	
5mer	peptide	Ac-Ile-Tyr(PO3H2)-Gly-Glu-Phe-NH2	was	supplied	from	Bachem	as	ammonium	salt.	It	is	a	
phosphorylated	synthetic	peptide	which	can	be	used	as	an	inhibitor	of	Src.	The	peptide	was	dissolved	
in	water	to	give	a	10	mM	stock	solution.	The	modification	with	different	equivalents	of	diazo	reagent	
was	carried	out	as	follows:		
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Stock	solution	
10	mM	peptide,	5	mM	MOPS	pH	7.1,	10	mM	or	100	mM	diazo	in	CH3CN.	
It	 turned	 out	 that,	 with	 3	 equiv.	 diazo,	 phosphorylated	 peptide	 was	 selectively	 modified	 at	 its	
phosphate	position	43%	of	conversion	(see	Figure	S3.16).	The	desired	product	was	manually	collect	by	
HPLC	and	confirmed	using	peptide	MS-MS	sequencing	methods	(See	table	S3.11-12).	
1	
200	µL	reaction	volume	
4	µL	peptide,	80	µL	MOPS	buffer	pH	7.10,	6	µL	diazo,	110	µL	water	
200	µM	peptide,	2	mM	MOPS,	3	equiv.	Diazo	
43%	of	the	peptide	converted	to	the	desired	monophosphate	modified	product	
	
2	
200	µL	reaction	volume	
4	µL	peptide,	80	µL	buffer	pH	7.10,	4	µL	diazo,	112	µL	water	
200	µM	peptide,	2mM	MOPS,	10	equiv.	diazo	
56%	of	peptide	converted	to	desired	monophosphate	modified	product	
14%	of	the	peptide	converted	to	double	modified	product,	(both	phosphate	and	glutamic	acid)	
	
3	
200	µL	reaction	volume	
4	µL	peptide,	80	µL	buffer	pH	7.10,	40	µL	diazo,	76	µL	water	
200	µM	peptide,	2	mM	MOPS,	100	equiv.	Diazo	
56%	of	peptide	converted	to	desired	monophosphate	modified	product	
27%	of	the	peptide	converted	to	double	modified	product,	(both	phosphate	and	glutamic	acid)	
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Figure	S3.15	UPLC	trace	of	the	modification	reaction	using	the	5mer	peptide	
	
5mer	peptide	dephosphorylated	form	Ac-IYGEF-NH2	
	
5mer	 peptide	was	 obtained	 from	Bachem	as	 ammonium	 salt	 and	was	 dissolved	 in	DMSO	as	 stock	
solution	due	 its	 low	solubility	 in	water.	The	modification	with	different	equiv.	of	diazo	reagent	was	
carried	 out	 in	 analogy	 to	 the	 setup	 for	 the	 phosphorylated	peptide,	 however	 no	modification	was	
observed	even	when	treated	with	20	equiv.	of	diazo	reagent.		
	
Figure	S3.16	UPLC	trace	of	5mer	peptide	modification	
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MS/MS	of	modified	products	
	
Table	S3.11	MS-MS	of	phosphate	modified	product	AcIYGEF	
	
ion	 slice	 m/z	 z	 sequence	
b2	 [1-2]	 534.1636	 1	 .IY.g	[1xAcetyl;	1xNO2-Benzyl	phosphate]	
b3	 [1-3]	 591.1851	 1	 .IYG.e	[1xAcetyl;	1xNO2-Benzyl	phosphate]	
b4	 [1-4]	 720.2276	 1	 .IYGE.f	[1xAcetyl;	1xNO2-Benzyl	phosphate]	
y4	 [2-5]	 729.228	 1	 i.YGEF.	[1xAmide;	1xNO2-Benzyl	phosphate]	
z4	 [2-5]	 712.2014	 1	 i.YGEF.	[1xAmide;	1xNO2-Benzyl	phosphate]	
y3	 [3-5]	 351.1663	 1	 y.GEF.	[1xAmide]	 	 	
z3	 [3-5]	 334.1397	 1	 y.GEF.	[1xAmide]	 	 	
y2	 [4-5]	 294.1448	 1	 g.EF.	[1xAmide]	 	 	
z2	 [4-5]	 277.1183	 1	 g.EF.	[1xAmide]	 	 	
y1	 [5-5]	 165.1022	 1	 e.F.	[1xAmide]	 	 	
z1	 [5-5]	 148.0757	 1	 e.F.	[1xAmide]	 	 	
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Table	S3.12	MS-MS	of	double	modified	product	AcIYGEF	
	
	
ion	 slice	 m/z	 z	 sequence	 	 	
b2	 [1-2]	 534.1636	 1	 .IY.g	[1xAcetyl;	1xNO2-Benzyl	phosphate]	 	 	
b3	 [1-3]	 591.1851	 1	 .IYG.e	[1xAcetyl;	1xNO2-Benzyl	phosphate]	 	 	
b4	 [1-4]	 855.2597	 1	 .IYGE.f	[1xAcetyl;	1xNO2-Benzyl	phosphate;	1xNO2-benzyl]	
y4	 [2-5]	 864.26	 1	 i.YGEF.	[1xAmide;	1xNO2-Benzyl	phosphate;	1xNO2-benzyl]	
z4	 [2-5]	 847.2335	 1	 i.YGEF.	[1xAmide;	1xNO2-Benzyl	phosphate;	1xNO2-benzyl]	
y3	 [3-5]	 486.1983	 1	 y.GEF.	[1xAmide;	1xNO2-benzyl]	 	 	
z3	 [3-5]	 469.1718	 1	 y.GEF.	[1xAmide;	1xNO2--benzyl]	 	 	
y2	 [4-5]	 429.1769	 1	 g.EF.	[1xAmide;	1xNO2-benzyl]	 	 	 	
z2	 [4-5]	 412.1503	 1	 g.EF.	[1xAmide;	1xNO2-benzyl]	 	 	 	
y1	 [5-5]	 165.1022	 1	 e.F.	[1xAmide]	 	 	 	 	
z1	 [5-5]	 148.0757	 1	 e.F.	[1xAmide]	 	 	 	 	
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Chapter	4	Investigation	of	substrate	tolerance	of	RNA	demethylase	FTO		
4.1	Reversible	DNA	methylation	in	gene	regulation	
Methylation	is	a	widespread	chemical	modification	in	DNA	and	RNA	which	plays	a	critical	signaling	role	
in	gene	regulation.141	In	mammalian	cells,	DNA	methylation	typically	occurs	mainly	at	the	five	positon	
of	cytosine	of	CpG	dinucleotides	which	can	impede	the	binding	of	transcriptional	proteins	leading	to	
gene	 silencing	 (Figure	 4.1).142	 A	 similar	 process	with	 adenine	methylation	 has	 been	 discovered	 on	
mRNA	giving	the	weight	to	the	possibility	of	regulation	of	transcriptome.143	The	reversible	methylation	
of	DNA	and	RNA	in	gene	expression	regulation	is	responsible	for	cellular	differentiation,	which	is	not	
only	critical	in	embryonic	development,	but	also	in	aging	related	diseases.	Understanding	how	gene	
expression	 is	 regulated	 and	 maintained	 at	 a	 stable	 level	 is	 essential	 for	 developing	 therapeutic	
strategies.	
The	mechanism	of	how	DNA	methylation	patterns	regulate	tissue-specific	gene	expression	and	large-
scale	gene	silencing	is	not	yet	fully	understood.144,	145	But	fundamentally,	most	chromatin	exists	in	a	
condensed,	transcriptionally	silent	state	as	heterochromatin	which	has	high	levels	of	DNA	methylation	
(Figure	 4.1,	 upper).	 Euchromatin,	 the	 lightly	 packed	 form	 of	 chromatin,	 usually	 has	 low	 DNA	
methylation	levels	and	less	condensed.	It	contains	most	actively	transcribed	genes	and	promotes	the	
tissue-specific	 gene	 expression	 (Figure	 4.1,	 lower).	 Genome-wide	 studies	 demonstrated	 5-
methylcytosine	(m5C)	 is	widespread	throughout	the	mammalian	genome	and	70%-80%	mammalian	
CpG	sites	are	methylated.146	A	global	loss	of	DNA	methylation	was	first	found	in	different	organs	of	rats	
during	aging,147	and	was	later	also	confirmed	in	human	genome	by	a	growing	body	of	literature.148	The	
decrease	 of	 DNA	 methylation	 during	 aging	 is	 thought	 to	 be	 responsible	 for	 the	 activation	 of	
transcription	and	gene	overexpression,	as	one	mechanism	leads	to	a	higher	incidence	of	age-related	
diseases	including	cancer.149		
	
Figure	4.1	DNA	methylation	regulates	gene	expression.	Upper:	high	levels	of	DNA	methylation	at	gene	promoters	may	
inhibit	the	binding	of	transcription	factors	or	recruiting	transcriptional	corepressors	resulting	in	inactive	genes.	Lower:	low	
levels	of	DNA	methylation	have	been	proposed	to	generate	active	genes	through	increased	binding	of	transcriptio	factors.	
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4.2	The	discovery	of	FTO	as	m6A	RNA	demethylase		
Although	the	reversible	methylation	of	DNA	as	epigenetic	marks	has	been	intensively	studied	and	well	
understood,	 the	similar	chemical	modification	of	RNA	starts	 to	gain	 increased	appreciation	 in	gene	
regulation	 only	 recently.	 But	 different	 than	 m5C	 in	 DNA,	 N6-Methyladenosine	 (m6A)	 is	 the	 most	
abundant	modification	 in	RNA.150	 	Even	though	this	methylation	was	 first	 found	 in	virus	 in	1974,151		
later	 it	 was	 detected	 in	 all	 higher	 eukaryotes,	 and	 is	 present	∼3	 times	 per	 mRNA	 on	 average	 in	
mammalian	cells.152,	153	The	biological	function	of	m6A	remained	elusive	for	decades.	Only	very	recently	
a	major	 breakthrough	of	 discovering	 the	 first	m6A	RNA	demethylase	 FTO,	which	 is	 a	 fat	mass	 and	
obesity-associated	 protein,	 revealed	 the	 reversible	 regulatory	mechanism	of	m6A	 at	 the	molecular	
level	for	the	first	time.154		
The	FTO	gene	was	first	found	in	mice	by	positional	cloning	in	1999155	and	later	drew	attention	because	
its	misregulation	is	associated	with	obesity	(Figure	4.2).156	Genome-wide	association	studies	in	multiple	
populations	 demonstrated	 that	 FTO	 variant	 alleles	 (homozygous	 =	 AA	 and	 heterozygous	 =	 AT)	 are	
predisposed	to	greater	adiposity	than	are	those	with	2	wild-type	alleles	(TT).156-159	Carriers	of	one	copy	
of	the	allele	(AT)	weighed	on	average	1.2	kilograms	more	than	people	with	no	copies	(TT).	The	16%	of	
European	 adults	 who	 are	 homozygous	 (AA)	 weighed	 about	 3	 kilograms	 more	 and	 had	 1.67-fold	
increased	odds	of	obesity	when	compared	with	those	not	inheriting	a	copy	(TT).	Thus	the	FTO	gene	
was	identified	as	the	first	obesity	risk	allele.		
Due	to	the	important	role	of	FTO	in	obesity,	it	triggered	a	great	interest	towards	its	enzymatic	activity.		
The	FTO	protein	was	first	shown	to	demethylate	N3-methylthymidine	in	single-stranded	DNA160	and	
N3-methyluridine	 in	single-stranded	RNA161	 in	vitro.	Later	the	crystal	structure162	of	the	FTO	protein	
revealed	an	active	domain	that	 is	similar	to	other	proteins	of	the	AlkB	family	which	are	DNA	repair	
enzymes	protecting	the	genome	from	alkylation	damage.	Additionally,	the	C-terminal	domain	of	the	
FTO	 protein	 showed	 the	 preference	 of	 binding	 ssRNA	 and	 ssDNA	 over	 dsDNA,	 indicating	 the	
demethylation	target	might	be	RNA	under	physiological	conditions.	It	was	not	until	2011	that	the	FTO	
protein	was	characterized	as	a	m6A	demethylase	in	RNA	expression	regulation.154	But	the	regulatory	
mechanism	 of	 m6A	 RNA	 in	 protein	 translation	 and	 the	 FTO	 mediated	 development	 of	 obesity	 in	
humans	remains	poorly	understood.	A	positive	relationship	between	the	number	of	FTO	risk	alleles	
and	plasma	ghrelin	 levels	was	found	which	might	 indicate,	the	‘hunger	hormone’	ghrelin’s	mRNA	is	
one	of	the	FTO	substrates	(Figure	4.2).163	People	with	the	obesity-risk	FTO	variant	alleles	have	higher	
circulating	levels	of	ghrelin	in	their	blood	due	to	the	high	level	of	ghrelin	mRNA,	which	could	be	a	result	
of	demethylation	of	methylated	ghrelin	mRNA	by	high	levels	of	the	FTO	protein.	Therefore	people	with	
FTO	gene	are	prone	to	hunger	due	to	the	high	level	of	ghrelin	and	prefer	an	energy	dense	diet	which	
in	the	end	leads	to	obesity.163	
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Figure	4.2	FTO	confers	an	increased	risk	of	obesity	by	subtly	changing	food	intake	and	preference.	
In	 the	past	5	years,	 the	development	of	chemical	methods	made	the	specific	modified	nucleic	acid	
monomers	available.	Combined	with	advanced	chemical	analysis	techniques,	He’s	group	could	confirm	
that	 an	 oxidative	 RNA	 demethylation	 process	 is	 catalyzed	 by	 the	 FTO	 protein	 generating	 N6-
hydroxymethyladenosine	(hm6A)	as	an	intermediate	modification,	and	N6-formyladenosine	(f6A)	as	a	
further	oxidized	product	(Scheme	4.1)154.	Chemically	synthesized	hm6A	and	f6A	standards	co-elute	with	
intermediates	generated	in	the	FTO	catalyzed	oxidation	process	in	the	HPLC	trace	and	have	the	same	
MS/MS	fragmentation	pattern.	Furthermore,	they	showed	hm6A	and	f6A	are	new	RNA	modifications	
in	mammalian	cells.	The	discovery	of	hydroxymethylated	and	formylated	adenosines	in	mRNA	further	
expanded	the	repertoire	of	chemical	diversity	of	RNA	modifications.	
	
Scheme	4.1	FTO	demethylates	m6A	through	oxidization	of	m6A	to	hm6A,	with	f6A	as	a	further	oxidized	product.	
The	 recent	 advances164,165	 in	 sequencing	 of	 methylation	 at	 single-base	 resolution	 provide	 a	
comprehensive	view	of	genomic	methylation	patterns,	and	should	promote	progress	in	understanding	
the	 chemistry	 ofreversible	 methylation.166	 Lastest	 studies	 have	 highlighted	 three	 DNA/RNA	
demethylases	families	which	are	responsible	for	gene	regulation	and	repair	(Figure	4.3).	The	FeII/α-
120	
	
ketoglutarate	(α-KG)-dependent	AlkB	family	demethylases	mainly	catalyze	oxidative	demethylation	of	
N-alkylated	nucleic	acid	bases	including	monoalkyl	and	exocyclic	bridged	adducts.167	For	simple	alkyl	
substrates,	 AlkB	 oxidizes	 the	 carbon	 attached	 to	 a	 nucleobase	 nitrogen	 atom	 (i.e.	 ring	 nitrogen	or	
exocyclic	amine).	The	ten-eleven	translocation	(TET)	proteins	are	AlkB	family	like	DNA	demethylases	
that	 mediate	 oxidation	 of	 methylcytosines	 to	 generate	 5-hydroxymethylcytosine	 (hm5C),	 5-
formylcytosine	(f5C),	and	5-carboxylcytosine	(ca5C).	Another	very	important	TYPE	of	demethylase	is	O6-
G-DNA	methyltransferase	(MGMT)	which	repairs	specifically	O6-methylguanine	alkylation	through	an	
SN2	mechanism.	The	cysteine	residue	in	MGMT	is	the	nucleophile	which	removes	the	methyl	group	on	
O6	 position	 of	 the	 guanosine.	 The	 various	 demethylases	 show	 different	 substrate	 recognition	
specificity	 through	 several	 demethylation	 mechanisms	 (Figure	 4.3).	 They	 also	 indicate	 that	 the	
chemical	 diversity	 of	 RNA	 synthetic	 modifications	 is	 invaluable	 for	 elucidating	 the	 functional	
consequences	of	such	demethylation.	
	
Figure	4.3	Selected	demethylases	show	high	recognition	of	methylated	nucleobases	
The	DNA	methylation	is	one	of	the	best	characterized	epigenetic	marks,	which	is	critical	for	diverse	
biological	processes,	especially	the	embryonic	development	and	cell	differentiation.	Despite	dramatic	
progress	in	epigenetics	during	the	past	decade,	the	dynamic	process	of	DNA	demethylation,	which	has	
a	profound	 impact	on	gene	expression,	 is	poorly	understood.168-170	 Early	efforts	 focused	on	 testing	
various	known	DNA	modifying	proteins,	such	as	DNA	repair	enzymes,	cytosine	deaminases,	and	DNA	
glycosylases	achieving	active	DNA	demethylation	through	different	mechanisms.171-175	Only	the	recent	
discovery	of	TET	proteins	as	an	m5C	oxidase	has	provided	major	 insights	 into	mechanisms	of	active	
DNA	demethylation.176	
The	output	of	gene	regulation	is	gene	expression,	which	is	often	interpreted	in	terms	of	protein	levels.	
The	reversible	methylation	of	RNA	can	directly	affect	protein	production.177	Therefore	regulation	at	
the	RNA	level	is	more	direct	than	DNA	regulation,	a	point	which	might	be	critical	in	the	where	transient	
gene	 expression	 is	 desirable.	 However,	 deciphering	 the	 regulatory	 mechanisms	 of	 reversible	 RNA	
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methylation	was	rather	underdeveloped	because	RNAs	are	known	as	short-lived	species.	Furthermore,	
transcriptome-wide	identification	of	the	various	modified	bases	at	single-base	resolution	still	remains	
a	 challenge.178	 Under	 these	 circumstances,	 it	 is	 often	 difficult	 to	 decide	 whether	 nucleobase	
methylation	is	a	lesion	or	an	epigenetic	mark.	FTO	is	the	homolog	of	AlkB	family	proteins	which	are	
known	for	DNA	repair	5	years	ago.	It	was	logical	to	think	that	the	substrate	of	FTO,	m6A,	is	rather	lesion	
repair	than	a	novel	regulatory	mechanism.	Nevertheless,	with	the	help	of	nucleic	acid	chemistry,	the	
importance	and	ubiquitous	nature	of	RNA	in	gene	regulation	became	widely	recognized.150	Very	recent	
studies	 suggested	 that	m6A	may	pose	an	 important	mark	 for	 recruiting	components	of	 the	splicing	
machinery	and	the	FTO	protein	increases	the	rate	of	splicing	by	regulating	the	RNA	binding	ability.179	
Understanding	of	the	link	between	FTO	and	energy	homeostasis	by	unraveling	mechanisms	of	splicing	
regulation	of	 its	methylated	 transcript	 targets	will	be	beneficial	 for	 the	FTO	gene	related	 therapies	
including	obesity,	diabetes,	Alzheimer.180	
Together,	chemical	modifications	 in	DNA	and	RNA	are	diverse	and	abundant.	With	our	expertise	 in	
nucleic	acid	modification,	we	were	motivated	to	develop	chemical	methodologies	for	deciphering	the	
full	 substrate	 tolerance	of	 FTO.	 If	 large	 functional	 rich	 substrates	 could	be	processed	by	FTO,	 then	
enzymatic	uncaging	might	allow	activation	of	chemically	modified	RNA	in	a	controlled	manner	(scheme	
4.2).		
	
Scheme	4.2		Investigation	of	the	tolerance	of	the	FTO	protein	toward	N6-alkylated	adenosine	RNA	target	
	
4.3	Results	and	discussion		
4.3.1	Synthesis	of	convertible	RNA	monomers	
The	availability	of	diverse	modified	RNA	derivatives	can	greatly	facilitate	the	understanding	of	their	
biological	activities.	However	site-specific	modification	of	single	RNA	monomer	is	laborious,	single	base	
alkylation	of	a	long	mRNA	strand	on	the	other	hand,	would	be	too	challenging.	Thus,	we	started	with	
a	15-mer	RNA	synthesis.		
There	are	several	possibilities	to	obtain	site-specifically	modified	RNA.	Incorporating	pre-modified	RNA	
phosphoramidite	 monomer	 in	 the	 oligonucleotide	 solid-phase	 synthesis	 can	 be	 the	 most	 straight	
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forward	procedure.	However	 this	method	requires	comlicated	synthesis	of	different	monomers	 for	
each	 ssRNA.	 An	 alternative	 approach	 to	 use	 the	 convertible	 nucleoside	 derivatives	 which	 can	 be	
treated	with	different	alkyl	amines	after	solid-supported	synthesis	(Scheme	4.3).		
	
Scheme	4.3	The	convertible	nucleoside	approach	to	afford	different	alkylated	RNA	
After	careful	consideration,	we	decided	to	use	the	convertible	nucleoside	approach	to	obtain	a	gram	
scale	convertible	phosphoramidite	monomer	according	to	a	reported	method.181	For	the	preparation	
of	 the	convertible	nucleoside	used	 to	generate	 functionalized	adenosines,	we	chose	 inosine	as	 the	
substrate	to	initiate	our	project	with	a	detailed	literature	procedure.	The	synthesis	of	4-chlorophenol	
modified	inosine	phosphate	proceeds	in	seven	steps	from	inosine	(Scheme	4.4).		After	tri-O-acetylation	
of	the	ribose	hydroxyl	groups,	activation	of	the	O6	position	for	nucleophilic	substitution	was	achieved	
through	 formation	of	 the	O6-[(2,4,6-triisopropylphenyl)sulfonyl]	 ester.	A	major	 side	product	 of	 this	
reaction,	 the	 N-sulfonated	 inosine,	 was	 easily	 separated	 from	 the	 desired	 product	 by	 flash	
chromatography.	The	sulfonate	ester	was	again	displaced	in	a	trimethylamine-mediated	reaction	with	
4-chlorophenol	to	produce	O6	modified	inosine.	Aminolysis	of	the	acetate	esters	in	methanol	yielded	
the	free	nucleoside	which	further	reacted	under	standard	RNA	phosphoramidite	synthesis	protocol	to	
give	the	convertible	RNA	monomer.	
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Scheme	4.4	Reported	synthetic	method	of	convertible	O6-4-chlorophenol	substituted	inosine	monomer	
After	 several	months’	 struggle,	we	 could	 obtain	 0.6	 gram	of	 the	 finally	 product	 and	 0.3	 gram	was	
incorporated	into	the	solid-phase	synthesizer	for	the	15mer-RNA	synthesis	with	the	sequence	of	5ʹ-
AUU-GUC-A(X)C-AGC-AGC-3ʹ,	 where	 X	 is	 the	 convertible	 monomer.	 However,	 due	 to	 technical	
problems,	the	purification	of	RNA	was	unsuccessful,	giving	a	mixture	of	unidentified	products.	
At	the	same	time,	other	strategies	were	considered	to	obtain	N6	alkylated	adenosine	phosphoramidite.	
However	there	is	no	straight	forward	procedure	due	to	the	similar	activity	of	three	alcohol	groups	of	
the	nucleoside	monomer.	One	pre-modified	adenosine	monomer	is	applicable	(Scheme	4.5).	Starting	
with	 N6	 chlorine	 substituted	 adenosine,	 after	 nucleophilic	 attack	 with	 alkyl	 amines,	 N6	 alkylated	
adenosine	was	obtained	with	high	yield.	Followed	by	standard	RNA	phosphoramidite	synthesis,	the	
desired	monomer	could	be	obtained,	but	the	method	is	still	laborious.	
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Scheme	4.5	Possible	N6A	alkylated	phosphoramidite	synthesis	
4.3.2	The	FTO	protein	production	
N-terminal	his-tagged	 truncated	human	FTO	was	designed	and	produced	as	previously	 reported.162	
After	 lysis	of	 the	cell	pellets,	 the	 filtered	supernatant	was	purified	by	Ni-NTA	chromatography.	The	
fractions	 were	 analyzed	 through	 denaturing	 SDS–PAGE	 gel	 (Figure	 4.4,	 A).	 However	 the	 obtained	
protein	after	purification	showed	two	main	bands	on	the	gel	(Figure	4.4,	B	lane	1).	Later	the	repeat	
experiment	didn’t	give	the	desired	protein.	
	
Figure	4.4	A:	Protein	purification	of	FTO	by	Ni-NTA,	F1-F7	are	fraction	after	adding	the	imidazole	elute	solution,	wash	1	
and	2	are	the	washing	fractions	before	the	elution;	B:	Purified	FTO,	lane	1	protein	after	dialysis;	lane	2	cell	lysate	
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4.4	Conclusion	and	outlook	
The	synthesis	of	convertible	RNA	phosphoramidite	monomer	demonstrated	that	tremendous	amount	
of	work	and	materials	 are	needed.	We	need	better	approaches	 to	have	 site-specific	modified	RNA	
which	certainly	is	still	a	challenge	for	chemists.	The	FTO	protein	production	is	also	difficult	and	requires	
further	optimization.	Mammalian	protein	production	in	E.	Coli	could	be	a	problem	because	sometimes	
the	bacteria	can	not	tolerate	the	foreign	protein	as	it	might	be	toxic	to	its	own	growth.		
In	a	short	time	frame,	we	couldn’t	solve	all	current	problems,	but	the	trials	we	have	made	could	be	
valuable	 for	our	 later	 research.	Commercial	 available	 convertible	RNA	phosphoramidite	 could	be	a	
better	solution	in	this	case	which	can	help	us	push	the	project	further	and	faster.	Cooperation	with	
biologists	might	help	chemists	to	solve	the	mammalian	protein	production	in	bacteria.		
Nevertheless,	 this	project	 is	very	 interesting.	New	discoveries	 in	the	area	are	exciting	and	updating	
very	fast.	The	presence	of	an	N1-methyl	group	on	adenine	bases	in	DNA	and	RNA	was	thought	to	be	a	
form	of	damage	(	see	also	in	Figure	4.3),	now	is	proposed	to	be	a	new	epigenetic	mark	in	mRNA.182	
According	to	He’s	group,	the	new	found	m1A	is	enriched	around	the	start	codon	upstream	of	the	first	
splice	site,	 is	dynamic	 in	response	to	physiological	conditions	and	correlates	positively	with	protein	
production,	strongly	indicating	a	functional	role	for	m1A	in	promoting	translation	of	methylated	mRNA.		
We	should	be	aware	of	recent	discoveries	as	these	provide	motivation	and	direction	for	our	chemistry	
research.	With	our	XHI	methods	and	versatile	diazo	compounds,	future	work	could	test	whether	our	
exo-amine	 modified	 oligonucleotides	 are	 tolerated	 by	 the	 FTO	 protein,	 AlkB	 protein,	 and	 other	
demethylases.	 In	 the	 future,	we	could	add	 functional	groups	 selectively	 to	nucleotides	and	uncage	
them	with	site	specific	recognition	enzymes.	
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4.5	Experimental	part	
4.5.1	General	
All	reagents	and	solvents	used	were	of	analytical	grade.	Buffers	were	prepared	with	ultrapure	water.	
All	chemicals	were	purchased	from	Sigma-Aldrich,	Fluka	or	Acros	and	used	as	received.	Analytical	TLC	
was	 performed	 on	 Silica	 gel	 60	 F254	 pre-coated	 aluminium	 sheets.	 Flash	 chromatography	 was	
performed	 on	 Silica	 gel	 60	 40-63	µm	 (230-400	mesh)	 (SiliCycle,	Quebec).	 1H	 and	 13C	NMR	 and	 2D	
spectra	of	modified	CDN	were	acquired	on	a	Bruker	AvanceIII+	600	MHz	using	Shigemi	NMR	tube.	
Other	compounds	were	recorded	on	400	MHz	proton	frequency	spectrometer	at	298	K.	Chemical	shifts	
relative	to	TMS	were	referenced	to	the	solvent’s	residual	peak	and	are	reported	in	ppm.	ESI	MS-MS	
spectra	 were	 obtained	 on	 a	 Bruker	 Esquire3000plus	 spectrometer	 by	 direct	 injection	 in	 positive	
polarity	of	the	ion	trap	detector.	High	resolution	mass	spectra	were	acquired	on	a	Bruker	maXis	4G	
QTOF	 ESI	 mass-spectrometer.	 MALDI	 TOF	 analyses	 were	 carried	 out	 on	 a	 Bruker	Microflex	 mass-
spectrometer	in	linear	positive	mode	using	sinapic	acid	as	matrice.	HPLC	procedures	were	carried	out	
on	an	Agilent	1100	LC	system	equipped	with	Eclipse	XDB-C8	5µm	4.6	x	100	mm	column	(Agilent)	for	
analytic	analysis.	Shimadzu	preparative	HPLC	(LC-20AP)	equipped	with	phenomenex	column	(Gemini®	
10	µm	C18	110	Å,	LC	Column	250	x	21.2	mm,	AXIA™	Packed)	was	employed	for	preparative	purification.	
100	mM	triethylammonium	acetate	(pH	7.2)	and	acetonitrile	was	used	as	a	mobile	phase.	For	analytical	
measurement:	1	mL/min:	0-35	%	acetonitrile	in	12	min,	35-80	%	acetonitrile	in	3	min,	80%	acetonitrile	
in	2	min.	For	preparative	separation:	flow	rate:	20	ml/min,	0%	acetonitrile	in	2	min,	0-60	%	acetonitrile	
in	27	min.		
	
4.5.2	Convertible	RNA	synthesis	
The	RNA	monomer	synthesis	was	carried	out	according	to	literature	procedure.181	The	product	of	each	
step	was	confirmed	by	NMR	and	compared	with	literature.	The	seven-step	synthesis	took	me	several	
months	to	obtain	0.6	g	of	the	finally	phosphoramidite	and	0.3	g	was	incorporated	into	the	solid-phase	
synthesizer	to	synthesize	a	15mer-RNA	with	the	sequence	of	5ʹ-AUU-GUC-A(X)C-AGC-AGC-3ʹ,	where	X	
is	 the	 convertible	 monomer.	 The	 standard	 1	 µmol	 RNA	 synthesis	 cycle	 was	 modified	 to	 have	 an	
extended	 coupling	 time	 of	 12	 min.	 All	 phosphoramidites,	 including	 the	 convertible	 nucleoside	
phosphoramidites	were	dissolved	to	a	concentration	of	0.1	M	in	anhydrous	CH3CN.		However	during	
the	 cycle,	 the	 G	 channel	was	 indicated	 to	 be	 blocked	 from	 the	 trityl	monitor	 even	 though	 all	 the	
channels	were	thoroughly	wash	with	CH3CN	before.		Nevertheless,	the	solid	phase	was	submitted	to	
the	deprotection	step.	
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The	 resin-bound	 oligonucleotide	 was	 first	 cleavaged	 from	 the	 resin	 with	 1.5	 mL	 of	 ethanolic	
methylamine	solution	(8	M)	for	2	hours,	then	heated	at	42	°	C	for	18	hours.	The	resulting	solution	was	
concentrated	 under	 vacuum.	 Removal	 of	 the	 2ʹ-O-silyl	 ether	 was	 afforded	 by	 treating	 the	
oligonucleotide	with	0.6	mL	of	1	M	tetrabutylammonium	fluoride	(TBAF)	in	THF	for	20	hours	at	room	
temperature.	 These	 reactions	were	quenched	by	 the	addition	of	0.8	mL	of	1	M	TEAA,	pH	7.5.	 The	
oligonucleotides	were	then	purified	by	preparative	HPLC.	However	the	HPLC	trace	didn’t	give	a	clean	
peak,	but	rather	a	mixture	of	many	fractions.	Further	purification	was	not	continued	and	the	repeat	
synthesis	of	RNA	was	postponed	until	the	arrival	of	the	new	DNA	synthesizer.	
4.5.3	FTO	protein	production	
N-terminal	his-tagged	truncated	human	FTO	protein	(his	6-FTO-ND	31)	was	designed	and	produced	as	
previously	 reported.162	 The	gene	 synthesis	and	 subcloning	were	done	by	genscript	 in	 the	 following	
detail:	
Gene	name:	FTO,	Length:	1440	bp,	Vector	name:	pUC57.	
Sequence	of	the	interest	
CATATGACCCCCAAAGATGATGAATTCTATCAGCAGTGGCAGCTGAAATATCCTAAACTAATTCTCCGAGAAGC
CAGCAGTGTATCTGAGGAGCTCCATAAAGAGGTTCAAGAAGCCTTTCTCACACTGCACAAGCATGGCTGCTTA
TTTCGGGACCTGGTTAGGATCCAAGGCAAAGATCTGCTCACTCCGGTATCTCGCATCCTCATTGGTAATCCAGG
CTGCACCTACAAGTACCTGAACACCAGGCTCTTTACGGTCCCCTGGCCAGTGAAAGGGTCTAATATAAAACACA
CCGAGGCTGAAATAGCCGCTGCTTGTGAGACCTTCCTCAAGCTCAATGACTACCTGCAGATAGAAACCATCCA
GGCTTTGGAAGAACTTGCTGCCAAAGAGAAGGCTAATGAGGATGCTGTGCCATTGTGTATGTCTGCAGATTTC
CCCAGGGTTGGGATGGGTTCATCCTACAACGGACAAGATGAAGTGGACATTAAGAGCAGAGCAGCATACAAC
GTAACTTTGCTGAATTTCATGGATCCTCAGAAAATGCCATACCTGAAAGAGGAACCTTATTTTGGCATGGGGAA
AATGGCAGTGAGCTGGCATCATGATGAAAATCTGGTGGACAGGTCAGCGGTGGCAGTGTACAGTTATAGCTG
TGAAGGCCCTGAAGAGGAAAGTGAGGATGACTCTCATCTCGAAGGCAGGGATCCTGATATTTGGCATGTTGG
TTTTAAGATCTCATGGGACATAGAGACACCTGGTTTGGCGATACCCCTTCACCAAGGAGACTGCTATTTCATGC
TTGATGATCTCAATGCCACCCACCAACACTGTGTTTTGGCCGGTTCACAACCTCGGTTTAGTTCCACCCACCGAG
TGGCAGAGTGCTCAACAGGAACCTTGGATTATATTTTACAACGCTGTCAGTTGGCTCTGCAGAATGTCTGTGAC
GATGTGGACAATGATGATGTCTCTTTGAAATCCTTTGAGCCTGCAGTTTTGAAACAAGGAGAAGAAATTCATA
ATGAGGTCGAGTTTGAGTGGCTGAGGCAGTTTTGGTTTCAAGGCAATCGATACAGAAAGTGCACTGACTGGT
GGTGTCAACCCATGGCTCAACTGGAAGCACTGTGGAAGAAGATGGAGGGTGTGACAAATGCTGTGCTTCATG
AAGTTAAAAGAGAGGGGCTCCCCGTGGAACAAAGGAATGAAATCTTGACTGCCATCCTTGCCTCGCTCACTGC
ACGCCAGAACCTGAGGAGAGAATGGCATGCCAGGTGCCAGTCACGAATTGCCCGAACATTACCTGCTGATCA
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GAAGCCAGAATGTCGGCCATACTGGGAAAAGGATGATGCTTCGATGCCTCTGCCGTTTGACCTCACAGACATC
GTTTCAGAACTCAGAGGTCAGCTTCTGGAAGCAAAACCCTAGTAGCTCGAG	
The	cDNA	sequence	encoding	truncated	hFTO	was	subcloned	into	pET-28a	to	generate	a	His-tagged	
fusion	protein	(done	by	Genscript).	The	plasmids	were	transformed	into	E.	coli	BL21	Star	(DE3)	and	
bacteria	 were	 grown	 on	 LB-agar	 plates	 containing	 50	mg/l	 of	 kanamycin.	 Over-night	 pre-cultures,	
which	were	grown	aerobically	at	37	°C	with	a	shaking	speed	of	190	rpm,	were	used	to	inoculate	1	liter	
LB	medium	with	50	mg/l	kanamycin	and	grown	at	37	°C	and	250	rpm	until	OD600	reached	1.0.	Then	
the	bacterial	cells	were	induced	by	isopropyl-b-D-thiogalactopyranoside	(IPTG)	(0.5	mM)	at	15	°C	and	
grown	over-night	at	15	°C	and	250	rpm.	The	cells	were	harvested	by	centrifugation,	frozen	by	liquid	
nitrogen,	and	 stored	at	 -80	 °C.	All	 subsequent	 steps	were	performed	at	4	 °C.	The	cell	pellets	were	
resuspended	in	buffer	A	(50mM	imidazole,	300mM	NaCl,	50mM	sodium	phosphate,	pH	8.0),	sonicated	
on	 ice	 and	 centrifuged	at	 12,000	 rpm	 for	22	min.	 The	 filtered	 supernatant	was	purified	by	Ni-NTA	
chromatography.	The	 fractions	were	analyzed	through	denaturing	SDS–PAGE	(Figure	4.3).	However	
the	obtained	protein	after	purification	showed	two	main	bands	on	the	gel	(Figure	4.3,	B	lane	1).	Later	
the	repeat	experiment	didn’t	give	the	desired	protein.	
	
Figure	S4.1	A:	Protein	purification	of	FTO	by	Ni-NTA,	F1-F7	are	fraction	after	adding	the	imidazole	elute	solution,	wash	
1	and	2	are	the	washing	fractions	before	the	elution;	B:	Purified	FTO,	lane	1	protein	after	dialysis;	lane	2	cell	lysate	
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List	of	abbreviations	
2D	NMR	 two-dimensional	nuclear	magnetic	resonance	spectroscopy		
A	 adenine		
AlkB	 Alkylated	DNA	repair	protein		
ATP	 adenosine	triphosphate	
Bhc	 6-Bromo-4-diazomethyl-7-hydroxycoumarin	(Bhc-diazo)	
brIR	 c-di-GMP	responsive	transcription	regulator	
C	 cytosine	
ca5C	 5-carboxylcytosine		
c-di-AMP	 bis-(3'-5')-cyclic	dimeric	adenosine	monophosphate	
c-di-GMP	 bis-(3'-5')-cyclic	dimeric	guanosine	monophosphate	
CDN	 cyclic	dinucleotides		
c-GAMP	 cyclic	guanosine	monophosphate–adenosine	
c-GAS	 c-GAMP	synthase	
COSY	 correlation	spectroscopy	
CpG		 controlledpore	glass		
CpG		 CpG	dinucleotides		
C-Src	 proto-oncogene	tyrosine-protein	kinase		
CuAAC	 Cu-catalyzed	azide–alkyne	cycloaddition	
DAC	 diadenylyl	cyclase	
DFT	 Density	functional	theory		
DGC	 diguanylate	cyclase	
DgrA		 c-di-GMP	receptor	protein	
DHAP	 	dihydroxyacetone	phosphate		
DIPA	 N,N-diisopropylamine	
DIPEA	 N,N-diisopropylethylamine	
DisA	 the	DNA	integrity	scanning	protein		
DMF	 N,N-dimethylformamide	
DMSO	 dimethylsulfoxide	
DNA	 deoxyribonucleic	acid	
EDA	 Ethyl	diazoacetate		
EDC	 N-(3-Dimethylaminopropyl)-N’-ethylcarbonate	
EFGR	 epidermal	growth	factor	receptor	
EGF	 epidermal	growth	factor	
equiv.	 equivalent(s)	
f5C	 5-formylcytosine		
f6A	 N6-formyladenosine		
FTO	 fat	mass	and	obesity-associated	protein		
G	 guanine	
G	6-P	 glucose-6-phosphate	
GFP	 green	fluorescent	protein		
GTP	 guanosine-5'-triphosphate	
HIV	 human	immunodeficiency	virus		
hm5C	 5-hydroxymethylcytosine		
hm6A	 hydroxymethyladenosine		
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HMBC	 heteronuclear	multiple-bond	correlation	spectroscopy		
HMQC	 heteronuclear	multiple-quantum	correlation	spectroscopy	
HPLC	 high	pressure	liquid	chromatography	
IFN	 interferons	
IMAC	 Immobilized	metal	affinity	chromatography	
IP	 inositol	phosphate	
IPS	 inositol	3-phosphate	synthase	
m5C	 5-methylcytosine		
m6A	 N6-Methyladenosine		
MES	 2-(N-morpholino)ethanesulfonic	acid	
MGMT	 O6-methylguanine-DNA	methyltransferase		
MOPS	 3-(N-morpholino)propanesulfonic	acid	
Ms	 mesylate	
NAD+	 Nicotinamide	adenine	dinucleotide	
NHI	 N-H	bond	insertion	
NMR	 nuclear	magnetic	resonance	(spectroscopy)	
ONB	 ortho-nitrobenzyl		
PAGE	 polyacrylamide	gel	electrophoresis	
PBS	 phosphate-buffered	saline	
PDE	 phosphodiesterase	
PI	 inositol	phospholipids	
Pi	 PO42-	
PKA	 cyclic	AMP-dependent	protein	kinase		
PR	 prosthetic-group-removing	enzyme	or	phosphate-removing-enzyme	
PRPP	 phosphoribosyl	pyrophosphate		
RFP	 red	fluorescent	protein		
RNA	 ribonucleic	acid	
ROESY	 rotating	frame	nuclear	Overhauser	effect	spectroscopy		
ROS	 reactive	oxygen	species		
SAMe	 S-adenosylmethionine	
SDS	 Sodium	dodecyl	sulfate	
ssDNA		 Sing	strand	DNA	
ssRNA		 Sing	strand	RNA	
STING	 	stimulator	of	interferon	genes	
STING		 the	name	deriving	from	stimulator	of	interferon	genes	
T	 thymine	
TBS	 t-butyldimethyl	silyl	(ether,	chloride,	triflate,…)	
TET	 The	ten-eleven	translocation	Pproteins		
TFA	 trifluoroacetic	acid	
THF	 tetrahydrofuran	
THPTA	 tris(3-hydroxypropyltriazolyl-	methyl)amine		
TMS	 trimethylsilyl	(ether,	chloride,	triflate,…)	
U	 uracil	
UPLC-MS	 ultra	pressure	liquid	chromatography,	mass	spectroscopy	
XHI	 X-H	bond	insertion,	here	X=	N,	O,	S.	
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